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Lymphoid Neogenesis and Tertiary
Lymphoid Organs in Transplanted 
Organs
 
Alice Koenig1,2,3 and Olivier Thaunat1,2,3*
1 Service de Transplantation, Néphrologie et Immunologie Clinique, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, 
France, 2 INSERM UMR1111, Lyon, France, 3 Université de Lyon, Lyon, France
The progressive organization of immune effectors into functional ectopic lymphoid struc-
tures, named tertiary lymphoid organs (TLO), has been observed in many conditions 
in which target antigens fail to be eliminated by the immune system. Not surprisingly, 
TLO have been recurrently identified in chronically rejected allografts. Although signif-
icant progress has been made over the last decades in understanding the molecular 
mechanisms involved in TLO development (a process named lymphoid neogenesis), the 
role of intragraft TLO (if any) in chronic rejection remains elusive. The prevailing dogma is 
that TLO contribute to graft rejection by generating and propagating local humoral and 
cellular alloimmune responses. However, TLO have been recently observed in long-term 
accepting allografts, suggesting that they might also be able to regulate alloimmune 
responses. In this review, we discuss our current understanding of how TLO are induced 
and propose a unified model in which TLO can play deleterious or regulatory roles and 
therefore actively modulate the kinetics of chronic rejection.
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INTRODUCTION: THE CHALLENGE OF CHRONIC REJECTION  
IN TRANSPLANTATION
Vital organ failure is a life-threatening condition where a vital organ (i.e., kidney, heart, liver, or 
lung…) does not perform its expected function. Recent lifestyle changes in developed countries, and 
the increased incidence of chronic diseases such as hypertension, obesity, and diabetes, have set the 
stage for accelerated risk for, and the occurrence of, vital organ failure. As a result, vital organ failure 
is currently recognized as the leading cause of debility and premature death worldwide (www.who.
int). In France alone, the personal, societal, and economic consequences of vital organ failure have 
a cost of more than €70 billion a year (25% of total health expenditures).
Transplantation consists in the restoration of vital physiologic functions through the surgical 
substitution of a defective organ by a functioning graft retrieved from a donor. Patients with end-
stage vital organ failure depend on solid organ transplantation, which is their best (often their only) 
therapeutic option.
In clinical transplantation, the donor is from the same species but genetically different. 
Consequently, the immune system of the recipient inevitably recognizes the antigenic determinants 
(alloantigens) that differ between the recipient and the donor, particularly the highly polymorphic 
molecules from the major histocompatibility complex [i.e., human leukocyte antigen (HLA)] in 
humans. The alloimmune response that develops against the donor-specific HLA molecules is 
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FIGURE 1 | Tertiary lymphoid organs in a chronically rejected renal 
transplant. Biopsy of a renal transplant was performed for progressive 
deterioration of graft function, suggestive of chronic rejection. (A) HES 
staining revealed nodular infiltrates of mononuclear cells within graft 
parenchyma (original magnification: left panel, ×20; right panel, ×200). 
(B) Immunostainings unraveled the organized distribution of T cells (CD3+, 
left panel) and B cells (CD20, right panel). Original magnification: ×200.
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responsible for tissue damage, which leads to the failure of the 
transplanted organ, a process named “rejection.”
In the absence of a clinically applicable protocol able to 
induce the specific tolerance of the allogenic transplant by the 
recipient’s immune system (1, 2), the prevention of rejection is 
currently dependent upon immunosuppressive drugs (3). These 
drugs produce generalized immunosuppression, which means 
that any reduction in immune responsiveness to the allograft is 
accompanied by reduced immunity to infections and malignant 
diseases. Chronic immune injuries that result from the incomplete 
blockade of the recipient’s alloimmune response (i.e., chronic 
rejection) are currently the main factor limiting graft function 
duration (4). No significant progress has been made on this issue 
over the last decades as highlighted by the stagnation of graft half-
life (5). A better understanding of the pathophysiology of chronic 
rejection is therefore a mandatory step in identifying innovative 
approaches that would prolong graft function duration.
INTRAGRAFT TERTIARY LYMPHOID 
ORGANS (TLO)
Rejected grafts are characterized by interstitial infiltration of cel-
lular effectors, mainly T cells and macrophages, but also dendritic 
cells, NK cells, B cells, and plasma cells.
In contrast with acute rejection, where infiltrates exhibit no 
particular spatial organization, during chronic rejection immune 
cells tend to organize themselves in structures that morphologi-
cally resemble the secondary lymphoid organs.
Analyzing all sorts of human kidney grafts removed for termi-
nal chronic rejection, we and others showed that in the majority 
of chronically rejected grafts the immune cells were grouped, 
conferring a nodular organization to the infiltrate (6, 7). These 
nodules exhibited a highly organized microarchitecture with clear 
cell subset segregation: the core, made of the B cells intermingled 
with a network of follicular dendritic cells, was surrounded by 
T cells and mature dendritic cells. CD138-expressing plasma cells 
were found within or in close vicinity to TLO, suggesting that 
part of these cells differentiated locally. As in canonical secondary 
lymphoid organs the compartmentalization of the different cell 
subsets appeared to be mediated by gradients of homeostatic 
chemokines CCL21 (in the T cell area) and CXCL13 (in the B cell 
area). Furthermore, neolymphatic vessels and PNAd-expressing 
high endothelial venules (HEVs) were observed in the periphery 
of the nodules (8).
The structural organization of immune effectors observed in 
chronically rejected renal grafts (Figure 1) does not seem specific 
of this type of transplant since similar lymphoid structures have 
been observed in chronically rejected pancreas, livers, hearts (7, 
9–11), lungs (12), and even composite transplants (13–15). This 
phenomenon is not specific of the alloimmune setting either, 
since the very same lymphoid structures have previously been 
observed in various inflammatory conditions, including chronic 
infections, autoimmune diseases, and cancers (16, 17). Structural 
organization of immune effectors therefore appears as a generic 
response of the chronically stimulated immune system that can-
not eradicate targeted antigens.
Because the microarchitecture of organized immune infiltrates 
is highly reminiscent of that of secondary lymphoid organs, these 
lymphoid structures have been named TLO.
MOLECULAR MECHANISMS INVOLVED  
IN THE DEVELOPMENT OF SECONDARY 
LYMPHOID ORGANS
Primary immune responses are initiated in secondary lymphoid 
organs, which are located at strategic sites where antigens are 
most likely to be encountered.
The development of secondary lymphoid organs, a process 
named lymphoid organogenesis, is initiated during embryo-
genesis independently of antigen recognition at predetermined 
sites as a result of complex interactions between hematopoietic, 
mesenchymal, and endothelial cells (18, 19). Lymphoid organo-
genesis can be schematically divided into two consecutive steps: 
first the induction, then the organization phase.
The induction phase depends on lymphoid-tissue inducer cells, 
which arise in the fetal liver. Under the influence of TRANCE 
(at sites of peripheral lymph node development) or IL-7 (at 
mucosal sites) lymphoid-tissue inducer cells express membrane-
bound lymphotoxin: a heterotrimer containing lymphotoxin α 
and lymphotoxin β that allow lymphoid-tissue inducer cells to 
interact with the lymphotoxin β receptor (LTβR) of stromal cells. 
Signaling through the LTβR initiates NFκB signaling in stromal 
cells, which promotes the production of homeostatic chemokines 
(18, 19).
Homeostatic chemokines are crucial for the organization 
phase. CXCL13 recruits circulating B cells to what becomes the B 
cell area of lymphoid tissues, and the T zone chemokines (CCL19 
and CCL21) attract T and dendritic cells to shape the T cell area 
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FIGURE 2 | Graphical summary of our current understanding of intragraft lymphoid neogenesis. The main molecular mechanisms involved in the initiation 
(upper row) and the subsequent organization (middle row) of tertiary lymphoid organs (TLO) within transplanted organs are showed. The diverse functions of 
intragraft TLO and their respective impact on graft survival are presented (lower row).
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(18, 19). The lymphotoxin signaling pathway is also crucial in 
promoting the differentiation of HEVs, which are postcapil-
lary venules expressing specific adhesion molecules (known as 
addressins) that have a crucial role in lymphocyte trafficking to 
secondary lymphoid organs (18, 19).
MOLECULAR MECHANISMS OF 
LYMPHOID NEOGENESIS IN 
TRANSPLANTATION
Chronic rejection provides optimal conditions for studying the 
molecular mechanisms involved in the development of TLO 
(Figure  2). Indeed, (i) TLO have systematically been detected 
in chronically rejected grafts; (ii) the antigens targeted by the 
immune system are known (recipient-mismatched HLA antigens 
of the transplanted tissues); and (iii) chronically rejected grafts 
are sometimes removed, providing a large amount of diseased 
tissue, which can be comprehensively analyzed.
In-depth analysis of a series of detransplanted human renal 
grafts revealed the heterogenous nature of the cellular composi-
tion of TLO (8). Two types of B cell nodules could be identified: 
nodules composed of a uniform CD20pos B cell population express-
ing IgD and Bcl-2 were similar to primary follicles, while nodules 
with a core of CD20posIgDnegBcl-2neg B cells, highly expressing 
Bcl-6 that had pushed aside the CD20posIgDposBcl-2pos B cells, 
resembled secondary follicles, i.e., germinal centers (8). The ratio 
between these two types of structures differed between samples, 
and the number of ectopic germinal centers did not increase with 
the quantity of primary nodules. The phenotypic heterogeneity of 
TLO correlated more with the expression profile of a set of genes 
(CCL19, CCL21, CXCL12, CXCL13, CCR7, CXCR4, and CXCR5) 
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involved in the formation and the maintenance of canonical 
secondary lymphoid organs (i.e., the lymphoid organogenesis 
described in the previous section) (18, 19). The complete reca-
pitulation of this genetic program in chronically rejected grafts 
resulted in the generation of fully functional ectopic germinal 
centers that allowed for the efficient maturation of B cells into 
memory B cells and plasma cells (Figure 2). In contrast, when 
this recapitulation was incomplete, local B cell maturation was 
impeded (8). These results highlighted the similarity between the 
molecular processes involved in the development of canonical 
secondary lymphoid organs and those involved in the organiza-
tion of immune effectors during chronic inflammation, a process 
named lymphoid neogenesis.
If the molecular mechanisms responsible for the organiza-
tion and maintenance of secondary lymphoid organs and TLO 
appear similar, the initiation of the cascade is likely to be different 
(Figure 2). The formation of secondary lymphoid organs in the 
embryo is developmentally programed and results from the inter-
action between lymphotoxin-α1β2-expressing lymphoid-tissue 
inducer cells and lymphotoxin-β receptor-expressing stromal 
organizer cells (18, 19). In contrast, TLO development seems 
independent of lymphoid-tissue inducer cells (20, 21). Yet, sev-
eral studies have documented the importance of the lymphotoxin 
pathway in lymphoid neogenesis (21, 22), including in a trans-
plantation setting (23), by demonstrating that the development of 
TLO was abolished by treatment with inhibitory LTβR–Ig fusion 
protein. We must then ask who provides lymphotoxin signaling 
in the chronic rejection setting. Beyond lymphoid-tissue inducer 
cells, lymphotoxin-α and lymphotoxin-β are also expressed 
by activated lymphocytes (24). It is therefore conceivable that 
activated T and/or B cells replace lymphoid-tissue inducer cells 
to initiate lymphoid neogenesis in rejected grafts (Figure  2) 
as already demonstrated for the induction of TLO in the gut 
(21). Another possibility is that lymphotoxin is dispensable for 
the formation of TLO. Lymphotoxin-α and lymphotoxin-β are 
two related members of the large TNF ligand family (25). Since 
homologous genes and gene products often have redundant 
physiological functions, it seems reasonable to propose that 
other ligands and/or receptors of the TNF superfamily could 
act as alternative pathways for TLO induction (Figure  2). In 
line with this hypothesis, the provision of the alternative LTβR 
ligand LIGHT (aka tumor necrosis factor superfamily member 
14) by activated T cells infiltrating inflamed pancreas have been
shown to be crucial for the formation of TLO (26). Furthermore,
TNF-α, which is produced within rejected grafts (27), has been
shown to be critical for the development of TLO in a murine
model of atherosclerosis (20). TNF-α does not bind to LTβR but
to distinct TNF receptors (25). Using apolipoprotein E-deficient
mice, which spontaneously develop atherosclerotic lesions in
their aorta, the Antonino Nicoletti’s group recently demonstrated 
that the blockade of LTβR signaling had no effect, whereas that
of TNFR1/2 signaling reduced the expression of homeostatic
chemokines and the subsequent development of TLO (20).
Finally, it has recently been reported that IL-17 produced by
CD4+ T cells (i.e., Th17 cells) was essential for the formation
of both (i) TLO in the central nervous system of mice during
experimental autoimmune encephalomyelitis (the animal model
of multiple sclerosis) (28) and (ii) the development of inducible 
bronchus-associated lymphoid tissue, an ectopic lymphoid tissue 
that forms in the lungs after pulmonary inflammation (29, 30). 
In the latter setting, IL-17 acted by triggering the expression of 
homeostatic chemokines independently of lymphotoxin signaling 
(Figure 2). If this hypothesis was proven true in transplantation, 
initiation of lymphoid neogenesis in chronically rejected grafts 
could therefore be totally independent of both lymphoid-tissue 
inducer cells and the lymphotoxin/TNF pathway. Interestingly, 
we have recently reported that a Th17 polarization of CD4+ 
T cells infiltrating the graft was associated with increased TLO 
development during clinical chronic rejection (31).
It is conceivable that instead of conflicting with each other, 
these different works reveal the fact that several pathways can 
promote the initiation of TLO depending on the initiating events. 
This hypothesis was recently substantiated by the demonstration 
that the development of bronchus-associated lymphoid tissue 
was triggered by different pathways according to the pathogen 
responsible for lung inflammation (29).
While significant progress has been made in the identification 
of the molecular mechanisms that participate to the development 
of TLO, the endogenous signals capable of inhibiting the lymphoid 
neogenesis are far more elusive. Through evaluation of synovial 
tissues from rheumatoid arthritis patients it has been recently 
reported that low interleukin-27 (IL-27) expression corresponds 
with an increased incidence of TLO and gene signatures associ-
ated with their development and activity. The presence of synovial 
TLO was also noted in mice deficient in the IL-27 receptor after 
the onset of inflammatory arthritis (32). IL-27 might therefore 
represent a negative regulator of TLO development. Whether this 
is also true for chronic rejection remains to be demonstrated.
DO INTRAGRAFT TLO PROMOTE 
CHRONIC REJECTION?
Tertiary lymphoid organs differ from canonical secondary 
lymphoid organs inasmuch as they develop in an inflammatory 
milieu (31, 33), enriched in neoantigens released from injured tis-
sue and trapped by defective lymphatic drainage (34). Comparing 
the cellular composition of TLO of chronically rejected grafts 
with one of the secondary lymphoid organs, we observed a drastic 
increase in the percentage of activated and memory CD4+ T cell 
in intragraft TLO and a symmetric decrease in T regulatory 
subsets (IL-10-producing Tr1 cells and Foxp3pos Tregs) in both a 
murine experimental model and human samples (33, 35).
These peculiarities suggest that the local immune response that 
develops in intragraft TLO might be less tightly regulated than in 
secondary lymphoid organs and are therefore more aggressive. In 
line with this hypothesis, we (33) and others (23) have shown that 
intragraft TLO are a major site where B cell tolerance breakdown 
occurs during chronic rejection (Figure 2). Interestingly, the gen-
eration of autoantibodies following solid organ transplantation 
has long been reported to correlate with chronic rejection, and 
the deleterious impact of some autoantibodies on graft survival 
has been demonstrated (36, 37). Furthermore, comparing the 
alloimmune responses elicited in intragraft TLO, spleen, and 
draining lymph nodes in a rat model of chronic rejection, our 
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group observed increased production of anti-HLA antibodies in 
TLO as compared with canonical secondary lymphoid organs 
(35). Not only were the humoral alloimmune responses elicited 
in TLO quantitatively enhanced but they also displayed a more 
diverse repertoire, a finding that we confirmed in the clinical 
setting by the analysis of chronically rejected human kidney 
allografts (8).
Tertiary lymphoid organs could also contribute to chronic 
destruction of the graft through antibody-independent functions 
of B cells. B cells are indeed unique antigen-presenting cells because 
(i) they have an antigen-specific receptor (B cell receptor), which
when engaged by surface-tethered antigens leads to the formation 
of an immunological synapse that coordinates cell signaling events 
and promotes antigen uptake for presentation on MHC class II
molecules (38), even when the antigen is membrane-tethered or
is present in limiting quantities and (ii) B cells have the capacity
to clonally expand, thereby becoming the numerically dominant
antigen-presenting cells. Interestingly, it has been reported that
the presence of B cell clusters within the graft during rejection was 
associated with reduced graft survival and resistance to steroid
therapy, independently of C4d (a breakdown product generated
during classical complement pathway activation) deposition or
alloantibody detection (39). Some authors have proposed that
this could be due to the local presentation of antigen to effector
T cells by intragraft B cells (40). This hypothesis is supported by
experimental data from the group of Fadi Lakkis, who showed
that in a murine skin graft model, TLO perpetuate the rejection
process by supporting naïve T cell activation within the graft (41).
Strikingly, the same authors also demonstrated that TLO generate 
T cell memory immune responses (41).
In addition to presenting antigen, B cells can also enhance 
T cell-mediated immune responses through the secretion of 
cytokines and chemokines. Studies from the group of Frances 
Lund (42) have shown that B cells can be functionally subdivided 
based on their cytokine profile. B cells activated in the presence 
of TH1-type cytokines (referred to as Be-1 cells) secrete IFNγ and 
IL-12 but not IL-4, IL-13, or IL-2. By contrast, B cells activated 
in the presence of TH2-type cytokines (Be-2 cells) secrete IL-2, 
lymphotoxin, IL-4, and IL-13 but make minimal amounts of IFNγ 
and IL-12. Both Be-1 and Be-2 cells seem able to produce IL-10, 
TNFα, and IL-6. The importance of B cell cytokines in promot-
ing T cell responses has been illustrated in several models. For 
example, in vitro generated effector B cells that produced either 
TH1- or TH2-type cytokines were shown to promote the activa-
tion and differentiation of naïve T cells into effector TH1 and TH2 
cells, respectively (43). The importance of B cell cytokines in pro-
moting T cell responses has been confirmed in vivo. In a murine 
model of Toxoplasma gondii infection, TNF production by B cells 
was shown to be required for the generation of an optimal TH1 
cell protective response (44). In another set of experiments, the 
generation of a protective TH2 memory response to H. polygyrus 
was shown to depend on IL-2-producing B cells (45). The exact 
role of cytokine-producing B cells in enhancing intra-TLO T cell 
responses remains to be evaluated.
Since grafts in which TLO were harboring germinal center 
reactions had a shorter life expectancy (Figure  2), we have 
proposed that lymphoid neogenesis could play a detrimental role 
during chronic rejection (8). However, the validity of this conclu-
sion is limited by the fact that only explanted grafts have been 
analyzed, i.e., organs displaying extreme rejection damage that 
are sometimes (notably in the case of renal grafts) removed after 
immunosuppressive therapy withdrawal. The definitive demon-
stration that TLO are involved in the pathophysiology of chronic 
rejection would require selectively impairing the development of 
intragraft TLO while leaving the rest of the recipient’s immune 
system unaffected. Addressing this issue is not trivial because, 
as discussed above, TLO share many biological pathways with 
canonical lymphoid tissue, and hence an adequate experimental 
model is not currently available. Therefore, most of the attempts 
to validate the data obtained in murine experimental models and 
in human detransplanted grafts have relied on graft biopsies. The 
identification of TLO within the grafts before the development of 
the lesions indeed appears as a prerequisite for confirming the role 
of lymphoid neogenesis in chronic rejection. This implies a study 
of protocol biopsies, which has long been introduced as standard 
follow up in transplantation (46). Unfortunately, the numerous 
studies aiming at evaluating the correlation between the presence 
of TLO in protocol biopsies and the later development of chronic 
rejection have reached conflicting conclusions (Table 1).
The absence of an unequivocal deleterious role for B cell 
clusters has led to the conclusion that these structures could be 
like “fish in a sunken ship,” i.e., although fish are frequently seen 
in a sunken boat, they play no role in the process responsible for 
the shipwreck.
INTRAGRAFT TLO: FRIENDS AND FOES?
An alternative explanation could reconcile these apparently 
conflicting results. As discussed above, the proportion of B cells 
that infiltrate chronically rejected kidney grafts does not correlate 
with the functionality of intragraft TLO (8). The attraction of B 
cells within inflamed tissue appears therefore to be a generic 
phenomenon with no intrinsic deleterious consequences on 
the graft. However, when intragraft B cells meet the appropriate 
microenvironment, and upon the complete recapitulation of 
the lymphoid organogenesis program, B cell nodules organize 
themselves into functional ectopic germinal centers, which 
harbor the development of a local aggressive immune response. 
Because graft biopsies provide only a very limited amount of tis-
sue (which is already an important limitation for evaluation in a 
patchy process such as lymphoid neogenesis), they do not allow 
for functional analysis of the ectopic lymphoid organs and are 
therefore inappropriate for analyzing the role of B cell clusters in 
rejected grafts.
Another layer of complexity has recently been brought into 
the picture by experimental evidence that certain B cell subsets 
are endowed with an immune regulatory role (47). For instance, 
IL-10-producing B cells have been shown to efficiently prevent 
the induction of autoimmune disease in several mouse models 
(48–50). Tolerance in transplantation is defined as the mainte-
nance of graft function in the absence of therapeutic immunosup-
pression for at least 12 months. About 100 tolerant patients have 
been identified among renal transplant recipients over the last 
decade (51). These patients, defined as “operationally tolerant,” 
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TABLE 1 | Summary of biopsy-based studies evaluating the role of graft-infiltrating B cells.
Reference Population Biopsy indication Histologic criteria Key findings
KIDNEY RECIPIENTS
Sarwal  
et al. (39)
51 patients Biopsy with acute graft rejection CD20+ cell count >275/HPF B cell clusters associated with glucocorticoid 
resistance and graft loss
Hippen  
et al. (58)
27 patients Biopsy with Banff 1A or 1B acute rejection CD20+ if “strong and diffuse 
staining”
CD20+ correlated with steroid-resistance 
rejection and reduced graft survival
Kayler  
et al. (59)
120 patients Biopsy with first episode of acute cellular 
rejection
Cluster of ≥15 CD20+ cells in the 
tubulo-interstitial compartment
CD20+ clusters are not prognostic factors for 
glucocorticoid resistance and graft loss
Bagnasco  
et al. (60)
58 patients  
(74 biopsies)
Biopsy with type 1 and type 2 acute cellular 
rejection during the first year post-Tx
B cell-rich when ≥1 cluster 
containing 100 CD20+ cells/HPF
No correlation between B cell-rich biopsies and 
worst graft outcome
Scheepstra 
et al. (61)
50 patients  
(54 biopsies)
Biopsy with clinically suspect and 
histologically confirmed acute rejection
B cell (CD20+) count >275/HPF Presence of B cells does not correlate with 
response to conventional therapy or graft 
outcome
CD20+ cluster if >30 cells
CD20+ without the interposition 
of tubules
Hwang  
et al. (62)
54 patients  
(67 biopsies)
Biopsy with acute cellular rejection CD20+ count >275/HPF CD38+ B cells ± CD20+ B cells correlated with 
poor clinical outcomesCD38+ if >30% infiltration
Martin  
et al. (63)
18 patients Serial biopsies for 10 recipients with chronic 
dysfunction and 8 with long-term normal 
graft function
Plasma cells count Patients developing chronic rejection present 
plasma cells, DSA, and C4d depositions more 
often than control group on their biopsy
Cd4 deposits
DSA elution from biopsy
Abbas  
et al. (64)
50 patients Biopsy for cause Plasma cell-rich acute rejection if 
>10% plasma cells
Plasma cell-rich acute rejection correlated with 
a poor graft outcome when associated with 
DSA
HEART RECIPIENTS
Yamani  
et al. (65)
140 patients Systematic biopsy Nodular endocardial infiltrates 
(quilty lesions)
Quilty lesions are associated with increased 
development of coronary vasculopathy at 1 year
Chu  
et al. (66)
285 patients Systematic biopsy Quilty lesions Patients with quilty lesions and no anti-HLA 
class II DSA are more likely to develop graft 
arteriosclerosis at 5 years
Hiemann  
et al. (67)
873 patients  
(9,713 biopsies)
Systematic biopsy Quilty lesions Quilty lesions are associated with an increased 
risk for stenotic microvasculopathy and a poor 
graft outcome
Zakliczynski 
et al. (68)
344 patients Systematic biopsy Quilty lesions Positive correlation between quilty lesions and 
an increased risk of acute rejection but not with 
the occurrence of coronary artery vasculopathy
Frank  
et al. (69)
79 patients  
(37 with DSA)
Biopsy with or without graft dysfunction Ratios of T:B cells and CD4:CD8 
T cells
Patients with DSA have lower CD4:CD8 T cell 
ratio than controls
T:B cell ratio was similar in patients with and 
without DSA
COMPOSITE TISSUE RECIPIENTS
Hautz  
et al. (14)
6 human hand 
recipients  
(187 biopsies)
Systematic and for cause biopsies CD3, CD4, CD8, CD20 PNAd 
stainings
PNAd expression in graft vessels correlated with 
rejection and T- and B-cell infiltration
DSA, donor-specific antibodies; HLA, human leukocyte antigen; HPF, high power field; PNAd, peripheral lymph node addressin; Tx, transplantation.
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are healthy, do not exhibit more infections or malignancies than 
healthy volunteers, and do not display clinical evidence of immune 
incompetence (51). When compared with transplanted patients 
with stable graft function under pharmacologic immunosuppres-
sion, operationally tolerant patients exhibited an increase in both 
absolute number and frequency of total B cells (52). Furthermore, 
two independent microarray analyses of PBMC revealed a higher 
expression of B cell-related genes and their associated molecular 
pathways in tolerant recipients (53, 54). It is therefore conceivable 
that in certain conditions intragraft B cell infiltrate, instead of 
being neutral or deleterious, could actually promote graft survival 
(Figure  2). This theory has been nicely illustrated by murine 
experimental studies that recently reported the formation of 
TLO within tolerated allografts (55–57). If such a local protective 
response can prevent terminal failure of grafts, then not only 
would such samples having “tolerogenic” TLO be absent from 
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the studies based on the analysis of detransplanted grafts but it 
could also explain the difficulty of biopsy-based studies to reach 
an unequivocal conclusion.
CONCLUSION
Transplanted organ expresses donor-specific alloantigens, which 
stimulate a recipient’s immune system. Prevention of acute rejec-
tion of the graft is achieved using a combination of non-specific 
immunosuppressive drugs that can only partially block the allo-
immune effectors. The residual enduring alloimmune response 
promotes immune injuries known as chronic rejection, the main 
cause of late allograft loss. As in other chronic immune diseases, 
immune effectors within chronically rejected allografts progres-
sively organize into functional TLO that display the same micro-
architecture as secondary lymphoid organs, a process known as 
lymphoid neogenesis. Because biopsy-based studies have reached 
conflicting conclusions regarding the pathological significance 
of these TLO, it has been proposed that the presence of TLO in 
rejected grafts is a non-specific response to local inflammation-
induced production of chemokines. While that can indeed some-
times be the case, it should not be excluded that under appropriate 
conditions, lymphoid neogenesis turns non-functional TLO into 
ectopic germinal centers, in which a local aggressive humoral 
immune response can be elicited. Alternatively, functional TLO 
can also regulate immune responses and slow down the destruc-
tion process.
Therefore, we propose that TLO be considered as active play-
ers, able to modulate the kinetics of the natural history of chronic 
rejection. Future works will determine if the versatility of TLO 
can be manipulated to design innovative therapeutic interven-
tions that would improve graft life expectancy.
AUTHOR CONTRIBUTIONS
All the authors listed have made substantial, direct, and intel-
lectual contribution to the work and approved it for publication.
ACKNOWLEDGMENTS
The authors wish to thank the Drs. Maud Rabeyrin and Brigitte 
McGregor, from the Pathology Department of Edouard Herriot 
Hospital (Lyon University Hospital), for their help in collecting 
the pathological samples. The authors wish to thank Mathilde 
Koenig and Servier Medical Art (creativecommons.org/licenses/
by/3.0/fr/) for their contribution to the design of the figure.
FUNDING
OT is supported by the Agence Nationale pour la Recherche 
(ANR-12-PDOC-0019), the Agence de la Biomédecine (AOR-
2013), the Société Françophone de Transplantation, and the 
Etablissement Français du Sang.
REFERENCES
1. Leventhal J, Abecassis M, Miller J, Gallon L, Ravindra K, Tollerud DJ, et al.
Chimerism and tolerance without GVHD or engraftment syndrome in HLA-
mismatched combined kidney and hematopoietic stem cell transplantation.
Sci Transl Med (2012) 4:124ra28. doi:10.1126/scitranslmed.3003509 
2. Cetrulo CL, Drijkoningen T, Sachs DH. Tolerance induction via mixed
chimerism in vascularized composite allotransplantation: is it time for clin-
ical application? Curr Opin Organ Transplant (2015) 20:602–7. doi:10.1097/
MOT.0000000000000248 
3. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl
J Med (2004) 351:2715–29. doi:10.1056/NEJMra033540 
4. Sellarés J, de Freitas DG, Mengel M, Reeve J, Einecke G, Sis B, et  al.
Understanding the causes of kidney transplant failure: the dominant role
of antibody-mediated rejection and nonadherence. Am J Transplant (2012)
12:388–99. doi:10.1111/j.1600-6143.2011.03840.x 
5. Lodhi SA, Lamb KE, Meier-Kriesche HU. Solid organ allograft survival
improvement in the United States: the long-term does not mirror the
dramatic short-term success. Am J Transplant (2011) 11:1226–35.
doi:10.1111/j.1600-6143.2011.03539.x 
6. Kerjaschki D, Regele HM, Moosberger I, Nagy-Bojarski K, Watschinger B,
Soleiman A, et al. Lymphatic neoangiogenesis in human kidney transplants
is associated with immunologically active lymphocytic infiltrates. J Am Soc 
Nephrol (2004) 15:603–12. doi:10.1097/01.ASN.0000113316.52371.2E 
7. Thaunat O, Field A-C, Dai J, Louedec L, Patey N, Bloch M-F, et al. Lymphoid 
neogenesis in chronic rejection: evidence for a local humoral alloimmune
response. Proc Natl Acad Sci U S A (2005) 102:14723–8. doi:10.1073/
pnas.0507223102 
8. Thaunat O, Patey N, Caligiuri G, Gautreau C, Mamani-Matsuda M, Mekki Y, 
et al. Chronic rejection triggers the development of an aggressive intragraft 
immune response through recapitulation of lymphoid organogenesis.
J Immunol (2010) 185:717–28. doi:10.4049/jimmunol.0903589 
9. Thaunat O, Patey N, Morelon E, Michel J-B, Nicoletti A. Lymphoid neogenesis 
in chronic rejection: the murderer is in the house. Curr Opin Immunol (2006) 
18:576–9. doi:10.1016/j.coi.2006.07.006 
10. Thaunat O, Nicoletti A. Lymphoid neogenesis in chronic rejection. Curr 
Opin Organ Transplant (2008) 13:16–9. doi:10.1097/MOT.0b013e328
2f3df15 
11. Wehner JR, Fox-Talbot K, Halushka MK, Ellis C, Zachary AA, Baldwin WM. B 
cells and plasma cells in coronaries of chronically rejected cardiac transplants. 
Transplantation (2010) 89:1141–8. doi:10.1097/TP.0b013e3181d3f271 
12. Sato M, Hirayama S, Hwang DM, Lara-Guerra H, Wagnetz D, Waddell TK,
et  al. The role of intrapulmonary de novo lymphoid tissue in obliterative
bronchiolitis after lung transplantation. J Immunol (2009) 182:7307–16.
doi:10.4049/jimmunol.0803606 
13. Kanitakis J, Karayannopoulou G, Lanzetta M, Petruzzo P. Graft vasculopathy 
in the skin of a human hand allograft: implications for diagnosis of rejection of 
vascularized composite allografts. Transpl Int (2014) 27:e118–23. doi:10.1111/
tri.12399 
14. Hautz T, Zelger BG, Nasr IW, Mundinger GS, Barth RN, Rodriguez ED, et al. 
Lymphoid neogenesis in skin of human hand, nonhuman primate, and rat
vascularized composite allografts. Transpl Int (2014) 27:966–76. doi:10.1111/
tri.12358 
15. Thaunat O, Badet L, Dubois V, Kanitakis J, Petruzzo P, Morelon E.
Immunopathology of rejection: do the rules of solid organ apply to vascu-
larized composite allotransplantation? Curr Opin Organ Transplant (2015)
20:596–601. doi:10.1097/MOT.0000000000000242 
16. Dieu-Nosjean M-C, Giraldo NA, Kaplon H, Germain C, Fridman WH,
Sautès-Fridman C. Tertiary lymphoid structures, drivers of the anti-tumor
responses in human cancers. Immunol Rev (2016) 271:260–75. doi:10.1111/
imr.12405 
17. Pitzalis C, Jones GW, Bombardieri M, Jones SA. Ectopic lymphoid-like
structures in infection, cancer and autoimmunity. Nat Rev Immunol (2014)
14:447–62. doi:10.1038/nri3700 
168
Koenig and Thaunat Lymphoid Neogenesis in Transplanted Organs
Frontiers in Immunology | www.frontiersin.org
18. Randall TD, Carragher DM, Rangel-Moreno J. Development of secondary
lymphoid organs. Annu Rev Immunol (2008) 26:627–50. doi:10.1146/annurev.
immunol.26.021607.090257 
19. Van de Pavert SA, Mebius RE. New insights into the development of lymphoid 
tissues. Nat Rev Immunol (2010) 10:664–74. doi:10.1038/nri2832 
20. Guedj K, Khallou-Laschet J, Clement M, Morvan M, Gaston A-T, Fornasa G, 
et al. M1 macrophages act as LTβR-independent lymphoid tissue inducer cells 
during atherosclerosis-related lymphoid neogenesis. Cardiovasc Res (2014)
101:434–43. doi:10.1093/cvr/cvt263 
21. Lochner M, Ohnmacht C, Presley L, Bruhns P, Si-Tahar M, Sawa S, et al.
Microbiota-induced tertiary lymphoid tissues aggravate inflammatory disease 
in the absence of RORgamma t and LTi cells. J Exp Med (2011) 208:125–34.
doi:10.1084/jem.20100052 
22. Columba-Cabezas S, Griguoli M, Rosicarelli B, Magliozzi R, Ria F, Serafini B, 
et  al. Suppression of established experimental autoimmune encephalomy-
elitis and formation of meningeal lymphoid follicles by lymphotoxin beta
receptor-Ig fusion protein. J Neuroimmunol (2006) 179:76–86. doi:10.1016/
j.jneuroim.2006.06.015 
23. Motallebzadeh R, Rehakova S, Conlon TM, Win TS, Callaghan CJ, Goddard M, 
et al. Blocking lymphotoxin signaling abrogates the development of ectopic
lymphoid tissue within cardiac allografts and inhibits effector antibody
responses. FASEB J (2012) 26:51–62. doi:10.1096/fj.11-186973 
24. Ware CF, Crowe PD, Grayson MH, Androlewicz MJ, Browning JL. Expression 
of surface lymphotoxin and tumor necrosis factor on activated T, B, and
natural killer cells. J Immunol (1992) 149:3881–8. 
25. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfam-
ilies: integrating mammalian biology. Cell (2001) 104:487–501. doi:10.1016/
S0092-8674(01)00237-9 
26. Lee Y, Chin RK, Christiansen P, Sun Y, Tumanov AV, Wang J, et al. Recruitment 
and activation of naive T cells in the islets by lymphotoxin beta receptor- 
dependent tertiary lymphoid structure. Immunity (2006) 25:499–509.
doi:10.1016/j.immuni.2006.06.016 
27. Krams SM, Falco DA, Villanueva JC, Rabkin J, Tomlanovich SJ, Vincenti F,
et al. Cytokine and T cell receptor gene expression at the site of allograft rejec-
tion. Transplantation (1992) 53:151–6. doi:10.1097/00007890-199201000-
00031 
28. Peters A, Pitcher LA, Sullivan JM, Mitsdoerffer M, Acton SE, Franz B, et al.
Th17 cells induce ectopic lymphoid follicles in central nervous system tissue
inflammation. Immunity (2011) 35:986–96. doi:10.1016/j.immuni.2011.
10.015 
29. Fleige H, Ravens S, Moschovakis GL, Bölter J, Willenzon S, Sutter G, et al.
IL-17-induced CXCL12 recruits B cells and induces follicle formation in
BALT in the absence of differentiated FDCs. J Exp Med (2014) 211:643–51.
doi:10.1084/jem.20131737 
30. Rangel-Moreno J, Carragher DM, de la Luz Garcia-Hernandez M, Hwang
JY, Kusser K, Hartson L, et al. The development of inducible bronchus-as-
sociated lymphoid tissue depends on IL-17. Nat Immunol (2011) 12:639–46.
doi:10.1038/ni.2053 
31. Deteix C, Attuil-Audenis V, Duthey A, Patey N, McGregor B, Dubois V,
et al. Intragraft Th17 infiltrate promotes lymphoid neogenesis and hastens
clinical chronic rejection. J Immunol (2010) 184:5344–51. doi:10.4049/
jimmunol.0902999 
32. Jones GW, Bombardieri M, Greenhill CJ, McLeod L, Nerviani A, Rocher-Ros 
V, et al. Interleukin-27 inhibits ectopic lymphoid-like structure development 
in early inflammatory arthritis. J Exp Med (2015) 212:1793–802. doi:10.1084/
jem.20132307 
33. Thaunat O, Graff-Dubois S, Fabien N, Duthey A, Attuil-Audenis V, Nicoletti 
A, et  al. A stepwise breakdown of B-cell tolerance occurs within renal
allografts during chronic rejection. Kidney Int (2012) 81:207–19. doi:10.1038/
ki.2011.317 
34. Thaunat O, Kerjaschki D, Nicoletti A. Is defective lymphatic drainage a trigger 
for lymphoid neogenesis? Trends Immunol (2006) 27:441–5. doi:10.1016/j.
it.2006.08.003 
35. Thaunat O, Graff-Dubois S, Brouard S, Gautreau C, Varthaman A, Fabien N, 
et  al. Immune responses elicited in tertiary lymphoid tissues display
distinctive features. PLoS One (2010) 5:e11398. doi:10.1371/journal.pone.
0011398 
36. Dragun D, Müller DN, Bräsen JH, Fritsche L, Nieminen-Kelhä M,
Dechend  R, et  al. Angiotensin II type 1-receptor activating antibodies in
renal-allograft rejection. N Engl J Med (2005) 352:558–69. doi:10.1056/NEJ
Moa035717 
37. Sicard A, Chen C-C, Morelon E, Thaunat O. Alloimmune-induced intragraft 
lymphoid neogenesis promotes B-cell tolerance breakdown that accelerates
chronic rejection. Curr Opin Organ Transplant (2016) 21:368–74. doi:10.1097/
MOT.0000000000000329 
38. Carrasco YR, Batista FD. B cell recognition of membrane-bound antigen:
an exquisite way of sensing ligands. Curr Opin Immunol (2006) 18:286–91.
doi:10.1016/j.coi.2006.03.013 
39. Sarwal M, Chua M-S, Kambham N, Hsieh S-C, Satterwhite T, Masek M,
et al. Molecular heterogeneity in acute renal allograft rejection identified by
DNA microarray profiling. N Engl J Med (2003) 349:125–38. doi:10.1056/
NEJMoa035588 
40. Zarkhin V, Kambham N, Li L, Kwok S, Hsieh S-C, Salvatierra O, et  al.
Characterization of intra-graft B cells during renal allograft rejection. Kidney 
Int (2008) 74:664–73. doi:10.1038/ki.2008.249 
41. Nasr IW, Reel M, Oberbarnscheidt MH, Mounzer RH, Baddoura FK,
Ruddle NH, et al. Tertiary lymphoid tissues generate effector and memory
T cells that lead to allograft rejection. Am J Transplant (2007) 7:1071–9.
doi:10.1111/j.1600-6143.2007.01756.x 
42. Lund FE, Randall TD. Effector and regulatory B cells: modulators of
CD4+ T cell immunity. Nat Rev Immunol (2010) 10:236–47. doi:10.1038/
nri2729 
43. Harris DP, Haynes L, Sayles PC, Duso DK, Eaton SM, Lepak NM, et  al.
Reciprocal regulation of polarized cytokine production by effector B and
T cells. Nat Immunol (2000) 1:475–82. doi:10.1038/82717 
44. Menard LC, Minns LA, Darche S, Mielcarz DW, Foureau DM, Roos D, et al. 
B cells amplify IFN-gamma production by T cells via a TNF-alpha-mediated 
mechanism. J Immunol (2007) 179:4857–66. doi:10.4049/jimmunol.179.
7.4857 
45. Wojciechowski W, Harris DP, Sprague F, Mousseau B, Makris M, Kusser
K, et al. Cytokine-producing effector B cells regulate type 2 immunity to
H. polygyrus. Immunity (2009) 30:421–33. doi:10.1016/j.immuni.2009.
01.006 
46. Thaunat O, Legendre C, Morelon E, Kreis H, Mamzer-Bruneel M-F. 
To biopsy or not to biopsy? Should we screen the histology of stable renal
grafts? Transplantation (2007) 84:671–6. doi:10.1097/01.tp.0000282870.
71282.ed 
47. Rosser EC, Mauri C. Regulatory B cells: origin, phenotype, and function.
Immunity (2015) 42:607–12. doi:10.1016/j.immuni.2015.04.005 
48. Fillatreau S, Gray D, Anderton SM. Not always the bad guys: B cells as regula-
tors of autoimmune pathology. Nat Rev Immunol (2008) 8:391–7. doi:10.1038/
nri2315 
49. Bouaziz J-D, Yanaba K, Tedder TF. Regulatory B cells as inhibitors of
immune responses and inflammation. Immunol Rev (2008) 224:201–14.
doi:10.1111/j.1600-065X.2008.00661.x 
50. Thaunat O, Morelon E, Defrance T. Am“B”valent: anti-CD20 antibodies
unravel the dual role of B cells in immunopathogenesis. Blood (2010)
116:515–21. doi:10.1182/blood-2010-01-266668 
51. Brouard S, Pallier A, Renaudin K, Foucher Y, Danger R, Devys A, et  al.
The natural history of clinical operational tolerance after kidney transplan-
tation through twenty-seven cases. Am J Transplant (2012) 12:3296–307.
doi:10.1111/j.1600-6143.2012.04249.x 
52. Pallier A, Hillion S, Danger R, Giral M, Racapé M, Degauque N, et  al.
Patients with drug-free long-term graft function display increased numbers
of peripheral B cells with a memory and inhibitory phenotype. Kidney Int 
(2010) 78:503–13. doi:10.1038/ki.2010.162 
53. Newell KA, Asare A, Kirk AD, Gisler TD, Bourcier K, Suthanthiran M,
et  al. Identification of a B cell signature associated with renal transplant
tolerance in humans. J Clin Invest (2010) 120:1836–47. doi:10.1172/
JCI39933 
54. Sagoo P, Perucha E, Sawitzki B, Tomiuk S, Stephens DA, Miqueu P, et al.
Development of a cross-platform biomarker signature to detect renal trans-
plant tolerance in humans. J Clin Invest (2010) 120:1848–61. doi:10.1172/
JCI39922 
169
Koenig and Thaunat Lymphoid Neogenesis in Transplanted Organs
Frontiers in Immunology | www.frontiersin.org
55. Brown K, Sacks SH, Wong W. Tertiary lymphoid organs in renal allografts
can be associated with donor-specific tolerance rather than rejection. Eur 
J Immunol (2011) 41:89–96. doi:10.1002/eji.201040759 
56. Le Texier L, Thebault P, Lavault A, Usal C, Merieau E, Quillard T, et  al.
Long-term allograft tolerance is characterized by the accumulation of B
cells exhibiting an inhibited profile. Am J Transplant (2011) 11:429–38.
doi:10.1111/j.1600-6143.2010.03336.x 
57. Li W, Bribriesco AC, Nava RG, Brescia AA, Ibricevic A, Spahn JH, et al. Lung 
transplant acceptance is facilitated by early events in the graft and is associated 
with lymphoid neogenesis. Mucosal Immunol (2012) 5:544–54. doi:10.1038/
mi.2012.30 
58. Hippen BE, DeMattos A, Cook WJ, Kew CE, Gaston RS. Association
of CD20+ infiltrates with poorer clinical outcomes in acute cellu-
lar rejection of renal allografts. Am J Transplant (2005) 5:2248–52.
doi:10.1111/j.1600-6143.2005.01009.x
59. Kayler LK, Lakkis FG, Morgan C, Basu A, Blisard D, Tan HP, et al. Acute
cellular rejection with CD20-positive lymphoid clusters in kidney transplant 
patients following lymphocyte depletion. Am J Transplant (2007) 7:949–54.
doi:10.1111/j.1600-6143.2007.01737.x
60. Bagnasco SM, Tsai W, Rahman MH, Kraus ES, Barisoni L, Vega R, et al. CD20-
positive infiltrates in renal allograft biopsies with acute cellular rejection are
not associated with worse graft survival. Am J Transplant (2007) 7:1968–73.
doi:10.1111/j.1600-6143.2007.01885.x
61. Scheepstra C, Bemelman FJ, van der Loos C, Rowshani AT, van Donselaar-Van 
der Pant KAMI, Idu MM, et al. B cells in cluster or in a scattered pattern do
not correlate with clinical outcome of renal allograft rejection. Transplantation
(2008) 86:772–8. doi:10.1097/TP.0b013e3181860a74
62. Hwang HS, Song JH, Hyoung BJ, Lee SY, Jeon YJ, Kang SH, et al. Clinical
impacts of CD38+ B cells on acute cellular rejection with CD20+ B
cells in renal allograft. Transplantation (2010) 89:1489–95. doi:10.1097/
TP.0b013e3181dd35b8 
63. Martin L, Charon-Barra C, Bocrie O, Guignier F, D’Athis P, Dautin G, et al.
Detection of plasma cells, C4d deposits and donor-specific antibodies on
sequential graft biopsies of renal transplant recipients with chronic dysfunc-
tion. Transpl Immunol (2010) 22:110–4. doi:10.1016/j.trim.2009.11.001
64. Abbas K, Mubarak M, Zafar MN, Aziz T, Abbas H, Muzaffar R, et al. Plasma 
cell-rich acute rejections in living-related kidney transplantation: a clinico-
pathological study of 50 cases. Clin Transplant (2015) 29:835–41. doi:10.1111/
ctr.12589
65. Yamani MH, Ratliff NB, Starling RC, Tuzcu EM, Yu Y, Cook DJ, et al. Quilty 
lesions are associated with increased expression of vitronectin receptor
(alphavbeta3) and subsequent development of coronary vasculopathy. J Heart 
Lung Transplant (2003) 22:687–90. doi:10.1016/S1053-2498(02)01181-6
66. Chu KE, Ho EK, de la Torre L, Vasilescu ER, Marboe CC. The relationship of 
nodular endocardial infiltrates (Quilty lesions) to survival, patient age, anti-
HLA antibodies, and coronary artery disease following heart transplantation. 
Cardiovasc Pathol (2005) 14:219–24. doi:10.1016/j.carpath.2005.03.009 
67. Hiemann NE, Knosalla C, Wellnhofer E, Lehmkuhl HB, Hetzer R, Meyer R.
Quilty indicates increased risk for microvasculopathy and poor survival after 
heart transplantation. J Heart Lung Transplant (2008) 27:289–96. doi:10.1016/j.
healun.2007.11.573
68. Zakliczynski M, Nozynski J, Konecka-Mrowka D, Pyka L, Trybunia D,
Swierad M, et al. Quilty effect correlates with biopsy-proven acute cellular
rejection but does not predict transplanted heart coronary artery vasculopathy. 
J Heart Lung Transplant (2009) 28:255–9. doi:10.1016/j.healun.2008.12.011
69. Frank R, Dean SA, Molina MR, Kamoun M, Lal P. Correlations of lymphocyte 
subset infiltrates with donor-specific antibodies and acute antibody-mediated 
rejection in endomyocardial biopsies. Cardiovasc Pathol (2015) 24:168–72.
doi:10.1016/j.carpath.2014.11.001 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2016 Koenig and Thaunat. This is an open-access article distributed 
under the terms of the Creative Commons Attribution License (CC BY). The use, 
distribution or reproduction in other forums is permitted, provided the original 
author(s) or licensor are credited and that the original publication in this journal 
is cited, in accordance with accepted academic practice. No use, distribution or 
reproduction is permitted which does not comply with these terms.
170
 
ORIGINAL RESEARCH
published: 19 February 2018
doi: 10.3389/fimmu.2018.00275
Frontiers in Immunology | www.frontiersin.org
Edited by: 
Zhenhua Dai, 
Guangdong Province Traditional 
Chinese Medical Hospital, China
Reviewed by: 
Lloyd Joseph Andrew D’Orsogna, 
Fiona Stanley Hospital, Australia 
Federica Casiraghi, 
Istituto Di Ricerche Farmacologiche 
Mario Negri, Italy
*Correspondence:
Olivier Thaunat 
olivier.thaunat@inserm.fr
Specialty section: 
This article was submitted to 
Alloimmunity and Transplantation, 
a section of the journal 
Frontiers in Immunology
Received: 28 August 2017
Accepted: 30 January 2018
Published: 19 February 2018
Citation: 
Chen C-C, Koenig A, Saison C, 
Dahdal S, Rigault G, Barba T, 
Taillardet M, Chartoire D, Ovize M, 
Morelon E, Defrance T and 
Thaunat O (2018) CD4+ T Cell Help 
Is Mandatory for Naive and Memory 
Donor-Specific Antibody Responses: 
Impact of Therapeutic 
Immunosuppression. 
Front. Immunol. 9:275. 
doi: 10.3389/fimmu.2018.00275
CD4+ T Cell Help Is Mandatory
for Naive and Memory Donor-
Specific Antibody Responses: Impact 
of Therapeutic Immunosuppression
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Cardioprotection Laboratory, Hospices Civils de Lyon, CIC, Bron, France, 3 Edouard Herriot University Hospital, Department 
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Antibody-mediated rejection is currently the leading cause of transplant failure. Prevailing 
dogma predicts that B  cells differentiate into anti-donor-specific antibody (DSA)-
producing plasma cells only with the help of CD4+ T cells. Yet, previous studies have 
shown that dependence on helper T  cells decreases when high amounts of protein 
antigen are recruited to the spleen, two conditions potentially met by organ transplanta-
tion. This could explain why a significant proportion of transplant recipients develop DSA 
despite therapeutic immunosuppression. Using murine models, we confirmed that heart 
transplantation, but not skin grafting, is associated with accumulation of a high quan-
tity of alloantigens in recipients’ spleen. Nevertheless, neither naive nor memory DSA 
responses could be observed after transplantation of an allogeneic heart into recipients 
genetically deficient for CD4+ T cells. These findings suggest that DSA generation rather 
result from insufficient blockade of the helper function of CD4+ T cells by therapeutic 
immunosuppression. To test this second theory, different subsets of circulating T cells: 
CD8+, CD4+, and T follicular helper [CD4+CXCDR5+, T follicular helper cells (Tfh)], 
were analyzed in 9 healthy controls and 22 renal recipients. In line with our hypothesis, 
we observed that triple maintenance immunosuppression (CNI + MMF + steroids) effi-
ciently blocked activation-induced upregulation of CD25 on CD8+, but not on CD4+ 
T cells. Although the level of expression of CD40L and ICOS was lower on activated Tfh 
of immunosuppressed patients, the percentage of CD40L-expressing Tfh was the same 
than control patients, as was Tfh production of IL21. Induction therapy with antithymo-
cyte globulin (ATG) resulted in prolonged depletion of Tfh and reduction of CD4+ T cells 
number with depleting monoclonal antibody in murine model resulted in exponential 
decrease in DSA titers. Furthermore, induction with ATG also had long-term beneficial 
influence on Tfh function after immune reconstitution. We conclude that CD4+ T cell help 
is mandatory for naive and memory DSA responses, making Tfh cells attractive targets 
for improving the prevention of DSA generation and to prolong allograft survival. Waiting 
for innovative treatments to be translated into the clinical field ATG induction seems to 
currently offer the best clinical prospect to achieve this goal.
Keywords: transplantation, transplant immunology, alloimmune response, antibody-mediated rejection, donor-
specific antibody, immunosuppression
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INTRODUCTION
Progress in therapeutic immunosuppression achieved over the 
last decades has dramatically reduced the incidence of T  cell-
mediated rejection, which is no longer considered as a significant 
cause of transplant loss (1).
Unexpectedly, this progress has barely impacted the half-life 
of transplanted organs that has stagnated over the same period 
(2). These disappointing results are due to the lack of impact 
of modern immunosuppressive drugs on the humoral arm of 
recipient’s alloimmune response (3). Indeed, while under modern 
immunosuppression regimen, less than 10% of kidney recipients 
experience an acute cellular rejection episode, the prevalence 
of de novo anti-donor antibodies [donor specific antibody 
(DSA)] is estimated 10–20% 5 years posttransplantation (4, 5). 
Consequently, antibody-mediated rejection (AMR) is now widely 
recognized as the first cause of transplant failure (6–10).
Immunosuppressive drugs used in maintenance therapy 
mainly act on T cells (3, 11). However, from an immunological 
point of view, it is surprising that the strict control of cellular (i.e., 
T  cell) immune response obtained with modern immunosup-
pressive armamentarium did not translate into a more profound 
impairment of the generation of DSA. Because of their protein 
nature, HLA molecules are indeed expected to behave as typical 
T-cell-dependent antigens, which means that donor-HLA specific 
B  cells should be critically dependent upon the help of CD4+
T cells to differentiate into DSA-producing plasma cells (12). This 
apparent paradox suggests that, in transplantation, some DSA
responses might be elicited without the help of CD4+ T cells.
This iconoclastic hypothesis is supported by experimental 
findings from the group of Zinkernagel that reported the gen-
eration of neutralizing antibody against vesicular stomatitis virus 
in CD4+ T  cell-depleted mice (13). Interestingly, dependence 
on T  cell help in this model went decreasing when increasing 
amounts of protein antigens were recruited to the spleen, leading 
the authors to conclude that both antigen dose and localization 
in secondary lymphoid organs are key to circumvent T cell help 
for induction of B cell responses (13).
It is noteworthy that organ transplantation could meet these 
two conditions since donor specific HLA molecules are highly 
expressed by the endothelial cells of graft vasculature, which is 
directly connected to recipient’s vessels.
We, therefore, undertook this study to test whether transplant 
recipients could generate DSA in the absence of CD4+ T cell help.
MATERIALS AND METHODS
Human Study
To determine the capacity of T  cells to get activated under 
immunosuppression, we prospectively enrolled 22 patients 
who underwent kidney transplantation at the Lyon University 
Hospital between 2015 and 2016. Inclusion criteria were (i) first 
transplantation (kidney or kidney–pancreas), (ii) no anti-HLA 
antibody at the time of the transplantation. These 22 patients were 
compared to 9 healthy controls.
Whole blood samples were collected by venepuncture 
into heparin-containing vials, once in controls and before 
transplantation and at 3 months and 1 year after transplantation 
for transplanted patients.
Peripheral blood mononuclear cells (PBMCs) and plasma 
were isolated by Ficoll gradient centrifugation. Plasma was then 
centrifuged at 4,000  g for 10  min to remove platelets. PBMCs 
were plated 1 h in petri dishes to discard adherent cells (mono-
cytes) and then 1 × 106 non-adherent cells were cultured 24 h 
at 37°C in 5% CO2 in 1 mL of patient’s own plasma (containing 
or not immunosuppressive drugs) in the presence or absence of 
human T-activator CD3/CD28 beads (Gibco Dynabeads®). For 
IL21 staining, 1  μL of Brefeldin A (BD Bioscience) was added 
for the last 5 h of the culture. After 24 h of culture, Dynabeads 
were removed with a magnet and PBMCs were analyzed by flow 
cytometry as detailed below.
This study was carried out in accordance with French legisla-
tion on biomedical research. All subjects gave written informed 
consent in accordance with the Declaration of Helsinki. The 
protocol and the biocollection were authorized by the Ministry 
of Research and the Rhône-Alpes Regional Health Agency (#AC-
2011-1375 and #AC-2016-2706).
Mice
Wild-type C57BL/6 (H-2b) and BALB/c (H-2d) mice were 
purchased from Charles River Laboratories (Saint Germain sur 
l’Arbresle, France).
C57BL/6-Tg(CAG-EGFP)1Osb/j (GFP) mice were purchased 
from The Jackson Laboratory (Bar Harbor, ME, USA).
MHC II knock out (AßKO) mice on C57BL/6 genetic back-
ground were provided by Dr. Benoist and Mathis (Boston, MA, 
USA) (14).
HLA A2 transgenic mice on C57BL/6 genetic background (15) 
were kindly provided by Dr Lemonnier (Paris, France).
RAG2 Knock Out (RAG2 KO) mice on C57BL/6 background 
came from CDTA (Cryopreservation Distribution Typage et 
Archivage animal, Orléans, France). Mice 8–15 weeks of age were 
used and maintained under specific pathogen-free conditions 
in our animal facility: Plateau de Biologie Expérimentale de la 
Souris (PBES, ENS Lyon, France).
This study was carried out in accordance with the French 
legislation on live animal experimentation. The protocol was 
approved both by local “CECCAPP” (http://www.sfr-biosciences.
fr/ethique/experimentation-animale/ceccapp) and national AFiS 
ethical committees (#02870.01).
Models of Allosensitization
Skin Grafting
Skin grafting was performed using the method described 
by Billingham et  al. (16). Briefly, a piece of skin graft about 
1 cm × 1 cm in size was harvested from the trunk of donor and 
it was then implanted on the back of the recipient, fixed by silk 
sutures, and protected for 7 days with bandage.
Heterotopic Heart Transplantation
Cervical heterotopic heart transplantations were performed as 
in Chen (17). Briefly, cardiac allografts were transplanted into 
subcutaneous space of right neck. Anastomoses were performed 
by connecting end-to-end the ascending aorta of the graft with 
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the recipient’s common carotid artery and by pulling the main 
pulmonary artery with the external jugular vein.
Intravenous Allogeneic Cell Injection
To mimic the allosensitization that results from solid organ trans-
plantation, 10 × 106 splenocytes from HLA A2 mice were injected 
intravenously to wild-type C57BL/6. In contrast with subcutane-
ous injection, IV injection of allogeneic splenocytes indeed allows 
delivering a high quantity of alloantigen to the spleen of recipient 
(Figure S1A in Supplementary Material) and triggered DSA 
generation (Figure S1B in Supplementary Material).
CD4+ T Cell Depletion In Vivo
Seminal experimental studies addressing the role of helper T cells 
in rejection in vivo have relied on the treatment of wild-type 
(WT) mice with depleting anti-CD4 monoclonal antibodies 
(mAbs) (18, 19).
In the present study, we used IP administration of GK1.5, a 
rat IgG2b anti-murine CD4 mAb (20), commonly used to induce 
CD4+ T cell depletion in mice (21).
Cell Lines
The human erythroleukemia cell line K562 (22) lacking expres-
sion of all MHC I and II molecules and the single antigen 
expressing cell Line (SAL) A2, a K562 cell line transfected with 
plasmid coding for HLA A2 and selection genes for the resistance 
to neomycin and ampicillin (23) were kindly provided by Dr. 
Doxiadis (Leiden, The Netherlands).
K562 cells were cultured in RPMI-1640 (Invitrogen) comple-
mented with fetal calf serum 10% (Dutscher), l-Glutamine 2 mM 
(Invitrogen), penicillin 100  U/mL, streptomycin 100  μM, and 
HEPES 25 mM (Invitrogen).
Single antigen expressing cell line A2 cells were cultured in the 
same medium as K562 complemented with G418, a neomycin 
derivative (Invitrogen) at the concentration of 1.75 mg/mL.
Flow Cytometry
After a 24 h culture, human PBMCs were stained 30 min at room 
temperature in the dark with the relevant fluorescent antibodies 
directed against CD3 (UCHT1), CD4 (SK3), CD8 (SK1), CD25 
(2  A3), CXCR5 (RF8B2), CD40L (TRAP1), IL21 (3A3-N2.1), 
ICOS (ISA-3); all from BD Biosciences except ISA-3 from ebiosci-
ence. Cells were then stained with and a viability dye LIVE/DEAD 
Aqua (Invitrogen) according to the manufacturer’s instructions 
and fixed with Cytofix/Cytoperm® fixation/permeabilization kit 
(BD Biosciences) before analysis.
A FACS ARIA II flow cytometer was used for flow cytometry. 
Data were analysed with BD FACS Diva software (BD Biosciences).
Murine single-cell suspensions from spleen, lymph nodes, 
thymus, or blood were incubated with a blocking anti-mouse 
Fc receptor antibody (2.4G2, home-made hybrydoma). Cells 
were then incubated at 4°C with relevant fluorescent antibodies: 
CD3 (145-2C11), CD4 (RM4-4), CD8 (53-6.7) and CD19 (1D3) 
(all from BD Biosciences). Before analysis by flow cytometry, 
DAPI (4′,6-diamidino-2-phenylindole dihydrochloride, Sigma-
Aldrich) was added to the cell suspension to exclude dead cells. 
Samples acquisitions were made on a BD LSR II flow cytometer 
(BD Biosciences). Data were analyzed with FlowJo software (Tree 
Star).
Cell Sorting and Adoptive Transfer of  
B Lymphocytes
For isolation of B lymphocytes, splenocytes from immunized mice 
were stained with phycoerythrin (PE)-conjugated antibodies 
against CD3ε (145-2C11), CD4 (RM4-5), CD8 (53-6.7), CD11b 
(M1/70), CD11c (HL3), NK-1.1 (PK136), Ter119/Erythroid cells 
(TER-119), CD117 (2B8), and PerCP-Cy5.5 conjugated antibody 
against B220 (RA3-6B2) (all from BD Biosciences). After stain-
ing, cells were negatively separated by LD magnetic columns with 
anti-PE Microbeads labeling (Miltenyi Biotec). The separated cell 
suspensions underwent cell sorting by using a BD FACS Aria cell 
sorter (BD Biosciences) to collect PE negative and PerCP-Cy5.5 
positive cells. 5 × 106 purified B lymphocytes were transferred to 
RAG2 KO mice by intravenous injection.
Detection of Anti-HLA A2 Antibodies
1 × 105 SAL A2 or K562 (negative control) cells were incubated 
with mice sera diluted at 1/1,000 for 30 min at 4°C. After washing, 
cells were stained with PE-conjugated anti-light chain antibody 
(187.1) (BD Biosciences) and analyzed by flow cytometry. To rule 
out the possibility to miss a low titer of anti-HLA A2 antibodies, 
all negative sera were systematically screened again at a 1/100 
dilution. The titer of anti-HLA A2 antibodies at each time point 
(dx) was calculated with the following formula:
normalised DSA titer
MFI dx MFI dx
MFI d MFI
SAL K
SAL K
=
( ) ( )
( )
/
/
562
560 2 0d( )
The normalized DSA titer, therefore, reflects the fold 
increases of specific signal over the baseline (measured before 
transplantation).
Detection of Anti-HLA A2 Specific B Cells 
by ELISpot Assay
Single-cell suspensions were stained with PE-conjugated 
anti-B220 (RA3-6B2) (BD Biosciences). B  cells were positively 
separated by passing through LS magnetic column with anti-PE 
microbeads labeling. After separation, cells underwent in vitro 
activation with a mixture of the TLR7/8 ligand R848 at 1 μg/mL 
and recombinant mouse IL-2 at 10 ng/mL (Mabtech) for 72 h. 
Then, cells were cultured for 24 h in the 96-well plates precoated 
with capture anti-IgG antibody (ELISpotPLUS mouse IgG kit, 
Mabtech). Detection of spots was performed by adding either 
anti-IgG biotinylated detection antibody (Mabtech) or biotin-
labeled HLA-A*02:01 Pentamer (ProImmune) for 2 h, followed 
by incubation with streptavidin-ALP (Mabtech) for 1  h and 
development by BCIP/NBT-plus substrate (Mabtech).
Detection of Anti-NP Antibodies by ELISA
For some experiments, mice were immunized intraperitoneally 
with 75 μg NP-KLH mixed with 100 μL Inject Alum Adjuvant 
(Thermo Scientific, Courtaboeuf, France) or 200 μg NP-Dextran. 
Preimmune sera and sera obtained once a week after immunization 
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FIGURE 1 | Presentation of experimental model. (A) Representative flow cytometry profiles of CD3+ T cells in PBMC and secondary lymphoid organs is shown for 
wild-type C57BL/6 (upper row) and AβKO (lower row) mice. Mean and SD from analysis of 10 animals of each strain are indicated for the % of CD4+ and CD8+ 
T cells. (B) Evolution over time of anti-NP IgG titer (mean ± SD) after immunization with the thymo-dependent model antigen NP-KLH is shown for wild-type 
C57BL/6 (n = 3, dashed line) and AβKO (n = 3, black line). (C) Anti-NP antibody titer was measured by ELISA in the circulation of AβKO mice (n = 3) before and 
every 7 days postimmunization with the thymo-independent model antigen NP-dextran (mean ± SD). (D) Splenocytes from C57BL/6 (negative controls) and HLA 
A2 transgenic mice were incubated with fluorescent-conjugated mice anti-human HLA I monoclonal antibody (mAb) (W6/32). Representative flow cytometry 
histograms are shown. (E) To quantify donor specific antibody (DSA), diluted sera were incubated with K562 or single antigen expressing cell line (SAL)-A2 for 
30 min at 4°C. Cells were washed and incubated with a phycoerythrin (PE)-conjugated anti-light chain mAb before measurement of PE mean fluorescence intensity 
by flow cytometry. Anti-A2 antibody titer was normalized as explained in Section “Materials and Methods.” The normalized DSA titer reflects the fold increases of 
specific signal over the baseline. (F) Representative examples of cytometry profiles obtained after incubation of K562 and SAL-A2 with an anti-A2 immune serum 
are shown.
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were tested for IgM and IgG anti-NP antibodies. Maxisorp plates 
(Nunc) were coated with NP 23-conjugated BSA. Serially diluted 
serum samples were added for 1  h 30 at room temperature. 
Anti-NP IgM and IgG Abs were detected using alkaline phos-
phatase conjugated goat anti-mouse IgM or IgG Abs (1/2,000 
dilution) followed by phosphatase substrate (Sigma-Aldrich). The 
plates were then read at 405 nm/490 nm with an automatic reader 
(Zeiss VERSAmax). OD was converted to concentration based on 
standard curves with sera from C57BL/6 mice immunized with 
NP-KLH using a four-parameter logistic equation (Softmax Pro 
5.3 software; Molecular Devices).
Statistical Analyses
Statistical significance of differences was tested with chi-square 
test for proportions and non-parametric tests for continuous 
variables: Mann–Whitney or Kruskal–Wallis with Dunn’s multi-
ple comparisons for unpaired dataset and Friedman with Dunn’s 
multiple comparisons for paired dataset.
Skin graft survivals were compared using the log-rank test.
The differences between the groups were considered statisti-
cally significant for p < 0.05 and were reported as asterisk symbols 
(*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001).
RESULTS
Presentation of the Experimental Model
AβKO mice, which are genetically modified C57BL/6 mice devoid 
of CD4+ T cells were used as recipients. AβKO mice lack major 
histocompatibility complex class II (MHCII) molecules (14). 
As a result, positive selection of CD4+ T cells can not occur in 
the thymus and AβKO mice show near-complete elimination of 
CD4+ T lymphocytes in the periphery, the lymph nodes, and the 
spleen (Figure 1A). The few remaining detectable CD4+ T cells 
are anyhow unable to provide efficient help to B  cells because 
the latter do not express MHCII. This was demonstrated by the 
complete abrogation of the IgG response to a NP-KLH, a model 
of thymo-dependent antigen (24) (Figure 1B). Importantly, this 
lack of IgG response in AβKO mice was not due to an abnormal 
175
FIGURE 2 | Site of allosensitization and CD4+ T cell help for naive donor-specific antibody response. (A) Skin from C57BL/6 or HLA-A2 transgenic (A2) donor was 
grafted to C57BL/6 or AβKO recipient. Survivals of skin graft were compared between the three groups using Log rank test. (B) A2 skin was grafted to C57BL/6 or 
AβKO recipients. Evolution of normalized donor specific antibody (DSA) titer (mean ± SD) in the circulation of recipients is shown. Log-rank test; **p < 0.01. Skin 
graft or heart transplant from GFP+ transgenic donor was grafted/transplanted to C57BL/6 recipient. (C) The location of draining and non-draining lymph node 
according to the sensitization procedure is shown on the scheme. Two days post-procedure the percentage (D) and absolute number (E) of GFP+ cells was 
enumerated by flow cytometry in the secondary lymphoid organs of recipients (each symbol represents a mice, mean is indicated). (F) A2 heart was transplanted to 
C57BL/6 or AβKO recipients. Evolution of normalized DSA titer (mean ± SD) in the circulation of recipients is shown.
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B  cell compartment since (i) B-lymphocytes occur in normal 
numbers and are capable of terminal differentiation to plasma 
cells in these animals (14), and (ii) we showed that AβKO mice 
indeed generated NP-specific IgM in response to vaccination 
with NP-dextran (Figure  1C), a model of thymo-independent 
antigen (25).
To simplify the monitoring of donor-specific antibody (DSA) 
response in recipient mice we used donors with the same genetic 
background (C57BL/6, H2b) except for the transgenic expression 
of the human MHC I molecule HLA-A2 [kind gift from Dr 
Lemonnier (15); Figure 1D].
In this model, the DSA response, which is exclusively directed 
against the HLA-A2 molecule was easily monitored using single 
antigen-expressing (SAL-A2) cell line [kind gift from Doxiadis 
(23)] and the sensitive and specific flow cross match assay 
(Figures 1E,F), a technique routinely used for the follow-up of 
transplant recipients in the clinic (26).
CD4+ T Cell Help Is Mandatory for Naive
DSA Response
Because AβKO mice have a normal CD8+ T cell compartment 
(Figure 1A), they efficiently rejected an allogeneic A2 skin graft 
with only a slight delay as compared with C57BL/6 WT controls 
(respective mean survival 14.75  ±  1.5 vs 8.75  ±  1.5  days, Log 
Rank: p = 0.0058; Figure 2A).
Donor-specific antibody response was monitored in naive 
recipients grafted with an A2 skin. Anti HLA-A2 alloantibodies 
appeared in the serum of WT recipients between day 7 and 14 post-
transplantation, peaked at day 21, and decreased slowly thereafter 
with the elimination of alloantigens due to the rejection process 
(Figure 2B). No DSA could be detected in the serum of AβKO.
These results confirm the conclusion of Steele et  al. (27) 
who reported that CD4+ T  cells are essential helper cells for 
B  cell alloantibody production in a similar murine model of 
MHC-disparate skin graft rejection. However, in the study by 
Ochsenbein et  al., dependence on T  cell help went decreasing 
when increasing amounts of antigen were recruited to the spleen 
(13). One possibility to explain the lack of DSA response in AβKO 
recipients grafted with A2 skin could be that this procedure 
provides too few alloantigens drained to the spleen of recipients 
(in contrast with transplantation, no vascular anastomosis is per-
formed between the circulations of donor and recipient during 
grafting). To test this hypothesis, C57BL/6 donor mice transgenic 
for the green fluorescent protein (GFP+) were used as donor 
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of skin graft or heart transplant (Figure  2C). The proportion 
(Figure 2D) and absolute number (Figure 2E) of GFP positive 
cells were quantified by flow cytometry at day 2 post-procedure 
in the draining lymph node, a distant non-draining lymph node, 
and the spleen of recipients. After skin grafting, only few GFP+ 
cells were detected, exclusively in the draining lymph node of 
recipient (Figures 2D,E). About 100 times more GFP+ cells were 
found in the draining lymph node of heart recipients. In addition, 
GFP+ cells were also detected in the spleen and the non-draining 
lymph node after heart transplantation (Figure 2D), demonstrat-
ing that alloantigens are drained trough recipient’s circulation 
after transplantation but not after grafting. In fact, when absolute 
numbers were considered, spleen appeared as the main site of 
allosensitization after transplantation (Figure 2E).
Despite these differences in alloantigen dose and localization 
in secondary lymphoid organs of recipients, we could not detect 
any DSA generation after A2 heart transplantation in AβKO 
recipients (Figure 2F). We conclude from this set of experiments 
that DSA generation in naive recipients requires CD4+ T cell help.
CD4+ T Cell Help Is Mandatory for
Memory DSA Response
In contrast with laboratory mice, the immune system of which is 
largely naïve (28), transplanted patients have an immune memory, 
including memory B cells (29). Interestingly, some studies have 
reported that ability of virus-specific memory B cells to secrete 
IgG is independent of cognate or bystander T cell help (30).
Transplantation with an A2 but not a BALB/c heart leads to 
the generation of anti-A2 specific memory B  cells that could 
be readily quantified in recipients’ spleen with ELISpot assay 
(Figure 3A). To determine whether the rechallenge of allospecific 
memory B cells can lead to the generation of DSA in the absence 
of CD4+ T cells, we passively transferred A2- or BALB/c-specific 
memory B  cells to C57BL/6 RAG2 KO recipients (Figure  3B). 
C57BL/6 RAG2 KO mice lack the recombinase necessary for 
TCR and BCR rearrangements and are, therefore, devoid of T 
and B cells (Figure 3C). In addition to the high degree of purity 
achieved when isolating B cells (99.83 ± 0.21%, Figure 3D), we 
ensured that no CD4+ T cell remained in C57BL/6 RAG2 KO 
post-cell transfer by administering anti-CD4 mAb (Figure 3B). 
As expected, B cells (but neither CD4+ nor CD8+ T cells) could 
be detected in the circulation of transferred C57BL/6 RAG2 KO 
animals up to the end of the follow-up period (Figure 3C). Not 
only were B cells detectable in transferred C57BL/6 RAG2 KO 
mice, but A2-specific memory B cells were able to differentiate 
into DSA-producing plasma cells, as demonstrated by ELISpot 
assays conducted with splenocytes harvested 100  days post-
transfer (Figure 3E).
However, and in striking contradiction with our hypothesis, 
the rechallenge of allospecific memory B  cells with A2 heart 
did not lead to the generation of DSA in the absence of CD4+ 
T cells (Figure 3F). The mandatory nature of CD4+ T cell help for 
DSA generation in sensitized recipients was further confirmed 
by demonstrating that co-transfer of purified CD4+ T cells with 
memory B  cells in C57BL/6 RAG2 KO mice was sufficient to 
restore alloantibody response after rechallenge (Figures S1C,D in 
Supplementary Material).
Impact of Maintenance 
Immunosuppression on T Follicular Helper 
Functions in the Clinic
Based on our previous results, it seems clear that DSA genera-
tion, both in naive and sensitized recipients, requires help from 
CD4+ T  cells. The fact that, despite therapeutic immunosup-
pression, 10–20% of transplant recipients develop de novo 
DSA within 5  years posttransplantation (3–5), suggests that 
immunosuppressive drugs do not efficiently block CD4+ T cell 
help to B cells.
To test this hypothesis, we prospectively monitored circulat-
ing T cells in 22 immunosuppressed renal recipients, 3 months 
(3 M) and 12 months (12 M) posttransplantation (Figure 4A). 
Clinical characteristics of the cohort are presented Table 1 and 
the trough levels of maintenance immunosuppressive drugs are 
shown Figure 4B. Immunosuppressed patients were compared to 
9 age- and sex-matched healthy controls. Indeed, comparing the 
evolution of T cell parameters before versus after transplantation 
for the same patients would not have allowed to disentangle the 
impact of immunosuppressive drugs from that of the correc-
tion of end stage renal failure, which has a major impact on the 
immune system (31).
To test whether maintenance immunosuppressive regimen is 
able to block T cells activation, PBMCs of patients were cultured 
with anti-CD3/CD28 microbeads in the presence of patient’s own 
plasma (Figure  4A). Surface expression of the α chain of IL-2 
receptor (CD25) was used to monitor activation of CD8+ and 
CD4+ T cells (32). As expected, in vitro stimulation of T cells from 
healthy controls led to significant upregulation of CD25 expres-
sion on both CD4+ and CD8+ subsets (Figure 4C). Interestingly, 
while the presence of plasma containing immunosuppressive 
drugs significantly reduced activation-induced upregulation of 
CD25 on CD8+ T cells, it had no significant impact on CD4+ 
T cells (Figure 4C).
To further document the lack of impact of maintenance immu-
nosuppression on thymo-dependent humoral immune response, 
we focused our analysis on T follicular helper cells (Tfh), a CD4+ 
T  cell subset specialized for providing help to B  cells (33, 34). 
Recent studies have indeed demonstrated that CD4+CXCR5+ 
human blood T cells represent the circulating compartment of 
Tfh (35), and we confirmed that CD3+CD4+CXCR5+Tfh could 
be detected in the circulation of both controls and transplanted 
patients (Figure 4A).
T follicular helper cells provide help to B  cells through a 
variety of molecules that are either expressed on their surface: 
CD40L (36) and ICOS (37), or are secreted: IL-21, a type I 
cytokine recognized as the most potent driver of B cell terminal 
differentiation (38, 39). In vitro activation with anti-CD3/CD28 
microbeads promoted the expression of CD40L (Figure  4D) 
and ICOS (Figure  4E) by the Tfh. As expected, triple main-
tenance immunosuppression significantly decreased the level 
of expression of both CD40L and ICOS on activated Tfh 
(Figures  4D,E). However, the impact of triple maintenance 
immunosuppression was incomplete because the drug combi-
nation failed to reduce the percentage of Tfh that expressed 
CD40L after stimulation (Figure 4D) or the production of IL21 
by Tfh (Figure 4F).
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FIGURE 3 | CD4+ T cell help is mandatory for memory donor-specific antibody (DSA) response. (A) Allogeneic heart from HLA A2 transgenic (A2) or BALB/c donor 
was transplanted to C57BL/6 recipient. Fifty days posttransplantation HLA A2-specific memory B cells were enumerated in the spleen of recipients by ELISpot. 
Representative wells are shown and the number of A2-specific memory B cells (mean ± SD) is plotted for the two groups (n = 4). (B) Graphical representation of the 
experimental setting used to evaluate the importance of CD4+ T cell help in memory DSA response. (C) Flow cytometry was used to quantify the proportion 
(mean ± SD) of B cells (B220+CD19+) and helper T cells (CD3+CD4+) in controls (C57BL/6; left column) and RAG2 KO recipients before memory B cell transfer 
(day 0, second column from the left), just prior heart transplantation (day 7, third column from the left), and 42 days after A2 heart transplantation (right column). (D) 
The purity of B cell suspension, obtained from the spleen of C57BL/6 mice sensitized with a A2 or a BALB/c heart transplantation, was evaluated by flow cytometry: 
before magnetic isolation (left panel), after magnetic isolation (middle panel) and after flow sorting (just prior transfer to RAG2KO mice, left panel). (E) HLA 
A2-specific memory B cells were enumerated by ELISpot in B cell suspensions before transfer (left histogram) and in the spleen of RAG2 KO animals transplanted 
with an A2 heart 100 days after transfer (right histogram). (F) Evolution of normalized donor-specific antibody titer (mean ± SD) was monitored in the circulation of 3 
groups of recipients transplanted with an A2 heart: wild-type C57BL/6 (positive controls, dotted line), RAG2 KO transferred with anti-BALB/c memory B cells 
(negative controls, dashed line), and RAG2 KO transferred with anti-A2 memory B cells (experimental group, black line).
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Reduction of CD4+ T Cells Number
Dampens Naive and Memory DSA 
Responses
Transplanted patients often receive induction therapy at the 
time of transplantation to prevent acute rejection during the 
early posttransplantation period. Induction immunosuppressive 
agents used in our center are either the lymphocyte-depleting 
agent rabbit antithymocyte globulin (ATG) or the anti-IL2 recep-
tor mAb basiliximab, which is non-depleting.
Induction with ATG induced a 90% drop in the number 
of cTfh at 3  months (Figure  5A). Beyond this time point, the 
number of cTfh started to increase slowly and was no longer 
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significantly different from baseline at 1 year posttransplantation 
(Figure  5A). As expected, induction with the non-depleting 
agent, basiliximab was not followed by any reduction in cTfh 
number. At the contrary, cTfh number was significantly increased 
(+36%) at 1  year posttransplantation in patients that received 
basiliximab (Figure 5A).
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TABLE 1 | Characteristics of study population.
Recipients n(%) or  
mean ± SD
All pts ATG BasiliX p-Value*
22 (100) 11 (50) 11 (50)
Age at transplantation (years) 47 ± 13 47 ± 16 47 ± 9 0.99
Men 14 (64) 6 (55) 8 (73) 0.66
Cause of ESRD 0.09
Glomerulonephritis 7 (31) 3 (27) 4 (36)
Diabetes mellitus 8 (36) 6 (55) 2 (18)
ADPKD 3 (14) 2 (18) 1 (9)
Other 4 (18) 0 (0) 4 (36)
Duration of dialysis before Tx 
(months)
22 ± 14 23 ± 12 21 ± 16 0.38
Donors
Donor age (years) 47 (13) 43 ± 14 47 ± 9 0.43
Men 13 (50) 6 (55) 4 (36) 0.67
Deceased donor 21 (81) 10 (91) 8 (73) 0.47
Expanded criteria donor 11 (42) 5 (45) 4 (36) 1
Transplantation
Number of HLA MisMX  
(A, B, DR)
3.7 ± 1.6 4.3 ± 1.5 3.2 ± 1.6 0.10
Cold ischemia time (hours) 11 ± 6 12 ± 4 11 ± 6 0.47
Induction therapy Not tested
Antithymocyte globulin 
(rabbit)
11 (50) 11 (100) 0 (0)
Basiliximab 11 (50) 0 (0) 11 (100)
Maintenance immunosuppression 0.54
Tacrolimus 16 (73) 9 (82) 7 (66)
Cyclosporin 6 (27) 2 (18) 4 (36)
Everolimus 2 (9) 0 (0) 2 (18)
Mycophenolate Mofetil 20 (91) 11 (100) 9 (82)
Corticosteroids 22 (100) 11 (100) 11 (100)
ADPKD, autosomal dominant polycystic kidney disease; ATG, antithymocyte globulin; 
BasiliX, basiliximab; ESRD, end-stage renal disease; MisMX, mismatches.
*Comparison between patients induced with ATG and basiliximab: chi-square test 
for comparison of proportions and Mann–Whitney test for comparison of continuous 
variables.
FIGURE 4 | Impact of maintenance immunosuppression on CD4+ T cell activation in the clinic. (A) T cells were prospectively monitored in the circulation of 9 
healthy controls and 22 patients after renal transplantation (3 months, 3M; and 12 months, 12M). Peripheral blood mononuclear cell (PBMC) and plasma (containing 
or not immunosuppressive drugs) were separated by Ficoll. (B) Tacrolimus trough levels (T0) and areas under the curve (AUC) of mycophenolate mofetil measured in 
the plasma of renal transplanted patients at 3 and 12M are plotted (each symbol is a patient). (C) Left panel: representative FACS profile of controls (Ctrl; left column) 
and renal recipients (3 M, middle column; 12 M, left column) The expression of the activation marker CD25 was measured by flow cytometry on the surface of 
CD4+ (top) and CD8+ (bottom) T cells. The analysis was performed after 24H culture in patient’s own plasma without (gray area) or with (black line) stimulation with 
CD3/CD28 microbeads. The percentage of CD25-expressing T cells after stimulation is indicated (mean ± SD). Right panel: the ratio of the percentage of CD4+ 
T cells expressing CD25 over the percentage of CD8+ T cells expressing CD25 after stimulation is plotted for the 9 controls (Ctrl, black symbols) and the 22 renal 
recipients at 3 and 12M (red symbols). Ratios were compared between Ctrl and renal recipients at M3 and M12: Kruskal–Wallis with Dunn’s multiple comparisons. 
**p < 0.01. (D,E) Flow cytometry was used to analyze the expression of helper molecules CD40L (D) or ICOS (E) on T follicular helper cells (Tfh) surface after 24H 
culture in control’s patient’s own plasma without (gray area) or with (black line) stimulation with CD3/CD28 microbeads. Left panel: representative FACS profile. 
Middle panel: percentage of Tfh that express the helper molecule. Right panel: level of expression of the helper molecule [mean fluorescence intensity (MFI)]. Each 
control (Ctrl, black) and renal recipient at 3 and 12M (red) is a symbol. (F) Flow cytometry was used to analyze the production of IL21 by Tfh in controls (Ctrl, black 
symbols) and renal recipients at 3 and 12M posttransplantation (red symbols) for whom frozen PBMCs were available. Left panel: representative FACS profile. 
Middle: percentage of IL21-expressing Tfh. Right: level of expression of IL21 (MFI). Percentage of positive Tfh and MFI were compared between Ctrl and renal 
recipients at M3 and M12: Kruskal–Wallis with Dunn’s multiple comparisons. *p < 0.05; ***p < 0.001; ****p < 0.0001.
Chen et al. CD4+ T-Cell Help and DSA Responses
Frontiers in Immunology | www.frontiersin.org
repeated IV administrations of different doses of GK1.5, we 
were able to obtain various levels of CD4+ T  cell depletion 
(Figure  5B). Due to (i) the large number of animals to be 
analyzed and (ii) the complexity of microsurgical models of 
transplantation (sequential transplantation of two hearts in the 
cervical area of the same mice is unfeasible, making analysis 
of memory response impossible), we used a simplified model 
of allosensitisation (presented in Figure S1 in Supplementary 
Material). DSA responses of C57BL/6 WT mice were induced 
by IV injection of purified splenocytes from HLA-A2 transgenic 
mice (Figure  5C). CD4+ T  cell depletion did not change the 
kinetic of DSA generation but resulted in significant reduction 
of DSA titers both in naive and memory responses (Figure 5D). 
Importantly, DSA titers strongly correlated with the number 
of remaining CD4+ T cells of recipient mice in an exponential 
regression model (r2 for naive and memory responses, respec-
tively, 0.86 and 0.84, Figure 5E).
Long-term Effect of ATG Induction on Tfh 
Functionality
Recovery of peripheral T-cell counts, including cTfh occurred 
gradually after cessation of ATG treatment (Figure 5A). However, 
beyond the quantitative impact of ATG, several studies have 
documented a long-term qualitative influence of the drug on 
T cell compartment (40). To determine if ATG induction could 
have long-term effects on Tfh function, we compared the profile 
of cTfh of renal recipients that received ATG or basiliximab as 
induction. The two groups did not differ regarding their clini-
cal characteristics (Table  1) or maintenance regimen (Table  1; 
Figure  6A). Although cTfh functions of the two groups were 
similar before transplantation (Figures  6B,C), cTfh of renal 
recipients that received ATG exhibited a significantly reduced 
activation-induced upregulation of CD40L (Figure  6B) and a 
similar trend was observed for ICOS (Figure 6C).
These results suggest that ATG induction could reduce the 
incidence of de novo DSA after renal transplantation. We were, 
however, unable to test this hypothesis in this study because only 
three patients of the 22 enrolled, have developed de novo DSA 
over the follow-up period (2 in the group ATG induction, 1 in the 
group basiliximab induction).
Our previous results indicate that while maintenance 
immunosuppression does not completely block Tfh functions, a 
prolonged depletion of cTfh can be achieved following induction 
with a depleting agent. We, therefore, analyzed the impact of 
such prolonged depletion in CD4+ T cells on naive and memory 
experimental DSA responses.
GK1.5 (20) is a rat IgG2b anti-murine CD4 mAb commonly 
used to induce CD4+ T  cell depletion in mice (21). Using 
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FIGURE 5 | Reduction of CD4+ T cells number dampens donor specific antibody (DSA) responses. (A) The number of circulating T follicular helper cells was 
evaluated in the cohort of 22 renal transplanted patients by flow cytometry and compared according to the nature of immunosuppressive drug used for induction: 
rabbit anti-thymoglobulin (anti-thymocyte globulin, red line; n = 11) or basiliximab (blue line; n = 11). Gray areas indicate 95 confidence intervals. Friedman paired 
test with Dunn’s multiple comparisons. **p < 0.01; ****p < 0.0001. (B) Various doses of anti-CD4 mAb GK1.5 were sequentially administered IP to wild-type 
C57BL/6 mice to obtain various level of CD4+ T cell depletion (n = 3 mice per group). Black arrows indicate the timing of mAb administrations. Evolution of the % of 
CD3+ cells in peripheral blood mononuclear cell (PBMC) (mean ± SD) over time is shown in the control (PBS) and the three experimental groups. (C) Graphical 
representation of the experimental setting used to evaluate the impact of the reduction of circulating CD4+ T cells number on naive and memory DSA responses. 
C57BL/6 mice were depleted with various dose of anti-CD4 mAb GK1.5 and sensitized at day 0 (naive response) and day 60 (memory response) by IV injection of 
10 × 106 PBMC from A2 transgenic donors. (D) Evolution of normalized DSA titer (mean ± SD) in the circulation of the control (PBS) and the three experimental 
groups with various level of CD4 + T cell depletion is shown. (E) The relation between the number of circulating CD4 + T cells and DSA titer is shown for naive (left 
panel) and memory (right panel) responses (mean ± SD). Exponential regression models are plotted (dashed line).
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FIGURE 6 | Antithymocyte globulin (ATG) induction has long-term impact on T follicular helper cells (Tfh) functionality. (A) Tacrolimus trough levels (T0; left panel) and 
areas under the curve (AUC) of mycophenolate mofetil (right panel) measured 3 months (3 M) and 12 months (12 M) after transplantation were compared for renal 
recipients that received induction by ATG (red symbols) or basiliximab (blue symbols). (B,C) Flow cytometry was used to analyze the expression of helper molecules 
CD40L (B) or ICOS (C) on Tfh surface after 24 h culture in patient’s own plasma and stimulation with CD3/CD28 microbeads. Left panel: percentage of activated 
Tfh that express the helper molecule. Right panel: level of expression of the helper molecule (mean fluorescence intensity, MFI). Analyses were performed just before 
transplantation [end stage renal disease (ESRD)/no immunosuppressive drugs, 0 M] and 3 months (3 M) and 12 months (12 M) after renal transplantation (no ESRD/
on immunosuppression). Renal recipients that received induction by ATG (red symbols) were compared to patients that received induction by basiliximab (blue 
symbols). Kruskal–Wallis with Dunn’s multiple comparisons. *p < 0.05; **p < 0.01.
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DISCUSSION
In this translational study, we confirmed that CD4+ T cells are 
essential for DSA generation in a murine model of MHC-disparate 
skin graft rejection (27). In contrast with grafting procedure (in 
which allosensitisation of recipient’s immune system takes place 
in the nearby draining lymph node), organ transplantation leads 
to the accumulation of donor-derived alloantigens in the spleen of 
recipients. While this condition was previously reported to abol-
ish the dependence on T cell help for the generation of antibody 
against viral protein antigens (13, 30), neither naive nor sensitized 
mice developed DSA after heart transplantation in the absence of 
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CD4+ T cells. These data along with other recent experimental 
studies (41, 42) demonstrate that CD4+ T cell help is mandatory 
for both naive and memory DSA responses after transplantation.
It implies that transplanted patients that develop DSA must 
have maintained a certain level of CD4+ T  cell functionality 
despite immunosuppressive drugs. To test this theory, we ana-
lyzed the impact of therapeutic immunosuppression on circulat-
ing CD4+ T cells in a cohort of 22 renal transplanted patients. 
In contrast with CD8+ T cells, exposure to the cocktail of drugs 
used for maintenance immunosuppression did not change sig-
nificantly the ability of CD4+ T cells to upregulate the activation 
marker CD25 upon CD3/CD28 stimulation. Further analyses, 
focused on Tfh, the subset specialized for providing help to B cells 
(33, 34), confirmed that maintenance immunosuppression only 
partially reduced CD40L and ICOS expression on activated Tfh 
surface and had no effect on their secretion of IL-21. These find-
ings provide molecular explanations as to why cTfh isolated from 
renal transplanted patients retain the capacity to induce B  cell 
differentiation into immunoglobulin-producing plasmablasts 
in vitro, as recently reported by an independent group (43).
Altogether our data suggest that, beyond non-adherence to 
immunosuppressive drugs, which has been identified in ~50% 
of patients that develop AMR (5, 8), the inability of maintenance 
immunosuppression to adequately block Tfh helper function is 
also a major cause for DSA generation posttransplantation.
While maintenance immunosuppressive drugs cocktail does not 
block Tfh function, our data indicate that it is possible to achieve 
prolonged Tfh depletion in patients if ATG is used as induction 
therapy. Interestingly, murine experimental model revealed an 
exponential positive correlation between the number of CD4+ 
T  cells and DSA titers generated both in primary and memory 
alloimmune responses. Futhermore, beyond its quantitative 
impact, ATG might also have a beneficial long-term influence on 
Tfh functionality after reconstitution. Indeed, cTfh of renal trans-
planted patients induced with ATG exhibited significantly reduced 
activation-induced upregulation of CD40L and ICOS as compared 
with cTfh of patients induced with basiliximab. These experimental 
findings are consistent with the clinical observation by Brokhof 
et al., which, as compared to basiliximab, induction with ATG is 
associated with a reduction in the occurrence of de novo DSA and 
AMR in a cohort of 114 renal transplant recipients (3, 44).
We conclude that CD4+ T  cell help is mandatory for both 
naive and memory DSA responses after transplantation and is not 
adequately blocked by current maintenance immunosuppressive 
drugs. Why these drugs, which are so effective in blocking CD8+ 
T cell-mediated cellular rejection, do not show similar efficiency 
on CD4+ T cell helper function is an important issue that future 
molecular studies will have to elucidate. Specific pathways involved 
in helper functions of Tfh indeed represent attractive targets for 
improving the prevention of DSA generation, and thereby to 
prolong allograft survival. In this regard, positive preliminary 
results reported with strategies aiming at blocking costimulation 
(45) or IL21 pathway (43) represent promising attempts. Waiting
for these innovative treatments to be translated into the clinical
field, it is important to keep in mind that ATG induction could
be effective to limit DSA response after transplantation through
both quantitative and qualitative impacts on Tfh subset.
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FIGURE S1 | Intravenous allogeneic cell injection model. (A) Upper panel: cell 
suspension was prepared from the spleen of a GFP transgenic mice and 
10 × 106 GFP + splenocytes were injected intravenously (i.v. red) or 
subcutaneously (s.c. blue) to wild-type C57BL/6 mice. Lower panel: 2 days 
post-procedure the percentage GFP+ cells was enumerated by flow cytometry in 
the secondary lymphoid organs of recipients (each symbol represents a mice; 
mean ± SD is indicated). (B) Upper panel: cell suspension was prepared from 
the spleen of an HLA A2 mice and 10 × 106 splenocytes were injected 
intravenously (red, n = 3) or subcutaneously (blue, n = 3) to wild-type C57BL/6 
mice. Lower panel: evolution of normalized donor specific antibody (DSA) titer 
(mean ± SD) in the circulation of recipients is shown. (C) Graphical 
representation of the experimental setting used to evaluate the importance of 
CD4 + T cell help in memory donor-specific antibody response. (D) Evolution of 
normalized DSA titer (mean ± SD) was monitored in the circulation of three 
groups of recipients sensitized by IV injection of A2 splenocytes: RAG2 KO 
transferred with anti-A2 memory B and CD4+ T cells (red line; n = 3), RAG2 KO 
transferred with anti-A2 memory B cells alone (red dashed line; n = 3) and 
untransferred RAG2 KO (gray line; n = 3).
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Abstract
Overlooked for decades, antibodies have taken center stage in renal transplantation and are now
widely recognized as the first cause of allograft failure. Diagnosis of antibody-mediated rejection has
considerably improved with identification of antibody-mediated lesions in graft biopsies and advances
made in the detection of circulating donor-specific antibodies. Unfortunately, this progress has not yet
translated into better outcomes for patients. Indeed, in the absence of a drug able to suppress antibody
generation by plasma cells, available therapies can only slow down graft destruction. This review
provides an overview of the current knowledge of antibody-mediated rejection and discusses future
interesting research directions.
The original sin of transplant immunologists
Since the first successful attempt performed in 1954,
kidney transplantation has emerged as the best option
for end-stage renal failure, providing both a better
quality of life and better survival to patients, for a third
of the cost of hemodialysis [1]. However, because in
clinical transplantation the donor is from the same
species but genetically different, the adaptive immune
system of the recipient recognizes alloantigens expressed
by the graft: that is, proteins present in different allelic
forms encoded at the same gene locus in different
individuals, such as major histocompatibility complex
(MHC) molecules. An immune response that develops
against alloantigens leads to the destruction of the
transplanted organ, a process termed “rejection”, which
remains the first cause of renal allograft failure.
The adaptive immune system comprises two distinct
effector mechanisms—cytotoxic T cells and antibodies—
and the question of which of these mechanisms
contribute to graft rejection has been central from the
very beginning of transplant immunology. Gorer [2] was
the first to report the development of antibodies against
alloantigens. In this early era, however, most of the
knowledge pertaining to the immunological mechan-
isms involved in rejection was derived from the skin graft
model popularized by Billingham and Medawar [3]. The
observations made in this model that (i) skin allografts
were not rejected in animals lacking T cells and that
(ii) adoptive transfer of purified T cells, but not
alloantibodies, was sufficient to restore the rejection of
skin allografts in immunodeficient rodents [4] stemmed
from the concept that T cells were “the” cell subset
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responsible for rejection of allogeneic transplants, a
vision that prevailed until the 2000s.
During the last decade, however, experimental and
clinical studies have challenged this “T cell-centric”
vision and brought antibodies back to the center stage
of transplant immunology [5].
Transplantation versus grafting: vessels’ origin
matters
The first evidence that humoral immunity can be
deleterious in the setting of clinical transplantation
came in the early 1970s from seminal clinical observa-
tions that (i) the presence of preformed circulating
donor-specific antibodies (DSAs) was associated with a
high risk for “hyperacute rejection” (that is, immediate
graft failure due to widespread capillary thrombosis and
necrosis [6]) and that (ii) de novo generation of DSAs
after transplantation correlated with poor outcomes and
histologic evidence of vascular obliterative lesions,
named “allograft vasculopathy” [7].
These clinical findings were in apparent contradiction
with the resistance of skin grafts to passive transfer of
alloantibodies [4]. The origin of this discrepancy lies in
the fact that, in contrast with grafted tissue, whose
vascularization develops from the recipient, the vessels of
renal allografts are anastomosed to those of the recipient,
placing donor allogeneic endothelial cells in direct
contact with the recipient‘s circulation. This makes a
crucial difference in the sensitivity of renal transplants to
the humoral arm of the recipient‘s alloimmune response.
Antibodies are indeedmassive proteins (150 kDa) largely
sequestrated in blood circulation [8]. Accordingly, when
Russell and colleagues [9] performed passive transfer of
alloantibodies to immunodeficient mice transplanted
with allogenic hearts in the late 1990s, they observed that
continuing injections of antiserum were sufficient to
drive the development of obstructive coronary lesions.
This first experimental demonstration that humoral
immunity is the prime instigator of allograft vasculo-
pathy [9] has since been confirmed in other models [10]
and in the clinical setting [11].
Pathophysiology of antibody-mediated rejection
Humoral response to allogeneic transplant
Recent experimental studies have shed light on the
natural history of antibody-mediated rejection (AMR)
(Figure 1) [12,13]. The sequence starts with the genera-
tion of antibodies directed against the graft (DSAs).
Although highly polymorphic mismatched HLA mole-
cules represent the most documented targets for DSAs, it
is clear that DSAs can also be directed against other kinds
of molecular targets, including polymorphic minor
histocompatibility antigens [14] and, following a break-
down of B-cell tolerance [15], non-polymorphic auto-
antigens [16]. Although some studies suggest that
“non-HLA” antibodies could participate in the develop-
ment of rejection [17], particularly those expressed on
the endothelial cell surface [18], such as anti-angiotensin
II type-1 receptor antibodies [19,20], their exact patho-
logical potential remains a matter of debate, and
hereafter, we will focus on anti-donor HLA antibodies
(abbreviated DSAs).
The generation of such high-affinity, class-switched
alloantibodies directed against a protein antigen requires
the development of a germinal center reaction, which
implies the expansion of CD4+ T cells with indirect
allospecificity (that is, CD4+ T cells whose T cell receptors
recognize alloantigens processed and presented in the
context of MHC class II molecules expressed by recipient
antigen-presenting cells) (Figure 1) [21].
The initiation of a T cell-dependent humoral immune
response takes place within the recipient‘s canonical
secondary lymphoid organs: spleen and draining lymph
nodes (Figure 1) [22]. However, recent evidence suggests
that, with time, immune effectors infiltrating the graft
sometimes organize into ectopic lymphoid tissue (Figure 1)
[23,24], which harbors the maturation of a local humoral
immune response [25] that can also participate in the
rejection process [26].
Implication of the classical complement pathway in
acute antibody-mediated rejection
Binding of circulating DSAs to directly accessible graft
endothelial cells can trigger the activation of the classical
complement pathway, a central process in the pathophy-
siology of acute AMR (that is, AMR with acute graft
dysfunction). Briefly, C1q binding to DSAs complexed
with antigen activates the serine esterases C1s and C1r,
which allow the cleavage of C4. This results in the
deposition of C4d in tissue and the assembly of the
classical pathway C3 convertase. The latter cleaves C3 into
C3a and C3b. C3a is a potent proinflammatory mediator
that causes leukocyte recruitment, whereas C3b propa-
gates the complement cascade, leading to the formation of
sublytic membrane attack complexes responsible for the
activation of endothelial cells (Figure 1) [27].
Complement is dispensable for chronic/subclinical
antibody-mediated rejection
In contrast with acute AMR, activation of the classical
complement pathway appears to be dispensable for the
development of chronic/subclinical AMR lesions. The first
evidence supporting this concept came from Colvin and
colleagues, who transplanted RAG KO immunodeficient
F1000Prime Reports 2015, 7:51 http://f1000.com/prime/reports/m/7/51
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mice with allogenic hearts and observed that the passive
transfer of non-complement-fixing DSAs was sufficient to
promote allograft vasculopathy [28]. Innate immune cells
can indeed bind to the fragment crystallizable (Fc) region
of antibodies and release lytic enzymes (a mechanism
called antibody-dependent cell-mediated cytotoxicity, or
ADCC) (Figure 1), which mediate smoldering endothelial
cell damage. The recognition of this pathological mechan-
ism in the clinic led to the recognition of C4d-negative
forms of AMR, often diagnosed on screening biopsy (that
is, subclinical AMR) [29]. Chronic vascular inflammation
in turn promotes the progressive development of typical
vascular lesions (that is, transplant glomerulopathy,
allograft vasculopathy, and lamination of the peritubular
capillary basement membrane). Finally, progressive tissue
destruction leads to irreversible loss of graft function,
proteinuria, and hypertension (that is, chronic AMR).
The question of which type of innate immune effectors
plays the key role in AMR is still a matter of debate.
Hirohashi and colleagues [30] showed that depletion of
natural killer cells was sufficient to abrogate DSA-
induced arterial lesions. The validity of these experi-
mental data in the clinic is supported by transcriptomic
analysis of renal graft biopsies from patients with chronic
AMR [31]. However, it is likely that other cell types,
including neutrophils and monocytes, are also involved
(Figure 1). Recent data from the clinic even suggest that
Figure 1. Schematic representation of antibody-mediated rejection pathophysiology
Mechanisms of action of therapies are indicated. Therapies currently used are in bold red; drugs under evaluation are in dashed orange. AMR, antibody-
mediated rejection; Conv, convertase; IV, intravenous; MAC, membrane attack complex; MHC, major histocompatibility complex; mTOR, mammalian target
of rapamycin; NK, natural killer.
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expanded circulating cytomegalovirus-responsive
gd T cells could participate in allograft lesions mediated
by DSAs through ADCC, offering a new pathophysiolo-
gic link between cytomegalovirus infection and allograft
dysfunction [32].
Finally, some experimental studies demonstrated that
DSAs can directly trigger activating signals in endothelial
cells through MHC molecule cross-linking (Figure 1),
which promotes exocytosis of Weibel-Palade bodies,
activates the coagulation cascade, and increases the
expression of adhesion molecules and growth factors
[33]. This mechanism could also participate in the
development of complement-independent AMR lesions.
One pathophysiology, several clinical courses
If clinical studies have largely validated the sequence of
molecular events established in experimental models of
AMR [34,35], the progression along the successive stages
of the pathology can, however, follow different clinical
courses [36]. For some patients, AMR is made clinically
patent by the occurrence of one or more episodes of graft
dysfunction. In contrast, other kidney graft recipients
with DSAs experience smoldering forms of AMR (that is,
subclinical AMR), characterized by persistent microvas-
cular abnormalities without acute graft dysfunction [29].
The quantity (titer) of circulating DSAs is an obvious factor
influencing the clinical expression of the disease [37,38].
Qualitative factors, linked to antibody structure, are also
important sources of clinical heterogeneity. The immuno-
globulin (Ig)molecule is shaped like a Y,with two identical
halves, each made up of a heavy chain and a light chain.
The two arms of the Y, each formed by the amino terminal
extremity of a heavy chain and a light chain, contain the
antigen-binding site. Higher avidity could explain why
some patients develop clinically patent AMRwith lowDSA
titer. At the base of the Y, composed of the carboxy terminal
extremity of the constant region of the two heavy chains, is
the Fc region.During a T cell-dependent humoral response,
class-switch recombination occurs in the germinal center,
leading to the replacement of the constant region of the Ig
heavy chain. Accordingly, anti-HLA alloantibodies of a
wide range of isotypes (IgG1, G2, G3, G4, Ig A1, A2, IgM)
can be eluted from explanted renal allografts [39]. Through
their Fc portion, each heavy-chain isotype displays a
different capability to bind C1q (and therefore to trigger
the classical complement pathway) and to recruit immune
effectors through their Fc receptors. Interestingly, it has
been reported that patients with exclusively weak comple-
ment-activating DSAs (that is, IgG1 and IgG4) tend to
experience less acute AMR and better outcome [40-42].
Another possible source of heterogeneity comes from the
carbohydrate chains that are attached to Fc [43]. Age,
gender, and disease status are all factors influencing Ig Fc
glycosylation [43]. In the case of IgG, terminal sugars affect
the binding to the FcgRIIIa receptor and thereby influence
ADCC, whereas terminal galactose residues affect antibody
binding to C1q and thereby modulate IgG complement-
dependent activity [44].
Challenges in antibody-mediated rejection
diagnosis
The recognition of subclinical forms of the disease
implies that, upon detection of circulating DSAs, a renal
biopsy should be performed, even in the absence of
clinically patent graft dysfunction (that is, “screening
biopsies”) [45]. In 2005, the Banff Conference on
Allograft Pathology defined criteria for diagnosing
AMR [46], which include the three following cardinal
features: (a) presence of circulating DSAs, (b) morpho-
logic evidence of antibody-mediated tissue injury
(glomerular or peritubullar capillaries inflammation
score > 0), and (c) positive staining for C4d in
peritubular capillaries (used as a surrogate marker for
local classical complement pathway activation) [47].
Since then, however, the value of C4d for the diagnosis
of AMR has been questioned. Although there is little
doubt that complement activation is important for
DSAs to trigger clinically patent “acute” AMR [48], a
high percentage of graft biopsies with morphologic
evidence of antibody-mediated tissue injury are C4d-
negative [49]. This notion has been strengthened by
transcriptomic analyses, which demonstrate a similar
increased level of expression for endothelial genes in
C4d-negative and C4d-positive AMR biopsies [50].
Finally, the direct demonstration that DSAs can trigger
chronic arterial lesions in murine experimental models
without complement participation [28] led to the
recognition of C4d-negative AMR in the most recent
Banff classification [51].
(R)evolution in anti-HLA antibody monitoring
In line with the growing clinical interest in AMR, tools
available for DSA detection have considerably improved
over the last few decades [52]. Historically, the first test to
detect circulating DSAs was the complement-dependent
cytotoxicity (CDC) assay performed between recipient
sera and donor lymphocytes.
In the early 1980s, flow cytometry cross-match (FCXM)
emerged as an alternative to CDC assays [53]. Although
the FCXM was 10- to 100-fold more sensitive to detect
DSAs, it rapidly appeared that T cell or (especially) B-cell
FCXM (or both) lacked specificity because of (i) auto-
antibodies binding to donor lymphocytes and (ii) binding
of Ig to lymphocyte Fc receptors (independently of their
antigen specificity). These limitations explained the
F1000Prime Reports 2015, 7:51 http://f1000.com/prime/reports/m/7/51
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discrepancies among centers in outcomes of patients with
positive FCXM and led to confusion regarding the clinical
utility of the FCXM.
The revolutionary development in DSA screening was the
introduction of solid-phase membrane-independent
assays. The enzyme-linked immunosorbent assay was
the first assay to use purified HLA proteins [54] and was
soon followed by flow cytometric and multiplex assays.
All of these approaches coupled purified HLA antigens to
inert plastic or latex. Currently, genetic engineering is
being used to produce microparticles coated with single
HLA alleles, offering the possibility not only to detect
circulating DSAs with exquisite sensitivity but also to
readily identify their specificities [55].
Solid-phase antibody detection assays are not devoid of
limitations [56]. Technical issues include the following:
(i) the different nature (natural versus recombinant) of
antigens on screening and specificity products; (ii) the
definition of the threshold level (mean fluorescent
intensity, or MFI) to consider an antibody as being
“present”; (iii) the conformation of HLA antigens (intact
or denatured) upon adherence to the beads; (iv) the
density of antigen on the beads; and (v) interfering
factors that mask the detection of DSAs (sometimes
named the “prozone phenomenon”) [57].
Although the solid-phase antibody detection assays have
permitted the detection of DSAs not detectable by CDC
assay, the clinical significance of these antibodies is
incompletely understood. Recent studies have indeed
shown that not all DSAs identified by solid-phase
antibody detection assays predict a poor outcome [58],
underlying the need for tools allowing better stratifica-
tion of the risk.
Risk stratification in antibody-mediated rejection
Some approaches to stratifying the risk of graft loss in
AMR rely on graft biopsy. Bachelet and colleagues [59]
have shown, for instance, that the presence of DSAs
bound to the graft (as assessed by solid-phase antibody
detection assays on eluate from needle core graft
biopsies) was predictive of unfavorable short-term
transplant outcome. Coupling analysis of histological
features with transcriptomic profiling of graft biopsy
with the “molecular microscope” system seems to be
another interesting way to improve risk stratification in
AMR [60].
As discussed above, complement activation is not
necessary for DSAs to drive vascular lesions. However,
because the combination of complement-dependent
and -independent mechanisms is synergistically
deleterious for the graft, complement activation is a good
candidate for risk stratification inAMR.C4d staining in renal
capillaries showed poor performance in predicting
AMRoutcome in several independent studies [49,50,61,62].
Recently, several manufacturers have modified their
solid-phase antibody detection assays to directly assess
the capacity of circulating DSAs to bind the complement
components of the classical pathway (that is, C1q [63],
C4d [64], or C3d [62]). A recent study has demonstrated
the value of these assays in predicting allograft loss in
AMR [62]. However, the direct correlation observed
between DSA titer (MFI value measured with classic
solid-phase antibody detection assays) and DSA ability
to trigger complement activation (which was predicted
by basic molecular immunology [65]) questions the
clinical utility of these tests. One possibility could be to
spare them for AMR patients with low DSA titer, for
which a C3d-binding assay has shown promise in
predicting graft loss [62].
Therapeutic challenges
It is widely accepted that a significant proportion of what
were once called “cortico-resistant rejections” were, in
fact, AMR. Although anti-thymocyte globulin (ATG),
which contains activity against numerous cell surface
proteins, can induce complement-independent apopto-
sis of naive, activated B cells, and plasma cells [66], ATG
alone is ineffective in AMR.
Historically, the first attempt to reduce DSAs’ deleterious
effects on graft endothelium relied on the use of high-
dose intravenous immunoglobulin (IVIg), a therapy with
incompletely understood mechanisms, which could
accelerate DSA catabolism, act as scavenger of activated
complement, and down-modulate the activation of
innate immune effectors [67].
Although IVIg remains an essential component of AMR
treatment, several studies have shown that better out-
comes were achieved when it was combined with a rapid
depletion of circulating DSAs (with plasmapheresis [68]
or immunoadsorption [69]). As expected from its
mechanism of action, this costly and tedious therapeutic
approach is not curative (DSA-producing plasma cells
are not affected) and therefore has only a suspensive
effect on antibody-mediated graft destruction [70]. In
short, it is realistic to consider that, in most cases, IVIg
and plasmapheresis will (at best) turn an acute form of
AMR into a subclinical disease.
In an attempt to provide a sustained therapeutic effect,
anti-CD20 monoclonal depleting antibody (rituximab),
a widely established treatment of B cell lymphoma, has
F1000Prime Reports 2015, 7:51 http://f1000.com/prime/reports/m/7/51
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been tested in AMR. Although the rationale of this
approach can be questioned (since CD20 is not
expressed on plasma cells), several small retrospective
series reported promising results [71,72] and a recent
meta-analysis of 10 of these studies concluded that
rituximab was a reasonable therapeutic option in the
treatment of AMR. The first controlled trial, published in
2009 [68], indeed concluded that a plasmapheresis/IVIg/
anti-CD20 regimen was associated with better graft
outcome in comparison with IVIg alone. However, the
benefit reported could be due to either DSA removal or B
cell depletion. In fact, the only multicenter randomized
study—Impact of Treatment With Rituximab on the
Progression of Humoral Acute Rejection After Renal
Transplantation (RITUX-ERAH) (ClinicalTrials.gov Iden-
tifier: NCT01350882 http://clinicaltrials.gov/ct2/show/
NCT01350882)—performed to investigate the effect of
rituximab on AMR, found no difference at 12 months on
graft loss, epidermal growth factor receptor (eGFR),
proteinuria, and glomerulitis score between placebo and
rituximab groups [73]. Therefore, the benefits reported in
small retrospective series should be carefully considered
since methodological and positive publication bias seems
likely. Furthermore, the use of rituximab in this context
may be associated with a higher risk of infection [74,75].
We have already seen above that intragraft complement
activation was associated with worse outcomes in AMR.
Thus, blocking complement cascade seems to be an
attractive therapeutic option, especially for patients with
DSAs able to bind complement components in solid-
phase assays [62]. Experimentally, C1 blockade pre-
vented acute AMR of kidney allografts in allosensitized
baboons [76]. Although C1 inhibition has not been
tested in clinical AMR yet, a C1 inhibitor for treatment of
patients with hereditary angioedema is already available
[77]. Eculizumab is a humanized monoclonal antibody
that targets complement protein C5 initially developed
to treat paroxysmal nocturnal hemoglobinuria [78].
Eculizumab appears to be effective in protecting renal
allografts from post-transplant recurrence of atypical
hemolytic uremic syndrome [79]. Only a few case reports
with short follow-ups are currently available in the
literature regarding eculizumab efficiency in AMR [80].
Although eculizumab in prophylaxis appears to be
effective at preventing acute AMR in sensitized patients
[81], it is unclear whether eculizumab contributes to the
development of accommodation and therefore how long
treatment should continue (a particularly important
issue given the expense of the drug). Another important
limitation of complement blockades is the fact that these
approaches are unlikely to prevent the development of
chronic antibody-mediated lesions, which also result
from complement-independent mechanisms.
In fact, only the disappearance of DSAs from the
recipient‘s circulation could stop graft destruction in
AMR (and achieve efficient desensitization). In the
absence of therapy able to deplete selectively DSA-
producing plasma cells, bortezomib—a selective inhibi-
tor of the 26S proteasome widely used for the treatment
of multiple myeloma—has been proposed. Bortezomib
induces apoptosis among plasma cells in whole bone
marrow cell cultures, thereby reducing the secretion of
alloantibodies (but also vaccinal antibodies) in vitro [82].
Clinical experience with this drug in the context of AMR is
still limited [83], but, based on these promising prelimin-
ary results, prospective studies have been launched to
evaluate bortezomib efficiency and tolerance profile in this
indication (ClinicalTrials.gov Identifier: NCT02201576
http://clinicaltrials.gov/ct2/show/NCT02201576, Clinical-
Trials.gov Identifier: NCT01873157 http://clinicaltrials.
gov/ct2/show/NCT01873157).
In the absence of efficient curative treatment for AMR,
emphasis should be placed on “primary” prevention of
de novo DSAs. This objective requires (i) avoiding futile
transfusions in candidates for transplantation, (ii) max-
imizing HLA compatibility between donor and recipient,
(iii) improving adherence to immunosuppressive treat-
ments [5], and (iv) optimizing maintenance of immu-
nosuppression. Particular attention should be paid to
this issue when immunosuppression is reduced [70].
In this regard, strategies aiming at suppressing anti-
calcineurin appear to be particularly at risk of de novo
DSA generation [84,85].
Conclusions
In the shadows since the early era of transplantation,
DSAs have recently been recognized as the first cause of
allograft failure. Although important advances have been
made in AMR diagnosis in this last decade, a curative
therapy is still lacking. Since current therapeutic strate-
gies can only slow down antibody-mediated destruction
of the graft, special emphasis should be placed on the
prevention of DSA generation. Finally, it should be kept
in mind that B cells are much more than plasma cell
precursors. B cells are endowed with important antibody-
independent functions, including immunoregulation
[86] and antigen presentation to T cells [87], which are
increasingly recognized as key in the balance between
rejection/tolerance of solid organ transplants.
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Abstract NK cell education is the process through which chronic engagement of inhibitory NK
cell receptors by self MHC-I molecules preserves cellular responsiveness. The molecular
mechanisms responsible for NK cell education remain unclear. Here, we show that mouse NK cell
education is associated with a higher basal activity of the mTOR/Akt pathway, commensurate to
the number of educating receptors. This higher activity was dependent on the SHP-1 phosphatase
and essential for the improved responsiveness of reactive NK cells. Upon stimulation, the mTOR/
Akt pathway amplified signaling through activating NK cell receptors by enhancing calcium flux and
LFA-1 integrin activation. Pharmacological inhibition of mTOR resulted in a proportional decrease in
NK cell reactivity. Reciprocally, acute cytokine stimulation restored reactivity of hyporesponsive NK
cells through mTOR activation. These results demonstrate that mTOR acts as a molecular rheostat
of NK cell reactivity controlled by educating receptors and uncover how cytokine stimulation
overcomes NK cell education.
DOI: https://doi.org/10.7554/eLife.26423.001
Introduction
Natural killer (NK) cells are group 1 innate lymphoid cells characterized by their ability to kill target
cells and to secrete cytokines such as IFN-g (Spits et al., 2013). Thereby, they take part in the early
response against infected and neoplastic cells. Target cell recognition and NK cell activation are con-
trolled by the balance between positive and negative signals arising from the engagement of an
array of NK activating receptors (NKar) and NK inhibitory receptors (NKir). While normal cells
express an excess of NKir ligands, stressed cells, such as tumor and infected cells, may lose
Marçais et al. eLife 2017;6:e26423. DOI: https://doi.org/10.7554/eLife.26423
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expression of NKir ligands (‘missing-self’) or acquire expression of NKar ligands (‘modified-self’),
thus tilting the balance towards activation. NKirs, which mostly recognize classical or non-classical
MHC-I molecules, are stochastically expressed, resulting in a variegated expression pattern.
Depending on the species, three types of NKir interact with MHC-I: Killer Immunoglobulin-like
Receptors (KIR) in primates, Ly49 receptors of the lectin-like family in rodents and the heterodimer
formed by CD94 and NKG2A in these species (Vivier et al., 2008).
In addition, considerable functional heterogeneity is observed in the NK cell population. Such cell
intrinsic differences led to the proposition that NK cell reactivity and consequently their ability to dis-
criminate self from non-self is the result of an education process (Anfossi et al., 2006;
Fernandez et al., 2005; Kim et al., 2005). There was however considerable debate over the molec-
ular process leading to education. Two theories were crafted to account for these observations: the
first one proposing that a priming (or arming) signal was required to confer reactivity to otherwise
hyporesponsive cells, the second positing that responsiveness is a default state that is lost upon
unopposed chronic stimulation of NKar (disarming) (Höglund and Brodin, 2010). The data accumu-
lated so far are in favor of the latter model, suggesting that intrinsic reactivity is lost upon chronic
engagement of NKar unless this is opposed by concomitant engagement of NKir. Indeed, there is
no evidence so far that priming signals are a prerequisite for acquisition of responsiveness. In con-
trast, disarming is the simplest explanation to account for the tolerance to self of NK cells raised in a
mosaic or chimeric environment (Johansson et al., 1997; Wu and Raulet, 1997). Moreover, the loss
of reactivity consequent to exposure of NK cells to activating ligands functionally demonstrates the
possibility to disarm reactive NK cells (Oppenheim et al., 2005; Tripathy et al., 2008).
At the molecular level, physical interaction between NKirs and their ligands is required to main-
tain responsiveness as (1) only NK cells expressing NKir engaged by MHC-I at the surface of sur-
rounding cells are reactive and as (2) NK cells expressing NKirs but developing in MHC-I deficient
humans or animals are functionally impaired (Fernandez et al., 2005; Kim et al., 2005;
Zimmer et al., 1998). In addition, the inhibitory signaling module acting downstream of NKirs is
required to maintain reactivity. Indeed, mutation of the immunoreceptor tyrosine-based motifs
(ITIM) of inhibitory Ly49 molecules or deficiency in the phosphatase SHP-1, recruited to NKirs upon
ligation, decreases responsiveness (Kim et al., 2005; Viant et al., 2014). Inhibition of the activating
signal by NKir thus serves two-distinct but related purposes: it counters inappropriate NK cell
eLife digest The cells of the immune system patrol the body to detect and destroy harmful
microbes and diseased cells. Natural killer cells are immune cells with a natural capacity to kill
infected or cancerous cells, as their name suggests. Importantly, they do so while sparing the
surrounding healthy cells.
As natural killer cells mature they go through an “education” process to learn to distinguish
between normal and abnormal cells. During education, the natural killer cells interact continuously
with nearby healthy cells. However, it remains unknown how these interactions change the natural
killer cells, or how these changes control their killing activity.
Marçais et al. now show that a protein called mTOR is essential to the education of natural killer
cells. Comparing natural killer cells that had or had not completed the education process revealed
that mTOR is more active in the educated cells. Moreover, inhibiting the activity of mTOR caused
educated natural killer cells to lose their ability to identify diseased cells, while stimulating mTOR
activity in uneducated natural killer cells mimicked the education process, allowing them to
recognize and eliminate diseased host cells.
Certain nutrients are known to control the activity of mTOR, which suggests these nutrients could
also affect how natural killer cells develop. In addition, manipulating the activity of mTOR could be
used to control the response of natural killer cells to diseased host cells, and so could form part of
treatments for cancer and infectious diseases. However, given that mTOR plays numerous roles
within different body cells, any potential therapies that are developed would need to be able to
manipulate mTOR specifically in natural killer cells.
DOI: https://doi.org/10.7554/eLife.26423.002
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activation and it prevents the desensitization induced by chronic stimulation thereby preserving NK
cell reactivity. In inbred C57BL/6 mice, Ly49C (specific for H2-Kb), Ly49I (specific for H2-Kb) and the
CD94/NKG2A receptor (specific for a Db peptide presented by Qa-1) have been shown to interact
with substantial affinity with self-MHC class I molecules, while other receptors show no or marginal
affinity (Hanke et al., 1999; Michaëlsson et al., 2000; Vance et al., 1998). Consequently, NK cell
populations expressing these receptors are educated in C57BL/6 mice, that is, they are more reac-
tive than their non-educated counterparts (Fernandez et al., 2005; Joncker et al., 2009; Kim et al.,
2005). Education is a dynamic process tuned by the number of engaged NKirs and the strength of
each interaction in a rheostat-like manner (Brodin et al., 2009a; Johansson et al., 2005;
Joncker et al., 2009). It is also reversible in as little as one or two days as shown in different experi-
mental set-ups (Ebihara et al., 2013; Elliott et al., 2010; Joncker et al., 2010). This suggests the
existence of a potent cellular process integrating activating and inhibitory educating signals of vari-
able strength (i.e. the strength of the NKar or NKir-ligand interaction and number of different inter-
actions over time) and controlling the display of effector functions in response to NKar stimulation.
Previous studies have shown that reactive NK cells are characterized by stronger calcium flux and
LFA-1 integrin activation upon NKar stimulation (Guia et al., 2011; Thomas et al., 2013). However,
the nature of the molecular process conditioning NK cell reactivity and negatively affected by
chronic engagement of NKar is unknown. To address this question, we systematically compared
phosphorylation levels of key molecules involved in immunoreceptor tyrosine-based activating motif
(ITAM) signaling in reactive vs. hyporesponsive NK cells at steady-state and following NKar stimula-
tion. We discovered that NK cell reactivity is associated with a higher basal activity of the mammalian
target of rapamycin (mTOR) pathway. Our genetic and pharmacological approaches collectively
demonstrate a prominent role of mTOR signaling in controlling steady-state NK cell responsiveness.
Results
Reactive NK cells display higher activity of the Akt/mTOR pathway at
steady-state and following acute NKar engagement
Seeking to identify molecular pathways involved in NK cell education, we systematically screened
the basal levels of 20 phosphorylations on 16 proteins involved in ITAM signaling between reactive
and hyporesponsive NK cells by flow cytometry (complete list in Table 1). This flow-cytometry based
approach allowed us to combine the advantages of single-cell analysis and comparison of equivalent
cell subset thanks to electronic gating. In C57BL/6 mice, the main educating NKirs are NKG2A and
Ly49C, defining four subsets of which the double-negative display the lowest, the double-positive
the highest and the single positives an intermediate responsiveness (Joncker et al., 2009). We also
analyzed B2m/ NK cells that are uniformly unreactive. Most of these phosphorylations are devel-
opmentally regulated (Figure 1—figure supplement 1), thus, to exclude any developmental bias,
we compared similar developmental stages defined by CD11b and CD27 (Figure 1—figure supple-
ment 2). Strikingly, all analyzed phosphorylations in the Akt/mTOR pathway correlated positively
with the level of NK cell reactivity (Figure 1A). This was true when comparing C57BL/6 and B2m/
NK cells as well as reactive and unreactive populations in C57BL/6 mice, regardless of the matura-
tion stage. In C57BL/6 populations, absence of either NKG2A or Ly49C had a measurable negative
effect, the absence of both leading to further decrease in the phosphorylation level. We also noted
a significant correlation between education status and the level of pNFkB S529 and S468 as well as
pLck Y505 and pItk Y180 (Figure 1A). However, as the most consistent differences lied in the Akt/
mTOR pathway, we decided to focus our analysis on this pathway.
The phosphatase SHP-1 is required to maintain an optimal NK cell reactivity (Viant et al., 2014).
To test its involvement in the maintenance of the basal activity of the Akt/mTOR pathway, we mea-
sured the phosphorylation levels of the ribosomal S6 protein and Akt in NK cells deficient in Ptpn6,
the gene encoding SHP-1. As a control, we also measured the level of phosphorylation of STAT5 in
these cells. The basal activity of the Akt/mTOR pathway was specifically decreased in NK cells from
Ncr1iCre/+ Ptpn6lox/lox mice compared to control NK cells while pSTAT5 levels were unchanged
(Figure 1B). Thus, basal activation of the Akt/mTOR pathway is correlated with NK cell reactivity and
controlled by SHP-1-dependent signaling downstream of NKirs.
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We next compared mTOR-related signaling events arising from NKar stimulation in reactive ver-
sus hyporesponsive NK cells. To this end, we stimulated splenocytes from C57BL/6 (around 85% of
NK cells are reactive in these mice) and B2m/ mice by crosslinking NK1.1 and we measured phos-
phorylation events over time. Phosphorylation of Akt on T308 and S473 and phosphorylation of the
ribosomal protein S6 were induced at higher levels in reactive NK cells compared to hyporesponsive
NK cells (Figure 1C,D). By contrast, other signaling events not linked to the mTOR pathway were
induced at similar levels (Figure 1C,D and Figure 1—figure supplement 3).
In summary, high activity of the Akt/mTOR pathway is a hallmark of reactive NK cells both at
steady-state and following stimulation through NKars. Importantly, considering that education is not
a discrete but rather a continuous process, absence of one or two of the educating NKir in C57BL/6
resulted in a commensurate loss in mTOR activity.
Chronic NK cell stimulation results in decreased phosphorylation of the
Akt/mTOR pathway which parallels the loss of reactivity
Education is rapidly reverted by unopposed chronic stimulation. Indeed, transfer of reactive NK cells
into a host devoid of MHC-I leads to their rapid loss of reactivity and to their tolerance to MHC-I
negative cells (Joncker et al., 2010). We thus sought to test whether chronic NKar stimulation
decreased the activity of the Akt/mTOR pathway in parallel with the decrease of reactivity. To this
purpose, we transferred reactive C57BL/6 NK cells into control C57BL/6 or B2m/ mice and mea-
sured basal Akt/mTOR phosphorylation levels and their reactivity 3 days after transfer. To quantify
the intensity of NKar signaling, we took advantage of a transcriptional reporter of the TCR signaling
(Moran et al., 2011). This reporter consists of a GFP under the control of the promoter sequence of
Nur77, an orphan nuclear receptor strongly induced in response to TCR stimulation. The signaling
pathways triggered by TCR or NKar engagement mobilizing the same signaling adaptors, we rea-
soned that the Nur77GFP construct might also report NKar triggering. Indeed, in vitro stimulation
with an NK1.1 agonist antibody or YAC-1 cells, a lymphoblastic cell line detected as foreign by
C57BL/6 NK cells, resulted in an increase in the GFP fluorescence (Figure 2—figure supplement 1).
Table 1. List of the antibodies used in this study and the phosphoepitopes they recognize.
Phosphoepitope Clone (Supplier)
pCD3z (Y142) K25-407.69 (BD)
pLck (Y505) 4/LCK-Y505 (BD)
pSyk (Y342) I120-722 (BD)
pSLP76 (Y128) J141-668.36.58 (BD)
pItk (Y180) N35-86 (BD)
pPLCg2 (Y759) K86-689.37 (BD)
pWIP (S478) K32-824 (BD)
p-p38 (T180/Y182) 36/p38 (pT180/pY182) (BD)
pERK1/2 (T203/Y205) 20A (BD)
p-c-Cbl (Y698) 47/c-Cbl (BD)
pJNK (T183/Y185) N9-66 (BD)
pNFkB p65 (S468) #3039 (CST)
pNFkB p65 (S529) K10-895.12.50 (CST)
pNFkB p65 (S536) 93H1 (CST)
pAkt (T308) C31E5E (CST)
pAkt (S473) M89-61 (BD)
pS6 (S235/236) D57.2.2E (CST)
p4EBP1 (T36/45) 236B4 (CST)
p-mTOR (S2448) D9C2 (CST)
p-mTOR (S2481) #2974 (CST)
DOI: https://doi.org/10.7554/eLife.26423.007
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Figure 1. Basal activity of the mTOR pathway is proportional to the level of NK cell reactivity, and dependent on SHP1. (A) Heatmap representing the
phosphorylation level of the phosphoepitopes indicated on the right in the different subsets of splenic resting NK cells indicated on top and gated as
defined in Figure 1—figure supplement 2. Mean Fluorescence Intensity was recorded for each phosphoepitope in each subset. Normalized
expression was calculated using the N+C+ subset of C57BL/6 mice as reference, as described in the Materials and Methods. The mean values are
shown (n = 6 mice of each genotype in three independent experiments, adjusted p-values were calculated as described in the Materials and methods
Figure 1 continued on next page
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Moreover, this increase was commensurate with reactivity so that higher GFP levels were reached in
reactive NKG2A+Ly49C+ NK cells, thus validating the expression of GFP as a reporter of NKar stimu-
lation. Transfer of Nur77GFP cells into B2m/ mice resulted in a transient increase in the GFP level
in the reactive subsets one day after transfer indicative of ongoing NKar signaling (Figure 2A). Inter-
estingly, this was followed, 3 days after transfer, by a significant decrease in steady-state GFP level
indicative of a loss of the cell capacity to signal following NKar stimulation. As previously reported,
NK cells transferred into B2m/ mice lost their reactivity while reactivity was maintained upon trans-
fer into C57BL/6 host (Figure 2B, anti-NK1.1 stimulation and Figure 2—figure supplement 2, anti-
NKp46 or YAC1 stimulation). Importantly, this was paralleled by a decrease in the phosphorylation
of S6 and Akt S473 and a loss of the gradient observed between the different subsets expressing
Ly49C and NKG2A (Figure 2C).
Collectively, these results demonstrate that the basal activity of the Akt/mTOR pathway is nega-
tively affected by persistent and unopposed NKar stimulation. This suggests that engagement of
Ly49C and NKG2A in C57BL/6 mice preserves Akt/mTOR basal activity resulting in higher basal
phosphorylation in the NK cell population expressing these NKir.
mTOR is essential for NK cell reactivity
To test if high mTOR activity was required for NK cell reactivity, we stimulated NK cells from Ncr1i-
Cre/+ Mtorlox/lox or control mice with plate-bound anti-NK1.1 antibody or YAC-1 cells and measured
NK cell degranulation relative to the expression of the major educating receptors Ly49C and
NKG2A. Control NK cells responded significantly better than mTOR-deficient NK cells, irrespective
of the subset analyzed (Figure 3A). Moreover, within control NK cells, reactive Ly49C+NKG2A+
degranulated more than the other subsets, while mTOR deficiency resulted in equally hyporespon-
sive subsets.
These results suggested a major role of mTOR in NK cell reactivity. However, mTOR deficiency
leads to a severe NK cell developmental block that may confound the interpretation of the results
(Marçais et al., 2014). To address this issue we took advantage of Torin2, a highly selective ATP-
competitive mTOR inhibitor targeting both mTORC1 and mTORC2 (Liu et al., 2011). We stimulated
mature NK cells from C57BL/6 and B2m/ mice with plate-bound anti-NK1.1 in the presence or
absence of the inhibitor. Torin2 significantly decreased the capacity of C57BL/6 NK cells to produce
IFN-g and to degranulate upon stimulation, regardless of the subset analyzed (Figure 3B). Moreover,
treatment of C57BL/6 NK cells with Torin2 abrogated the differences between highly reactive
(Ly49C+NKG2A+) and hyporesponsive (Ly49C-NKG2A-) cells. Treatment of hyporesponsive B2m/
NK cells led to a further decrease in their capacity to degranulate while their production of IFN-g
was unaffected. Similar results were obtained upon NKp46 stimulation (Figure 3—figure supple-
ment 1). Torin2 treated C57BL/6 NK cells thus functionally behaved like B2m/ hyporesponsive NK
Figure 1 continued
and compare the N+C+ subset to the indicated subset, *p<0.05, **p<0.01, ***p<0.001). (B) Histograms representing the phosphorylation level of the
indicated proteins in splenic resting NK cells from Ncr1iCre/+ or Ncr1iCre/+ Ptpn6lox/lox mice (representative of 5 mice of each genotype in three
independent experiments, t-test, **p<0.01; ***p<0.001, n.s. non significant). The MFI are indicated, in black for the Ncr1iCre/+ NK cells and in red for the
Ncr1iCre/+Ptpn6lox/lox NK cells. (C–D) Phosphorylation level of the indicated phospho-epitope in splenic NK cells from C57BL/6 or B2m/ mice
following NK1.1 stimulation for the indicated time. (C) Histogram overlays from one representative experiment. (D) MFI of the indicated phospho-
epitope (mean +SD) of 5 mice of each genotype in five independent experiments (t-test, *p<0.05).
DOI: https://doi.org/10.7554/eLife.26423.003
The following figure supplements are available for figure 1:
Figure supplement 1. Bar graph showing the phosphorylation level of the indicated phosphoepitopes in the different subsets of splenic resting
C57BL/6 NK cells defined by their expression of CD27 and CD11b.
DOI: https://doi.org/10.7554/eLife.26423.004
Figure supplement 2. Flow cytometry density plots presenting the analysis strategy to compare educated versus uneducated NK cells in C57BL/6 mice
and the phenotypically equivalent subsets in B2m/ mice.
DOI: https://doi.org/10.7554/eLife.26423.005
Figure supplement 3. Phosphorylation level of phospho-epitopes defined in Table 1 was measured by flow-cytometry in splenic NK cells from C57BL/
6 or B2m/ mice following NK1.1 stimulation for the indicated time.
DOI: https://doi.org/10.7554/eLife.26423.006
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cells. Similarly, Torin2 inhibited C57BL/6 NK cells from triggering YAC-1 lysis at a similar level seen
in hyporesponsive B2m/ NK cells (Figure 3C). Torin2 treatment had no effect on the lytic capacity
of B2m/ NK cells.
Education conditions the phenomenon of missing-self recognition. A classical readout to highlight
this property is to measure the rate of rejection of MHC-I negative target cells in vivo. To test
whether basal activity of the Akt/mTOR pathway was involved in this process, we transferred a mix
of C57BL/6 and NK-sensitive MHC-I negative (B2m/) target cells into C57BL/6 mice, previously
Figure 2. Reversion of education is accompanied by loss of the basal activity of the mTOR pathway. (A) Left: Representative histograms showing the
GFP fluorescence levels of Nur77GFP NK cells transferred into C57BL/6 or B2m/ mice and harvested 1 or 3 days after transfer. Non-transgenic host
cells are shown. Right: Bar graph showing the GFP levels of the indicated splenic NK cell subsets normalized to the N-C- population of Nur77GFP NK
cells transferred into C57BL/6 control mice (mean +SD, n = 6 mice of each genotype per time point in two independent experiments, two-way ANOVA;
***p<0.001, n.s. non significant). (B) Percentage (mean + SD) of IFN-g+ or CD107a+ cells among splenic host or transferred NK cells of the indicated
subset following a 4 hr stimulation with coated anti-NK1.1. The experiment was done 3 days after transfer (n = 6 mice of each genotype in two
independent experiments, two-way ANOVA comparing each subset to its counterpart in C57BL/6 mice, **p<0.01, ***p<0.001, n.s. non significant). (C)
Heatmap representing the phosphorylation level of the phosphoepitopes indicated on the right in the different subsets of splenic resting NK cells
indicated on top. Mean Fluorescence Intensity was recorded for each phosphoepitope in each subset. Normalized expression was calculated using the
N+C+ subset of C57BL/6 host NK cells as reference. The mean values are shown (n = 6 mice of each genotype in two independent experiments, t-tests
comparing the N+C+ subset to the indicated subset, *p<0.05, **p<0.01).
DOI: https://doi.org/10.7554/eLife.26423.008
The following figure supplements are available for figure 2:
Figure supplement 1. Left: Representative histograms showing the GFP fluorescence levels of Nur77GFP NK cells before or after a 4 hr stimulation with
anti-NK1.1 or YAC-1 cells.
DOI: https://doi.org/10.7554/eLife.26423.009
Figure supplement 2. Percentage (mean +SD) of IFN-g+ or CD107a+ cells among splenic host or transferred NK cells of the indicated subset following
4 hr stimulation with (A) coated anti-NKp46 or (B) YAC-1 cells.
DOI: https://doi.org/10.7554/eLife.26423.010
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treated or not with Torin2. While injection into control mice led to the disappearance of 50% of the
target cells, this rejection was abrogated in Torin2 treated animals, underlining the importance of
mTOR activity in NK cell recognition of missing-self under steady-state conditions (Figure 3D).
Altogether, these results demonstrate that mTOR is required for NK cell reactivity.
mTOR is a rheostat of NK cell reactivity through NKar
The ‘rheostat’ model of education proposes that the strength of the MHC-I input translates into a
quantitative modification of NK cell responsiveness (Brodin et al., 2009b). Indeed, several studies
reported that the higher the number of self–MHC-I receptors expressed by NK cells interacting with
their ligands, the stronger their responsiveness (Brodin et al., 2009a; Johansson et al., 2005;
Joncker et al., 2009). As shown in Figure 1, the level of mTOR activity was tightly correlated with
the number of educating NKirs in NK cells, suggesting that mTOR could serve as the molecular rheo-
stat translating the MHC-I input into quantitative tuning of the responsiveness. To directly test this
point, we analyzed how the ex vivo modulation of mTOR activity by pharmacologic mTOR inhibitors
changed NK cell responsiveness. We took advantage of four different inhibitors of graded mTOR
inhibitory potential: the macrolide Rapamycin that primarily inhibits mTORC1 and three ATP-com-
petitive inhibitors targeting both mTORC1 and mTORC2 to a varying extent: AZD2014, KU-0063794
(KU) and Torin2 (Garcı́a-Martı́nez et al., 2009; Guichard et al., 2015; Liu et al., 2011;
Figure 3. mTOR is essential for NK cell reactivity. (A) Percentage (mean +SD) of CD107a+ cells among splenic CD11blo NK cells of the indicated subset
from Ncr1iCre/+ or Ncr1iCre/+ Mtorlox/lox mice following 4 hr stimulation with coated anti-NK1.1 or YAC-1 cells (n = 5 mice of each genotype in three
independent experiments, t-tests comparing each subset in both genotype, *p<0.05, **p<0.01, n.s. non significant). (B) Percentage (mean +SD) of IFN-
g+ or CD107a+ cells among splenic NK cells of the indicated subset from C57BL/6 or B2m/ mice following 4 hr stimulation with coated anti-NK1.1 in
the presence or absence of 250 nM Torin2 (n = 9–10 mice of each genotype in five independent experiments, two-way ANOVA comparing each subset
to its counterpart in B2m/ mice, *p<0.05, **p<0.01, ***p<0.001, n.s. non significant). (C) Percentage (mean +SD) of dead YAC-1 cells after a 4 hr co-
culture with purified NK cells of the indicated genotype at the indicated Effector/Target ratio in the presence or absence of 250 nM Torin2 (n = 9
C57BL/6 and 7 B2m/ mice in four independent experiments, two-way ANOVA comparing each E/T ratio of C57BL/6 + Torin2 to C57BL/6, B2m/ or
B2m/ +Torin2 as indicated by the color, ***p<0.001, n.s. non significant). (D) Percentage of remaining B2m/ target cells following in vivo
cytotoxicity experiment as described in the Materials and methods. Each dot represents a single mouse, bars indicate mean and SD (n = 9 control
treated mice and 7 Torin2 treated mice in two independent experiments, t-test, ***p<0.001).
DOI: https://doi.org/10.7554/eLife.26423.011
The following figure supplement is available for figure 3:
Figure supplement 1. Percentage (mean +SD) of IFN-g+ or CD107a+ cells among splenic NK cells of the indicated subset from C57BL/6 or B2m/
mice following 4 hr stimulation with coated anti-NKp46 in the presence or absence of 250 nM Torin2 (n = 9–10 mice of each genotype in five
independent experiments, 2-way ANOVA comparing each subset to its counterpart in B2m/ mice, *p<0.05, **p<0.01, ***p<0.001, n.s. non
significant).
DOI: https://doi.org/10.7554/eLife.26423.012
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Sabatini et al., 1994; Yang et al., 2013). The use of different concentrations of those compounds
allowed us to modulate mTOR activity in NK cells over a dynamic range of 10-fold for mTORC1 or 2-
fold for mTORC2 as measured by phosphorylation of S6 and Akt S473 respectively (Figure 4A). Of
note, we confirmed that Rapamycin acted specifically on mTORC1 while AZD, KU and Torin2 inhib-
ited both complexes. Importantly, at these concentrations no significant changes in STAT5 phos-
phorylation or specific toxicity over a 24 hr incubation period were noted (Figure 4—figure
supplement 1A and B). We then correlated the S6 and Akt phosphorylation levels to the IFN-g pro-
duction and degranulation induced by NK1.1 crosslinking. S6 phosphorylation was positively corre-
lated with the effector functions in all conditions tested (Figure 4B). Similar correlations were found
between Akt phosphorylation and effector function upon AZD, KU or Torin2 treatment (Figure 4C).
However, this correlation was lost upon Rapamycin treatment, suggesting that mTORC2 activity
alone is not sufficient to sustain effector functions (Figure 4B,C). In addition, effector functions were
not correlated to STAT5 phosphorylation levels (Figure 4—figure supplement 1B,C). Similar results
were obtained upon stimulation of NK cells from Ncr1iCre and Ncr1iCre Mtorlox/lox mice and measure
of the phosphorylation levels of the S6 and Akt proteins in parallel thus genetically confirming the
results (Figure 4—figure supplement 1D).
Overall, these results demonstrate that mTOR acts as a molecular rheostat of NK cell responsive-
ness. Together with results in Figures 1 and 2, they demonstrate that NK cell education relies on
the modulation of mTOR activity that in turn controls NK cell responsiveness through NKars.
mTOR is essential for calcium response and integrin activation in NK
cells following NKar engagement
Next, we asked whether mTOR activity could regulate signaling via NKar. Previous studies estab-
lished that reactive NK cells display higher calcium flux (Guia et al., 2011) and higher integrin activa-
tion than hyporesponsive NK cells (Thomas et al., 2013). Hence we sought to test the impact of
mTOR activity on these cardinal events in lymphocyte activation. We first measured the calcium flux
in real time by flow cytometry following NK1.1 stimulation using fluorescent calcium probes and we
quantified the intensity of the fluorescence peak. When we challenged Ncr1iCre/+ (control) and Ncr1i-
Cre/+ Mtorlox/lox NK cells, NK1.1 cross-linking resulted in a detectable calcium flux in NK cells of both
genotypes (Figure 5A). However, the peak was lowered (15–20%) in the absence of mTOR. We next
applied the same protocol to control C57BL/6 NK cells in the presence or absence of Torin2 to
acutely inhibit mTOR. As shown in Figure 5B, mTOR inhibition resulted in a decreased calcium flux
characterized by a 20%-decrease in the peak intensity, thus phenocopying the impact of mTOR
deficiency.
Next, we assessed the effect of mTOR deficiency on LFA-1 integrin activation following NKar trig-
gering of inside-out signaling. For this purpose, we incubated NK cells from Ncr1iCre/+ and Ncr1iCre/+
Mtorlox/lox mice with beads coated with ICAM-1, the ligand of LFA-1, in the presence or absence of
NK1.1 cross-linking. At different times, we measured by flow-cytometry the percentage of beads-
associated NK cells as an indicator of LFA-1 activation in NK cells. As shown in Figure 5C, NK1.1
cross-linking failed to induce LFA-1 activation in mTOR-deficient NK cells contrary to control NK
cells. In parallel, we also tested the effect of acute mTOR inhibition on LFA-1 activation in mature
educated NK cells. As shown in Figure 5D, addition of Torin2 resulted in significant inhibition of
LFA-1 activation induced by NK1.1 stimulation.
Thus, using genetic and pharmacological tools, we showed that the mTOR pathway lies upstream
of two signaling events, calcium flux and LFA-1 integrin activation, which are elevated in reactive NK
cells.
Metabolic parameters of reactive and hyporesponsive NK cells
mTOR is a well-known regulator of the cell metabolism. We thus asked whether the higher activity of
mTOR measured in reactive NK cells resulted in detectable changes in metabolic activity. We first
measured cell size and granularity using the FSC and SSC flow-cytometry parameters. Reactive NK
cells from C57BL/6 control mice presented a slight but significant increase of both morphological
indicators when compared to hyporesponsive NK cells of B2m/ mice (Figure 6A). Similarly, their
mitochondrial content as well as glucose and fatty-acid uptake capacities estimated by measure of
the uptake of the glucose fluorescent analog 2-NBDG or the fatty-acid fluorescent analog Bodipy
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Figure 4. mTOR is a rheostat of NK cell reactivity through NKar. (A) Bar graph showing the phosphorylation level of S6 (left) and Akt S473 (right) in
splenic NK cells following 1 hr treatment with 100 ng/ml IL-15 in the presence or absence of the indicated mTOR inhibitors at the indicated
concentration (mean of the MFI normalized to the No inhibitor condition +SD, n = 9 mice in three independent experiments, one-way ANOVA
comparing the No inhibitor condition with the indicated condition, **p<0.01; ***p<0.001, n.s. non significant). (B–C) Linear regression plots showing the
correlation between (B) pS6 or (C) pAkt S473 as indicated and the percentage of IFN-g+ or CD107a+ NK cells following 4 hr stimulation with coated
anti-NK1.1 in the presence of 100 ng/ml IL-15 and mTOR inhibitors (mean ±SD, n = 9 mice in three independent experiments, the r2 and p-value
calculated by linear regression are indicated).
DOI: https://doi.org/10.7554/eLife.26423.013
The following figure supplement is available for figure 4:
Figure supplement 1. Bar graphs showing (A) the phosphorylation level of STAT5 in splenic NK cells following 1 hr treatment with 100 ng/ml IL-15 or
(B) the percentage of live NK cells following a 24 hr culture in the presence or absence of the indicated mTOR inhibitors at the indicated concentration
(A) mean of the MFI normalized to the No inhibitor condition or (B) percentage of live cells + SD, n = 9 mice in three independent experiments for
pSTAT5 and 4 mice in two independent experiments for Viability, one-way ANOVA comparing the No inhibitor condition with the indicated condition,
n.s. non significant).
DOI: https://doi.org/10.7554/eLife.26423.014
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FL-C16 were significantly higher (Figure 6B). In contrast, mitochondrial ROS production, lipid drop-
let content or lipid peroxidation were comparable in both cell types (data not shown). Differences
were also detectable for FSC and SSC values as well as fatty-acid uptake when comparing reactive
and hyporesponsive NK cell subsets present in the most mature CD27low population of C57BL/6
mice (Figure 6C).
In summary, the higher activity of the Akt/mTOR pathway observed in reactive cells increased
their metabolic activity compared to hyporesponsive NK cells, which may also contribute to their
enhanced responsiveness.
Cytokine stimulation overcomes NK cell education by inducing high
mTOR activity that restores NKar signaling
Several studies have demonstrated that hyporesponsive NK cells can be rendered reactive
(Ebihara et al., 2013; Elliott et al., 2010; Joncker et al., 2010; Sun and Lanier, 2008). The underly-
ing molecular mechanism has however remained elusive. We reasoned that if the mTOR pathway
was really a key determinant of NK cell reactivity, acute activation of this pathway should immedi-
ately restore reactivity of hyporesponsive cells. To test this hypothesis, we stimulated NK cells from
C57BL/6 or B2m/ mice with plate-bound antibodies stimulating NK1.1 or NKp46 and we simulta-
neously added IL-2, a cytokine known to potently activate mTOR (Marçais et al., 2014). To test the
requirement for the mTOR pathway in this process, cells were also treated or not with Torin2. IL-2
resulted in an increase of the cell capacity to produce IFN-g and to degranulate as measured by
CD107a exposure (Figure 7A). This acute treatment was sufficient for hyporesponsive cells to
acquire a level of reactivity equal or even higher than that of reactive NK cells from C57BL/6, regard-
less of the stimulating antibody. mTOR activity was required for this effect since the increase in reac-
tivity was suppressed by mTOR inhibition (Figure 7A). Similar results were obtained when using IL-
Figure 5. mTOR is essential for calcium response and integrin activation following NKar engagement. (A) Left: Representative histogram overlay
showing the Ca2+ flux intensity in splenic CD11blo NK cells from Ncr1iCre/+ or Ncr1iCre/+ Mtorlox/lox mice. NK cells were activated following incubation
with biotinylated anti-NK1.1 (Arrow) followed by cross-linking with streptavidin (Arrowhead). Right: Bar graph showing the Ratio Peak/basal normalized
to the ratio of control NK cells (mean +SD, t-test *p<0.05). (B) Left: Representative histogram overlay showing the Ca2+ flux intensity in splenic NK cells
from C57BL/6 mice in the presence or absence of 500 nM Torin2. Right: Bar graph showing the Ratio Peak/basal normalized to the ratio of control NK
cells (mean +SD, t-test ***p<0.001). (C) Percentage of splenic CD11blow NK cells from Ncr1iCre/+ or Ncr1iCre/+ Mtorlox/lox mice bound to beads coated
with ICAM-1 after the indicated incubation time with or without NK1.1 stimulation (mean +SD, n = 6 mice of each genotype in four independent
experiments, two-way ANOVA comparing the conditions with or without NK1.1 stimulation, n.s. non significant, **p<0.01, ***p<0.001). (D) Percentage
of splenic C57BL/6 NK cells bound to beads coated with ICAM-1 after the indicated incubation time with or without NK1.1 stimulation, in the presence
or absence of 250 nM Torin2 (mean +SD, n = 6 mice in four independent experiments, two-way ANOVA comparing the conditions with or without
NK1.1 stimulation, n.s. non significant, ***p<0.001).
DOI: https://doi.org/10.7554/eLife.26423.015
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15 instead of IL-2 (Figure 7—figure supplement 1). Acute IL-15 stimulation also restored the cyto-
toxic activity of hyporesponsive NK cells against YAC-1 cells while further enhancing cytotoxicity of
C57BL/6 cells (Figure 7B). Again, this effect was completely reversed upon concomitant Torin2
treatment. Taken together, these results show that induction of responsiveness in NK cells upon
cytokine exposure is a rapid phenomenon acting via mTOR activation.
In order to decipher the mechanism required for NK cell re-education, we next tested whether
acute IL-15 treatment restored early signaling in hyporesponsive cells. We first investigated the
impact of IL-15 treatment on the calcium flux triggered by NK1.1 stimulation in control or hypores-
ponsive NK cells. As expected, NK1.1 stimulation of hyporesponsive NK cells resulted in a very poor
calcium flux compared to reactive NK cells (Figure 7C). Strikingly, treatment with IL-15 increased the
calcium flux ability of reactive and hyporesponsive NK cells in an mTOR-dependent way (Figure 7C
and Figure 7—figure supplement 2). We then measured the impact of IL-15 treatment on LFA-1
activation following NK1.1 stimulation. The presence of IL-15 in the assay rendered hyporesponsive
NK cells able to activate LFA-1 upon NK1.1 stimulation and bind ICAM-1 coated beads (Figure 7D).
Figure 6. Metabolic parameters of reactive and hyporesponsive NK cells. (A) Bar graphs showing FSC and SSC values of splenic NK cell subsets from
C57BL/6 or B2m/ mice (mean +SD, n = 6 mice of each genotype in three independent experiments, t-test, ***p<0.001). MFI were normalized to the
CD11blo subset of C57BL/6 mice. (B) Bar graphs showing MFI of mitotracker staining, 2-NBDG or BodipyFL C16 incorporation of splenic NK cell
subsets from C57BL/6 or B2m/ mice (mean +SD, n = 6–10 mice of each genotype in three independent experiments, t-test, *p<0.05, **p<0.01,
***p<0.001, n.s. non significant). MFI were normalized to the CD11blo subset of C57BL/6 mice. (C) Bar graphs showing FSC and SSC values or BodipyFL
C16 incorporation of splenic NK cell subsets (gated on CD27low) from C57BL/6 or B2m/ mice (mean +SD, n = 6–10 mice of each genotype in three
independent experiments, t-test, n.s. non significant, *p<0.05, ***p<0.001). MFI were normalized to the N+C+ subset of C57BL/6 mice.
DOI: https://doi.org/10.7554/eLife.26423.016
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Figure 7. Cytokine stimulation overcomes NK cell education by inducing high mTOR activity that restores NKar signaling. (A) Percentage (mean +SD)
of IFN-g or CD107a positive cells among splenic NK cells from C57BL/6 or B2m/ mice following 4 hr stimulation with coated anti-NK1.1 or anti-NKp46
in the presence or absence of 200UI/ml IL-2 and 250 nM Torin2 as indicated (n = 9–10 mice of each genotype in five independent experiments, one-
way ANOVA comparing each condition to the C57BL/6 condition, *p<0.05, **p<0.01, ***p<0.001, n.s. non significant). (B) Percentage (mean +SD) of
dead YAC-1 cells after a 4 hr co-culture with purified NK cells from C57BL/6 or B2m/ mice at the indicated Effector/Target ratio in the presence or
absence of 10 ng/ml IL-15 and 250 nM Torin2 as indicated (n = 7 mice of each genotype in three independent experiments, the table on the right
presents the results of a two-way ANOVA comparing C57BL/6 with the other experimental conditions for the indicated Effector/Target ratio, **p<0.01,
***p<0.001 n.s. non significant). (C) Top: Representative histogram overlay showing the Ca2+ flux intensity in splenic NK cells from C57BL/6 or B2m/
mice with or without IL-15 (100 ng/ml). NK cells were activated following incubation with biotinylated anti-NK1.1 (Arrow) followed by cross-linking with
streptavidin (Arrowhead). Down: Bar graph showing the Ratio Peak/basal normalized to the ratio of control NK cells (mean +SD of n = 17–20 replicates
from 6 mice in six independent experiments, one-way ANOVA comparing the indicated conditions, **p<0.01, ***p<0.001). (D) Percentage of splenic NK
cells from B2m/ mice bound to beads coated with ICAM-1 after the indicated incubation time with or without NK1.1 stimulation, in the presence or
absence of 100 ng/ml IL-15 and 250 nM Torin2 (n = 6 mice in four independent experiments, two-way ANOVA comparing stimulated to non-stimulated
conditions, n.s. non significant, ***p<0.001).
DOI: https://doi.org/10.7554/eLife.26423.017
The following figure supplements are available for figure 7:
Figure supplement 1. Percentage (mean +SD) of IFN-g or CD107a positive cells among splenic NK cells from C57BL/6 or B2m/ mice following 4 hr
stimulation with coated anti-NK1.1 or anti-NKp46 in the presence or absence of 10 ng/ml IL-15 and 250 nM Torin2 as indicated (n = 4 mice of each
genotype in two independent experiments, one-way ANOVA comparing each condition to the C57BL/6 condition, *p<0.05, **p<0.01, ***p<0.001, n.s.
non significant).
DOI: https://doi.org/10.7554/eLife.26423.018
Figure supplement 2. Left: Representative histogram overlay showing the Ca2+ flux intensity in splenic NK cells from C57BL/6 or B2m/ mice with or
without IL-15 (100 ng/ml) and Torin2 (500 nM).
DOI: https://doi.org/10.7554/eLife.26423.019
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This effect was strongly decreased upon Torin2 treatment, underlying the non-redundant role of
mTOR in this process.
Altogether, these results show that acute stimulation of the mTOR pathway can restore the ability
of hyporesponsive NK cells to induce calcium flux and activate LFA-1 upon NKar engagement,
thereby re-establishing their reactivity.
Discussion
Here, to gain mechanistic insight into the phenomenon of NK cell education, we explored signal
transduction pathways downstream NKars in reactive and hyporesponsive NK cells. We found that
the activity of the Akt/mTOR pathway was selectively higher in reactive NK cells. This was character-
ized by higher basal phosphorylation of direct and indirect targets of both mTOR complexes
(mTORC1 and 2) in strict correlation with the reactivity level. In addition, this pattern was lost con-
comitantly with the loss of reactivity observed upon transfer of reactive cells in B2m/ hosts. Our
screen also revealed that two out of the three NFkB p65 phosphorylations investigated (S468 and
S529) correlated with reactivity. This could be the result of the heightened Akt/mTOR pathway activ-
ity, as mTORC2 has been involved in NFkB activation during CD4 T cell stimulation (Lee et al.,
2010). Alternatively, this could reveal the involvement of other pathways in the control of NK cell
reactivity.
What is the extracellular signal and the signaling pathway responsible for the maintenance of
mTOR basal activity in reactive NK cells specifically? An obvious candidate would be IL-15 as this
cytokine is a privileged activator of this pathway (Marçais et al., 2014). However, pSTAT5 levels
were identical between reactive and hyporesponsive NK cells (data not shown). Moreover, in vivo
treatment with antibodies blocking IL-15 signaling did not alter NK cell education (data not shown).
Finally, it is difficult to envisage how reactive cells would get preferential access to IL-15. Instead, in
line with the disarming hypothesis, we would favor a model in which basal mTOR activity is set inde-
pendently of education signals. This initial activity would then be decreased by disarming signals.
How mTOR activity is decreased by chronic NKar stimulation is still an open question. We hypothe-
size that in the absence of surrounding MHC-I or in NK cells lacking functional NKirs, unopposed
NKar signaling could lead to shut-down of the Akt/mTOR pathway due to depletion of necessary
intermediates or establishment of negative feedbacks as it has been demonstrated in the case of
induction of resistance to insulin (Um et al., 2006). Engagement of NKirs would prevent this desensi-
tization and maintain an optimal activity of the pathway. In favor of this hypothesis, we show that
SHP-1, the phosphatase triggered by NKir ligation and necessary to maintain NK cell reactivity
(Viant et al., 2014), was required to maintain an optimal activity of the mTOR pathway. Further-
more, transfer of Nur77GFP cells into B2m/ hosts was accompanied by an increase in the GFP level,
evidence of active NKar signaling, and followed by the loss of mTOR basal activity concomitant with
the loss of reactivity of NKG2A+Ly49C+ NK cells.
Previous studies have conclusively shown that NK cell education is not an on-off switch but rather
a variation on a continuous axis (Brodin et al., 2009a; Joncker et al., 2009). We propose that the
mTOR pathway is the long-sought molecular rheostat able to both respond to educating signals and
control effector functions in return. Indeed, we showed that activity of the Akt/mTOR pathway is reg-
ulated commensurate with the level of NKir engagement by MHC-I molecules. Furthermore, we
demonstrated that modulation of mTOR activity by exogenous cytokine or pharmacologic treat-
ments was directly correlated with NK cell responsiveness. Furthermore, mTOR could also regulate
NK cell responsiveness by integrating signals beyond NKir ligands. Considering the concept of the
extended rheostat model as described initially by Höglund and colleagues (Brodin et al., 2009b),
we envision extracellular inputs in an extended sense, including immunological as well as purely met-
abolic inputs. Interestingly, a number of environmental conditions, such as the presence of inflamma-
tory (Sun and Lanier, 2008) or anti-inflammatory cytokines (Sungur et al., 2013), but also the
presence of nutrients (Keppel et al., 2015), impact on NK cell responsiveness. All these stimuli posi-
tively or negatively affect mTOR activity (Efeyan et al., 2015; Marçais et al., 2014; Sinclair et al.,
2013; Viel et al., 2016). mTOR activity could thus be the nexus targeted by these different stimuli
which would explain their impact on NK cell responsiveness. Thus, considering mTOR as the rheostat
of NK cell responsiveness would help to build a common conceptual framework in which these
observations could be ordered.
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Finally, we also present evidence on how mTOR activity affects NK cell effector functions. We
demonstrated that mTOR activity controls two distinct events characterizing reactive NK cells and
required for the triggering of effector functions: Ca2+ flux and integrin activation. How could mTOR
activity control such apparently unrelated signaling events? Depending on the relative involvement
of mTORC1 or mTORC2, several possibilities can be considered. First, the fact that Rapamycin which
specifically inhibits mTORC1 is sufficient to decrease responsiveness unmasks the non-redundant
role of this complex. In line with the role of mTORC1 in the control of cellular metabolism, we
described that higher basal mTOR activity in educated cells translated into higher basal metabolism
as measured by morphological parameters as well as glucose and fatty-acid uptake and mitochon-
drial content. We and others have described the necessary role of the mTORC1-dependent metabo-
lism in the development of NK cell effector functions (Donnelly et al., 2014; Marçais et al., 2014).
In addition to improving the cellular fitness, metabolism could directly modulate signaling by con-
trolling the availability of key intermediates as recently described for Th17/Treg differentiation
(Araujo et al., 2017). Another possibility would be through the regulation of the actin cytoskeleton.
Indeed, an emerging mode of lymphocyte signaling regulation is through cytoskeleton-dependent
regulation of membrane receptors compartmentalization (Mattila et al., 2016), a process that has
been proposed to explain the reactivity of educated NK cells (Guia et al., 2011). mTORC2 has been
shown to regulate the cytoskeletal organization (Huang et al., 2013; Sarbassov et al., 2004) and
could therefore prime reactive NK cells by cytoskeletal modifications. An interesting parallel can also
be drawn with T cell anergy. Indeed, TCR stimulation in the absence of CD28 co-stimulation results
in T cell hyporesponsiveness to further re-stimulation. Numerous studies have shown that the precise
control of mTOR activity is at the heart of this phenomenon (Chappert and Schwartz, 2010;
Marcais et al., 2014; Zheng et al., 2007; 2009). Interestingly, this state is characterized by defec-
tive Ca2+ flux (Dubois et al., 1998). Further resembling hyporesponsive NK cells, treatment of aner-
gic T cells with IL-2 restores their responsiveness, an event that relies on mTOR activation
(Dubois et al., 1998; Zheng et al., 2007). Ca2+ flux is classically triggered by IP3-induced release of
endoplasmic reticulum stores which, upon detection by the STIM1/2 sensors, leads to opening of
the ORAI channels present on the plasma membrane and extracellular Ca2+ entry (Hogan and Rao,
2015). In addition, an underestimated Ca2+ store is the endo-lysosomal compartment
(Morgan et al., 2011), which constitutes a further link with mTOR since mTORC1 is activated on the
lysosomal surface and positively regulated by lysosomal nutrients (Efeyan et al., 2015) as well as by
calcium release from lysosomal stores (Li et al., 2016). Concerning regulation of integrin activation,
a putative link would be through the inhibition of GSK3b. Indeed, this kinase is inhibited by Akt fol-
lowing mTORC2 activation (Hagiwara et al., 2012), and a recent study showed that its inhibition
leads to better ability of NK cells to form conjugate via integrin activation (Parameswaran et al.,
2016). In addition, PKCq, a target of mTORC2 (Lee et al., 2010), activates WIP via S488 phosphory-
lation in lymphocytes (Fried et al., 2014). Since a macro-complex involving WIP, WASp, actin and
myosin IIa has been defined in NK cells (Krzewski et al., 2006), WIP activation could explain better
interaction with ICAM-1-coated beads in our assay and ultimately better docking to target cell.
In summary, these findings identify the activity of the mTOR pathway as the molecular rheostat
responsible for the control of basal NK cell reactivity in response to NKir ligation. In addition, this
provides a molecular basis for a number of previous experiments showing that NK cell education can
be overcome by cytokine treatment. Finally, our data underline the extreme versatility of the regula-
tion of NK cell responsiveness and further point to mTOR as a valid target for the manipulation of
NK cells for therapeutic purposes.
Materials and methods
Mice and adoptive transfers
Wild-type C57BL/6 mice were purchased from Charles River Laboratories (L’Arbresle). B2m/
(Koller et al., 1990), Ncr1iCre/+ Mtorlox/lox (Marçais et al., 2014) and Ncr1iCre/+ Ptpn6lox/lox mice
(Viant et al., 2014) were previously described, littermate control mice were used as controls.
Nur77GFP mice were previously described (Moran et al., 2011). Female mice 8 to 24 week-old were
used. Nur77GFP splenocytes were injected i.v. in C57BL/6 or B2m/ host. Each host received 25 
106 splenocytes labeled with CTV (1 mM, Molecular Probes) to allow subsequent identification. Host
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mice were sacrificed one or 3 days after for analysis of the spleen. This study was carried out in
accordance with the French recommendations in the Guide for the ethical evaluation of experiments
using laboratory animals and the European guidelines 86/609/CEE. All experimental studies were
approved by the bioethic local committee CECCAPP. Mice were bred in the Plateau de Biologie
Expérimentale de la Souris, our animal facility.
Flow cytometry
Single cell suspensions of spleens were obtained and stained. Intracellular stainings for phosphory-
lated proteins were done using Lyse/Fix and PermIII buffers (BD Bioscience). Measurement of glu-
cose uptake was performed as described (Marçais et al., 2014). Mitochondrial content was
measured using Mitotracker Green (Molecular Probes, 1 mM) incubated for 10 min at 37˚C in PBS.
Lipid uptake was measured using BodipyFL C16 (Molecular Probes, 1 mM) incubated for 30 min at
37˚C in complete medium. Surface staining were then performed to identify the different popula-
tions. Flow cytometry was carried out on a FACS LSR II or on a FACS Fortessa (Becton-Dickinson).
Data were analysed using FlowJo (Treestar). The following mAbs from eBioscience, BD Biosciences
or Biolegend were used: anti-CD19 (ebio1D3), anti-CD3 (145–2 C11), anti-NK1.1 (PK136), anti
NKp46 (29A1.4), anti-CD49b (DX5), anti-CD11b (M1/70), anti-CD27 (LG.7F9), anti-Ly49I (YLI90), anti-
NKG2A/C/E (20d5), anti-IFN-g (XMG1.2), anti-CD107a (1D4B). The mAb 4LO3311 recognizing
Ly49C was purified on protein A column from supernatant of the 4LO3311 hybridoma generously
provided by Pr. Suzanne Lemieux (Institut Armand Frappier, Québec). NKG2A positive cells were
identified using the 20d5 clone which also recognizes NKG2C and NKG2E, however, since mouse
resting NK cells only express NKG2A, we considered 20d5 reactive cells as NKG2A positive
(Vance et al., 1998).
Cell culture and stimulation
1.5  106 splenocytes were cultured on antibody coated plates (anti-NKp46 (Goat polyclonal, R&D),
anti-NK1.1 (PK136, BioXCell) at 10 mg/ml on Immulon 2HB or Nunclon plates) with Golgi-stop (BD
Biosciences) in the presence of anti-CD107a for 4 hr. Cytokines and mTOR inhibitors were used at
the following concentrations unless otherwise stated: rmIL-15 (Peprotech; 100 ng/ml), IL-2 (muIL-2
supernatant; 200 U/ml), Rapamycin (Calbiochem; 25 nM), KU-0063794 (Stemgent; 3 mM), AZD2014
(Selleckchem; 5 mM) and Torin2 (Tocris; 250 nM). Surface and intracellular stainings were then per-
formed and IFN-g production as well as CD107a exposure was measured by flow cytometry. In some
experiments, cell viability was determined using 7AAD (Invitrogen, 250 nM).
For phospho-flow stainings following short-term NK1.1 stimulation, 3  106 splenocytes were
stimulated using biotinylated NK1.1 (PK136, 5 mg/ml) followed 1 min 30 s later by streptavidin (Life
Technologies, 10 mg/ml) and fixed by addition of 10 volumes of Lyse/Fix at the indicated time point.
In vivo cytotoxicity assay
Recipient mice were treated by daily i.p. injection of Torin2 (10 mg/kg, vehicle: 40% H2O, 40%
PEG400 (Sigma), 20 % N methyl two pyrrolidone (Sigma)) for 6 days prior to target transfer. Spleno-
cytes from C57BL/6 or B2m/ mice were labeled respectively with CellTraceViolet (1 mM) or CFSE
(5 mM) (both from Life Technologies), and 10  106 cells (5  106 of each genotype) were transferred
by i.v. injection. 60 hr after transfer, splenocytes were isolated and analyzed by FACS. Percentage of
remaining B2m/ cells was calculated using the following formula: % remaining cells = 100 x (num-
ber B2m/ cells/number C57BL/6 cells) at 60 h /(number B2m/ cells/number C57BL/6 cells) in
input mix.
In vitro cytotoxicity assay
NK cells were first enriched by negative depletion prior to killing assay. Briefly, splenocytes suspen-
sion were incubated with biotinylated mAb against: CD3 (14–2 C11), TCRb (H57-597), TCRgd (GL3),
CD19 (ebio1D3), TER-119 (ter119) (eBioscience), followed by incubation with anti-biotin microbeads
(Miltenyi), and enrichment by magnetic separation on an AutoMACS. Enriched NK cells were co-cul-
tured for 4 hr with YAC-1 cells labeled with CFSE (Life Technologies) at different Effector to target
(E/T) ratios calculated based on the cell number and the percentage of NK cells after purification.
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The percentage of dead cells within CFSE positive YAC-1 cells was measured by flow cytometry after
staining with 7AAD.
Calcium flux
Calcium flux was measured essentially as described (Guia et al., 2011). Briefly, RBC-lysed spleno-
cytes suspension in RPMI/0.2% BSA/25 mM HEPES were stained at RT with the following mAb: anti-
CD3/CD19 PEeFluor610, anti-CD49b APC, anti-CD11b APCCy7, anti-CD27 PE. They were then
stained at 1  107 cells/ml with Indo-1 (1 mM, Life Technologies) for 30 min at 37˚C and washed two
times at 4˚C. They were resuspended in the above medium and placed at 37˚C for 30 min prior
acquisition in the presence or absence of rmIL-15 (100 ng/ml) or Torin2 (250 nM). Samples were
acquired on a LSRII (BD) as follow: 15 s baseline acquisition, addition of anti-NK1.1 biotin (PK136, 5
mg/ml), acquisition for 1 min 30 s, addition of Streptavidin (Life Technologies, 10 mg/ml) and, acquisi-
tion for another 3–5 min.
ICAM1 coated beads assay
One mg Protein G-coated 4–4.9 mm beads (Spherotec) was incubated for 30 min with 3.5 mg
ICAM1-hIgG1Fc (R&D) on a rotating wheel at RT in PBS. Beads were then pelleted by centrifugation
and washed two times with complete medium, counted on a FACS Accuri (BD) and resuspended at
1  107 beads/ml. In parallel, NK cells were purified (80–90% purity) using biotinylated antibodies
directed against CD3, CD19, CD5, CD24, F4/80 and Ly6G and anti-biotin beads. They were then
incubated with anti-NKp46-PE (29A1.4, BD) and purified anti-NK1.1 (PK136, BioXCell). 100,000 puri-
fied NK cells in 10 ml were placed in a U-bottom well and 100,000 ICAM-1 coated beads were
added. To cross-link NK1.1 and measure the effect of inside-out signaling, a Goat F(ab)’2 anti-mouse
IgG (10 mg/ml, Life Technologies) was added to the wells. Interaction was fixed at the indicated
time-point by addition of 100 ml Cytofix/Cytoperm (BD). The percentage of interaction (i.e. percent-
age of NKp46 positive cells attached to beads) was measured by flow cytometry.
Statistical analysis
Statistical analyses were performed using Prism 5 (Graph-Pad Software). Two tailed unpaired t-test,
and ANOVA tests with Bonferroni correction were used as indicated in the figure legends. Signifi-
cance is indicated as follows: *p<0.05; **p<0.01; ***p<0.001. The heatmap presented in Figure 1A
was established as follow: we first selected the phosphoepitopes for which the MFI (Mean Fluores-
cence Intensity) was significantly above the one of the FMO control (Student T-test). The MFI of the
15 selected phosphoepitopes for the 4 NC sub-populations defined in Figure 1—figure supplement
2 was then normalized to the MFI value of the NKG2A+Ly49C+ populations in the C57BL/6 mice and
the values obtained were averaged to calculate the means for each populations. These values were
used to establish the Heatmap using the Multiple Experiment Viewer application. We used the R sta-
tistical language to manage our database and carry out the statistical analysis (R version 3.3.2). We
splited the database into six datasets (2 Mouse strains * Differentiation subsets), each containing the
15 phospho-epitopes. We performed an ANOVA for each phospho-epitope to test for the phos-
phorylation difference between the 4 NC sub-populations. The parameters of the ANOVA Type I SS
were adapted to control for the experiment effect. The Bartlett Homogeneity of Variances Test was
applied first, when it failed to reject its H0, then the phospho-epitope was retained for the ANOVA
test. The normality of the residuals of the ANOVA model was checked graphically and numerically
with the Shapiro-Wilk Normality Test. When this test failed to reject its H0 then the adjusted P values
for multiple comparisons were extracted with the Tukey’s ’Honest Significant Difference’ method.
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Antoine Marçais, https://orcid.org/0000-0002-3591-6268
Thierry Walzer, http://orcid.org/0000-0002-0857-8179
Ethics
Animal experimentation: This study was carried out in accordance with the French recommendations
in the Guide for the ethical evaluation of experiments using laboratory animals and the European
guidelines 86/609/CEE. All experimental studies were approved by the bioethic local committee
CECCAPP (Permit number: CECCAPP_ENS_2014_018).
Decision letter and Author response
Decision letter https://doi.org/10.7554/eLife.26423.021
Author response https://doi.org/10.7554/eLife.26423.022
Additional files
Supplementary files
. Transparent reporting form
DOI: https://doi.org/10.7554/eLife.26423.020
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Method for predicting the risk of transplant rejection 
FIELD OF THE INVENTION: 
The present invention relates to a method for predicting the risk of transplant rejection 
in recipient subject. The present invention also relates to a method for treating or preventing 
transplant rejection. 
BACKGROUND OF THE INVENTION: 
Rejection represents the main cause of solid organ transplants loss and therefore an 
important unmet medical need in the current context of severe organ shortage.  
The current immunological paradigm is that rejection is due to the recognition of 
alloantigens (mainly the highly polymorphic donor-specific HLA molecules) by recipient’s 
adaptive immune system. Allorecognition, results in the generation of cytotoxic cellular 
effectors and/or donor specific antibodies (DSA), which drive graft destruction. While the 
cellular arm of the alloimmune response has progressively come under pharmacological 
control, current immunosuppressive armamentarium does not completely prevent the 
generation of DSA (Thaunat et al., 2016). As a result, antibody-mediated rejection (AMR) is 
now widely recognized as the first cause of allograft loss (Sellarés et al., 2012). 
A few years ago, it has been demonstrated in a murine experimental model of heart 
transplantation that parental grafts transplanted in F1 recipients developed chronic rejection 
with graft arteriosclerosis (Uehara et al., 2005). This process was unlikely to be due to 
adaptive immune system, because in parental => F1 combination the graft do not express any 
alloantigen). Instead, this experimental model suggested that other type of rejection could lead 
to vascular lesions and therefore limit the duration of graft function. Thus it is therefore 
needed to be able to predict the risk of transplant rejection in this case, in particular in 
transplanted patients with no detectable humoral response against the transplant (and notably 
the transplant endothelial cells) more particularly in transplanted patient who does not present 
donor specific antibodies. Considering the high morbidity associated with transplant rejection, 
it also remains highly clinically relevant to propose new adapted treatments for this 
previously unrecognized condition. 
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SUMMARY OF THE INVENTION: 
As mentioned above, the current paradigm is that allograft rejection is driven 
exclusively by recipient’s adaptive immune system. In the present context where cellular 
immunity, involving mostly CD8 T cells, is controlled by current immunosuppressive drugs, 
rejection is mostly due to humoral immunity, involving anti donor specific antibodies directed 
mostly against mismatch donor HLA molecules and leading to microvascular inflammation 
and to the graft (or transplant) rejection. 
The inventors have found that some transplanted patient has microvascular 
inflammation while having no donor specific antibodies. Surprisingly they discovered that the 
innate immune effectors NK cells could trigger microvascular inflammation and chronic 
rejection. NK-mediated rejection was due to the lack of expression by the graft of (at least) 
one type of HLA-I ligand for an inhibitory KIR expressed by recipient NK cells (a situation 
known as "missing self"). Missing self on graft endothelial cells was sufficient to induce the 
activation of NK cells in the recipient subject, which in turn trigger microvascular 
inflammation and ultimately lead to transplant rejection (typically chronic transplant 
rejection). 
Therefore the present invention relates to an in vitro method for predicting the risk of 
transplant rejection in a subject who is the recipient of a transplant from a transplant donor, 
said method comprising the detection of missing-self activation of NK (natural killer) cells, 
wherein the detection of missing-self activation of NK cells is indicative of a risk for 
transplant rejection. 
 
The invention also comprises a method of selecting a HLA compatible donor 
transplant for a candidate recipient subject comprising:  
- obtaining the inhibitory KIR genotype of the candidate recipient subject and the 
HLA-I genotype of the transplant donor and the candidate recipient subject; 
- comparing the HLA-I genotype and the KIR genotype of the candidate recipient 
subject et determining the functional KIRs; and 
- comparing the genotype of the recipient inhibitory functional KIRs of the candidate 
recipient subject with the donor HLA-I genotype, and 
- identifying whether or not a ligand of a functional inhibitory KIR (Killer-cell 
Immunoglobulin-like Receptor) of the recipient subject is absent in the transplant donor. 
The present invention also relates to an inhibitor of mTOR (mammalian target of 
rapamycin) for use in the prevention of transplant rejection in a subject who is the recipient of 
221
 
a transplant and selected as having at least one recipient inhibitory functional KIR directed 
against a corresponding HLA-I ligand missing in the donor HLA-I genotype. 
 
DETAILED DESCRIPTION OF THE INVENTION: 
 
1. Definitions: 
As used herein “transplant rejection” (or graft rejection) encompasses acute transplant 
rejection and chronic transplant rejection. Preferably the transplant rejection is chronic 
transplant rejection. Preferably also the transplant rejection is NK cell-mediated rejection, 
notably missing-self-induced NK-mediated rejection. 
Natural killer cells are the third population of lymphocytes defined by the CD3- 
CD56+ cell surface phenotype and share several features with CD8+ cytolytic T-lymphocytes 
in their development, morphology, cell surface phenotypes, killing mechanism, and cytokine 
production. NK cells express both activating and inhibitory receptors that are calibrated to 
ensure self-tolerance, while exerting early assaults against virus infection and tumor 
transformation. Having properties of both innate and adaptive immunity, NK cells 
spontaneously lyse target cells, as well as function as regulatory cells influencing subsequent 
antigen-specific T-cell and B-cell responses.  
The recipient NK cells can recognize and respond against an allograft by three 
possible mechanisms: missing-self recognition, induced-self recognition, and ADCC 
(Rajalingam R. Variable interactions of recipient killer cell immunoglobulin-like receptors 
with self and allogenic human leukocyte antigen class I ligands may influence the outcome of 
solid organ transplants. Curr Opin Organ Transplant (2008) 13:430–7). Because NK cells 
circulate in a state that can spontaneously deliver effector function, it is critical that they do 
not attack surrounding healthy cells. To prevent such detrimental autoreactivity, NK cells 
express an array of inhibitory receptors recognizing self-HLA class I molecules.  
Expression of four distinct HLA class I molecules (HLA-A, -B, -C, and -E) on normal 
healthy cells provides ligands for the inhibitory receptors of NK cells and, consequently, are 
resistant to NK cell attack. Down-regulation of HLA class I (HLA-I) expression due to certain 
viral infections, neoplastic transformations, or absence of relevant HLA class I ligands on the 
allograft at the setting of allogeneic transplantation, alleviates inhibitory signals, permitting 
NK cells to eliminate these unhealthy or allogeneic target cells, a phenomenon originally 
described as the “missing-self” hypothesis (see notably Ljunggren HG, Karre K. In search of 
the “missing self”: MHC molecules and NK cell recognition. Immunol Today (1990) 11:237–
222
 
44). In addition to the “missing-self” mechanism, the expression of ligands for activating 
receptors on stressed target cell surface might also contribute to NK cell attack, known as 
“induced-self” recognition. The activation receptors can directly recognize stress-induced 
ligands associated with certain physiological conditions, such as infection, tumor 
transformation, and transplanted allograft (Raulet DH, Vance RE, McMahon CW. Regulation 
of the natural killer cell receptor repertoire. Annu Rev Immunol (2001) 19:291–330).  
 
Thus, as used herein, “missing-self-induced NK-mediated rejection” means that 
transplant rejection is mediated by NK cells which activation is triggered by “missing self”. 
By “missing self” it is herein intended that the inhibitory receptors of NK cells missed 
their corresponding HLA-I ligand in the target cell, in particular on the transplant cells (and 
typically endothelial donor cells). 
 
Fourteen distinct KIRs (Killer-cell Immunoglobulin-like Receptors) have been 
characterized in humans that comprise either 2 or 3 (2D or 3D) Ig-like domains and either a 
long (L) or short (S) cytoplasmic tail (see table 1 below) (for review see also Rajalingam R. 
The Impact of HLA Class I-Specific Killer Cell Immunoglobulin-Like Receptors on 
Antibody-Dependent Natural Killer Cell-Mediated Cytotoxicity and Organ Allograft 
Rejection. Frontiers in Immunology. 2016;7:585 and Thielens A, Vivier E, Romagné F. NK 
cell MHC class I specific receptors (KIR): from biology to clinical intervention. Curr Opin 
Immunol. 2012 Apr;24(2):239–45. Parham P., MHC class I molecules and KIRs in human 
history, health and survival. Nat Rev Immunol. 2005 Mar;5(3):201-14). Six KIRs are 
activating types and the remaining KIRs are inhibitory types. Inhibitory KIRS notably 
comprise KIR2DL1, KIR2DL2, KIR2DL3, KIR3DL1, KIR3DL2, KIR2DL4, KIR2DL5, 
KIR3DL3. The cytoplasmic tails of the inhibitory KIRs carry an ITIM motif that trigger 
inhibitory signals upon binding to distinct HLA class I ligands (as detailed in table 1 below). 
The short-tailed activating KIRs lack ITIM, but carry a positively charged amino acid residue 
in the transmembrane region that allows the interaction with an adopter chain DAP-12 
KIRs that are expressed on the surface of NK cells recognize allotypic determinants 
(“KIR ligands”) shared by certain HLA class I allele groups. KIR2DL1 recognizes HLA-C 
alleles with a Lys80 residue (HLA-C2 (Cw2, Cw4, Cw5, Cw6, Cw15, Cw17, Cw18; “group 
2' alleles”), KIR2DL2 and KIR2DL3 recognize HLA-C with an Asn80 residue (HLA-Cw3 
and related, “group 1” alleles); KIR3DL1 is the receptor for HLA-B alleles sharing the Bw4 
supertypic specificity (HLA-Bw4 (B13, B27, B37, B44, B47, B38, B49, B51, B52, B53, B57, 
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B58, B59, B63, B77, B23, B24, B38)). Finally, KIR3DL2 was shown to function as a 
receptor for HLA-A3/-A11 alleles when bound to Epstein–Barr virus (EBV) peptides (see 
also below table 1). 
 
On the basis of gene content, KIR haplotypes are broadly classified into two groups. 
Group A haplotypes have a fixed gene content (KIR3DL3–2DL3–2DP1–2DL1–3DP1–
2DL4–3DL1–2DS4–3DL2) that encode four inhibitory KIRs, 2DL1, 2DL3, 3DL1, and 3DL2, 
specific for four major HLA class I ligands, C2, C1, Bw4, and A3/A11, respectively, and an 
activating KIR 2DS4, which is weakly specific for some HLA-C allotypes (C1 or C2 
epitope), as well as the HLA-A3/11 epitope. In contrast, group B haplotypes are variable both 
in numbers and combinations of KIR genes, and comprising several genes (2DL2, 2DL5, 
2DS1, 2DS2, 2DS3, 2DS5, and 3DS1) that are not part of the A haplotype. Moreover, B 
haplotypes possess KIRs that have no binding to HLA class I ligands, such as KIR2DL5, 
2DS2, 2DS3, and 2DS5. While group A haplotypes contain only KIR2DS4 as an activating 
gene, group B haplotypes contain up to five activating KIRs – KIR2DS1, 2DS2, 2DS3, 2DS5, 
and 3DS1. Inheritance of paternal and maternal haplotypes comprising different KIR gene 
contents generates human diversity in KIR genotypes. For example, homozygotes for group A 
haplotypes have only seven functional KIR genes, while the heterozygotes for group A and 
certain group B haplotypes may have all 14 functional KIR genes. All human populations 
have both group A and B KIR haplotypes, but their incidences vary substantially among 
populations. 
 
According to the present invention, a recipient inhibitory KIR is considered 
“functional” (the terms “successfully educated”, or “licensed” may also be used 
interchangeably), if the said recipient expresses its corresponding HLA-I ligand. 
 
The terms “subject” and “patient” are used interchangeably in the present application. 
A subject of the present invention is a mammal, preferably a human. 
In the present application, the terms “recipient”, “transplant recipient”, “transplanted 
recipient”, “transplanted patient”, or “subject recipient” are used interchangeably. In some 
embodiments a recipient according to the invention is a candidate recipient.  
The donor HLA-I corresponds to the HLA-I of the transplant donor. The term “donor” 
or “transplant donor” are also used interchangeably. The donor or the transplant donor may 
also be a putative transplant donor. 
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1. Method for the prognosis or for the diagnosis of transplant rejection and method 
for selecting a HLA compatible donor transplant for a candidate recipient subject 
The method of the invention may be performed before or after transplantation in the 
subject recipient. Thus, a subject according to the invention may have already received a 
transplant (transplanted subject) or may be a candidate for transplantation..  
 
In some embodiment, the recipient subject may have or not detectable microvascular 
inflammation (mvi) associated with the transplant. In some embodiments also, the subject 
who has received a transplant may also have or not detectable donor specific antibodies 
(DSA). In one embodiment, a subject who has received a transplant presents microvascular 
inflammation and does not have detectable DSA. In one other embodiment, a subject who has 
received a transplant does not present detectable microvascular inflammation and does not 
have detectable DSA. 
 
The present invention relates to an in vitro method for predicting the risk of transplant 
rejection in a subject who is the recipient of a transplant from a transplant donor by the 
detection of missing-self activation of NK (natural killer) cells. 
According to the invention a situation of "missing self" can be identified by 
comparison of the genotype of functional inhibitory KIR of the recipient with the HLA-I 
genotype of the donor. 
Indeed, according to the present invention, the identification of the absence in the 
transplant donor of a ligand for a functional inhibitory Killer-cell Immunoglobulin-like 
Receptor (KIR) of the recipient subject. In other words identification in the recipient subject 
of a functional inhibitory KIR missing his corresponding HLA-I ligand in the transplant (or in 
the putative transplant) is indicative of a risk for transplant rejection in the said recipient 
subject. 
Thus, for a given subject recipient / transplant donor couple, the lack of expression by 
the graft of at least one type of HLA-I ligand for a functional inhibitory KIR expressed by 
recipient NK cells is indicative of a risk for transplant rejection in the recipient.  
 
The presence of at least one inhibitory functional KIR in the recipient missing its 
corresponding HLA-I ligands in the transplant donor leads to the activation of NK cells. Thus, 
according to the invention, the presence of at least one recipient inhibitory KIR vs transplant 
donor HLA-I ligand mismatch is indicative of a higher risk (or an increase susceptibility) for 
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transplant rejection as compared to a patient wherein no recipient inhibitory KIR vs transplant 
donor HLA-I ligand mismatch is identified.  
Estimation of the risk for transplant rejection may be achieved based on statistical 
analysis performed on a statistically significant population of transplanted subjects with no 
recipient inhibitory KIR/ inhibitory KIR Ligand mismatch vs a statistically significant 
population of transplanted subjects having at least one recipient inhibitory KIR/ inhibitory 
KIR ligand mismatch. 
The risk of presenting a transplant rejection may be further improved in various 
clinical situations comprising the presence of microvascular inflammation, the pathological 
history of the patient (notably the ischemia/reperfusion and infectious histories of the patient). 
 
The invention also comprises a method of selecting a HLA compatible donor 
transplant for a candidate recipient subject, the method comprising:  
- comparing the genotype of the recipient inhibitory functional KIRs of the candidate 
recipient subject with the donor HLA-I genotype, and 
- identifying whether or not a ligand of a functional inhibitory KIR (Killer-cell 
Immunoglobulin-like Receptor) of the recipient subject is absent in the transplant donor. 
 
Preferably according to the method of selection of the invention, a transplant donor is 
selected such that no missing self would be created in the recipient subject. In other words, 
the transplant donor expresses the HLA-I ligands of the inhibitory functional KIRs of the 
candidate recipient subject.  
 
Typically, the method for predicting the risk of transplant rejection as well as the 
method for selecting a HLA compatible donor transplant for a candidate recipient subject of 
the invention comprises beforehand the steps of: 
- obtaining the inhibitory KIR genotype of the candidate recipient subject and the 
HLA-I genotype of the transplant donor and of the candidate recipient subject; 
- comparing the HLA-I genotype and the KIR genotype of the candidate recipient 
subject and determining the functional KIRs. 
 
Inhibitory KIRs according to the invention are notably as listed above. Preferentially 
inhibitory KIRs according to the invention are selected from the group comprising KIR2DL1, 
KIR2DL2, KIR2DL3, KIR2DL5, KIR3DL1, KIR3DL2 and KIR3DL3. Typically, KIR2DL4 
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is not considered as an inhibitory KIR because it has been reported as having both activating 
and inhibitory functions (Campbell and Purdy, 2011; Kikuchi-Maki et al., 2003). Most 
preferably, inhibitory KIRs according to the invention are selected from inhibitory KIRs for 
which the corresponding ligand is identified. Thus KIRs according to the invention typically 
comprise KIR2DL1, KIR2DL2, KIR2DL3, KIR3DL1, and KIR3DL2.  
In some embodiments, the inhibitory KIR genotype of the candidate recipient subject 
and the recipient and transplant donor HLA-I genotypes can be obtained by typing the subject 
recipient HLA-A, HLA-B and HLA-C alleles. 
The transplant donor may be categorized in the following inhibitory KIR-ligand 
groups: HLA-C group 1 alleles (HLA-C1), HLA-C group 2 alleles (HLA-C2), HLA-Bw4 
group alleles and HLA-A3/-A11 alleles.  
Comparison of the data on HLA-A, HLA-B, HLA-C1 and HLA-C2 of donors and 
recipients allows to determine whether HLA-I ligand of KIRs of the recipient are missing. 
Depending on the embodiment, seven inhibitory KIR/ inhibitory KIR-ligand pairs as defined 
above, and more preferably five inhibitory KIR/ inhibitory KIR-ligand pairs are analyzed.  
In one embodiment of the invention the presence of the HLA-1 Bw4 ligand of 
KIR3DL1 is assessed in transplant donor. Typically the functionality of KIR3DL1 in the 
recipient subject is also determined. 
The absence of at least HLA-1 Bw4 in a transplant donor is associated with a risk of 
transplant rejection in particular in recipient subject expressing functional KIR3DL1. 
In another embodiment, a putative transplant donor expressing HLA-1 Bw4 is selected 
for a given candidate recipient expressing KIR3DL1. 
 
Obtaining inhibitory KIR genotype of the candidate recipient subject and the recipient 
and transplant donor HLA-I genotypes is typically achieved using high resolution typing, 
such as by PCR-SSO reverse (One Lambda). 
 
Inhibitory KIRs and / or HLA-I typing may be performed on a biological sample from 
the recipient or the donor. A sample according to the invention can be a body fluid such as for 
example blood, serum, lymph, or any biological tissue. The biological sample may also be 
pretreated, for example, by homogenization, extraction, enzymatic and/or chemical treatments 
as commonly used in the field. 
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Optionally, the method for predicting the risk of transplant rejection in a subject, or 
the method for selecting a HLA compatible donor transplant for a candidate recipient subject 
further comprises a step of determining the proportion of NK cells bearing inhibitory 
functional KIRs directed against HLA-I ligand missing in donor HLA-I genotype.  
 
The size of the population of NK cells bearing inhibitory functional KIRs directed 
against HLA-I ligand missing in donor HLA-I genotype allows to quantify the strength of the 
"missing self". The risk of transplant rejection indeed vary as a function or the proportion of 
NK cells bearing inhibitory KIRs, directed against HLA-I ligand missing in the donor HLA-I 
genotype.  
 
Typically, a recipient subject having a high proportion of NK cells bearing inhibitory 
KIRs, notably functional inhibitory KIRs, directed against HLA-I ligand missing in the donor 
HLA-I genotype have a higher risk of transplant rejection as compared to a subject having a 
high proportion of NK cells bearing inhibitory functional KIRs directed against HLA-I ligand 
missing in the donor HLA-I genotype. 
A threshold, below which the risk may be considered as clinically acceptable, may be 
established based on statistical analysis of the clinical outcome (in terms of transplant 
rejection) of a population of transplanted patients having various proportion of NK cells 
bearing inhibitory functional KIRs directed against HLA-I ligands missing in the donor HLA-
I genotype. 
In one embodiment of a method of selecting a HLA compatible donor transplant for a 
candidate recipient subject, a transplant donor is selected whose, HLA-I ligands present at 
least one mismatch with the inhibitory functional KIRs of the candidate recipient, if the 
proportion of NK cells bearing inhibitory functional KIRs directed against HLA-I ligand 
missing in donor HLA-I genotype is below a threshold considered as statistically acceptable 
in terms of clinical outcome. 
As a matter of example, determination of the proportion of NK cells bearing inhibitory 
functional KIRs directed against HLA-I ligand missing in donor HLA-I genotype may be 
performed as illustrated in the results detailed in the experimental section (see example 2). 
 
Alternatively, in a method for predicting the risk of transplant rejection in a subject, 
the detection of missing-self activation of NK cells may be assessed by 
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- co-cultivating stimulated NK cells from the recipient subject with endothelial cells, 
preferably primary endothelial cells typically from the transplant donor or with endothelial 
cells (typically endothelial cell lines) expressing various combination of inhibitory KIR 
ligands ; and 
- detecting the presence of degranulation (using CD107a as a marker) or expression of 
chemokines (such as MIP1), as shown in the results. 
 
Optionally, the method for predicting the risk of transplant rejection in a subject, or 
the method for selecting a HLA compatible donor transplant for a candidate recipient subject 
further comprises the in vitro detection of NK cell-mediated rejection.  
The detection of NK cell mediated rejection may be achieved as illustrated in the 
examples. Typically, stimulated NK cells from the recipient subject are co-cultivated with 
donor endothelial cells (notably primary endothelial cells) expressing or not the inhibitory 
HLA-I ligands. NK cells are typically stimulated according to the current practice in the field 
such as with interleukin 2. Detection of the activation of NK cell may be achieved by 
detection of degranulation (using CD107a as a marker) or expression of chemokines (such as 
MIP1), as shown in the results.  
Detection of NK cell activation is indicative of a high risk for transplant rejection or 
for a diagnosis of transplant rejection. 
Detection of NK cell mediated rejection as described above may be performed 
routinely, for the monitoring of patient diagnosed with a high risk for transplant rejection, or 
to whom a prognostic of a risk of transplant rejection was set according to the method as 
previously defined. In particular, detection of NK cell mediated rejection in patients may be 
performed in patients, wherein the proportion of NK cells bearing inhibitory KIRs directed 
against HLA-I ligand missing in donor HLA-I genotype, is elevated (i.e.: typically above a 
statistically significant threshold).  
Taken together the method according to the invention allows the close monitoring of 
the risk of transplant rejection in a recipient patient such that invasive detection techniques 
such as biopsy may be avoided or delayed and an adapted curative or preventive treatment 
may be propose before transplant rejection. 
 
Preferably, according to the invention, the transplant is an organ or a tissue. According 
to the invention, transplant organ is preferably a solid transplant organ, notably selected from 
heart transplant, lung transplant, kidney transplant, liver transplant, pancreas transplant, 
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intestine transplant, thymus transplant. A tissue transplant encompasses, composite tissue 
transplant, bones transplant and tendons transplant (both referred to as musculoskeletal 
grafts), corneae transplant, skin transplant, heart valves transplant, nerves transplant and veins 
transplant. Most preferably the transplant is a solid organ transplant such as heart, kidney, 
liver or lung transplant. 
 
Transplant rejection according to the invention encompasses acute and chronic 
transplant rejection. Preferably, transplant rejection is chronic transplant rejection. 
 
2. Methods of prevention and/or treatment of transplant rejection 
The present invention also relates to a method of preventing or treating transplant 
rejection, notably NK cell transplant rejection in a transplanted subject in need thereof 
wherein: 
the subject is identified as having missing-self activation of NK, and wherein 
an effective amount of an inhibitor of the mammalian target of rapamycin (mTor) is 
administered to said subject.  
 
Preferably the subject is identified as having at least one inhibitory functional KIR 
directed against a HLA-I ligand missing in donor HLA-I genotype. In other words according 
to the invention, a subject is selected such that his graft lacks the expression of at least one 
HLA-I ligand for a functional inhibitory KIR expressed by his NK cells. 
Preferably the subject is identified as having a risk for transplant rejection, notably 
transplant rejection mediated by missing self NK activation, by performing the method for 
predicting the risk of transplant rejection, as previously described.  
Preferably the transplant rejection is transplant rejection mediated by missing self NK 
activation. In a preferred embodiment of the method, the recipient subject has no donor 
specific antibody (DSA). 
 
Definitions and optional steps of the method for predicting a risk of transplant 
rejection according to the invention have been described previously and apply to the present 
methods of treatment and prevention. 
 
mTOR, also known as the mechanistic target of rapamycin and FK506-binding protein 
12-rapamycin-associated protein 1 (FRAP1), is a kinase that in humans is encoded by the 
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MTOR gene. mTOR belongs to the family of phosphatidylinositol-3-kinase-related kinases 
(PIKKs). Members in this family are large in size (>2,500 amino acids) and harbor a kinase 
domain at their C-terminals that shares sequence similarity to phosphatidylinositol-3-kinase 
(PI3K). Despite having the sequence signature of a lipid kinase, mTOR is a protein kinase 
that phosphorylates threonine and serine residues in its substrates. In cells mTOR serves as 
the catalytic subunits of two multi-protein complexes termed as the mTOR complex 1 
(mTORC1) and complex 2 (mTORC2).  
mTORC1 is a major downstream component of the PI3K/AKT pathway that relays the 
signals from tumor suppressors PTEN, LKB1 and TSC1/2, and oncoproteins PI3K and AKT. 
Downstream mTORC1 controls cellular biogenesis through regulation of protein synthesis 
and turnover. It phosphorylates eIF4E binding protein 1 (4EBP1) and ribosomal protein S6 
kinase (S6K), two factors involved in translation initiation. Its activity controls protein 
turnover through repressing autophagy.  
mTORC2 is also involved in the PI3K/AKT pathway but its function is independent of 
mTORC1. It phosphorylates and stimulates AKT activation, and hence plays a critical role in 
AKT mediated cell survival 
Preferably the mTor inhibitor according to the invention is preferably an inhibitor of 
mTor C1. 
Inhibitors of mTor suitable for the invention are notably described in Zheng Y, Jiang 
Y. mTOR Inhibitors at a Glance. Molecular and cellular pharmacology. 2015;7(2):15-20. 
In particular, an mTor inhibitor according to the invention can be selected from 
rapamycin or one of its analogs termed as rapalogs (suc as Temsirolimus (CCI-779), 
Everolimus (RAD001), or Ridaforolimus (AP23573)), ATP competitive inhibitors, 
pyrimidine derivatives (such asPP242 and PP30, the morpholino-linked pyrimidine 
derivatives (such as WAY-600, WYE-687 and WYE354 (37), KU0063794,  the triazine 
derivative OSI-027, AZD8055, AZD2014 or Pink 128). 
Typically the mTor inhibitor inhibits mTorC1. Preferably, the inhibitor of mTor is 
selected from rapamycin and its analogs termed rapalogs. Most preferably, the mTor inhibitor 
is rapamycin. 
 
The terms “treatment”, “treating” or “treat” and the like refer to obtaining a desired 
pharmacological and/or physiological effect. This effect is preferentially therapeutic in terms 
of partial or complete stabilization or cure of transplant rejection and/or adverse effects 
attributable to transplant rejection (notably chronic transplant rejection). Treatment covers 
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any treatment of transplant rejection in a mammal, particularly a human, aimed at inhibiting 
the transplant rejection symptom(s), (i.e., arresting its development) or relieving the transplant 
rejection symptoms (i.e., causing regression of the transplant regression or symptoms).  
The terms “prevention”, “preventing” or “prevent” and the like also refer to obtaining 
a desired pharmacological and/or physiological prophylactic effect in terms or completely or 
partially preventing the transplant or a symptom thereof. It covers therefore any preventive 
treatment of transplant in a mammal, particularly a human, aimed at preventing the transplant 
rejection or symptom from occurring in a subject, who may be at risk, or predisposed to 
transplant rejection but has not yet been diagnosed as having it. 
 
The inhibitor of the can be administered by any suitable route, for example, 
intravenously, intranasally, peritoneally, intramuscularly, orally and other conventional 
methods.  
Said inhibitor according to the invention can be included in a composition. It can be 
mixed and/or carried with one or more liquid and/or solid pharmaceutically acceptable 
carriers, ingredients and/or excipients. As used herein, "pharmaceutically acceptable carrier" 
is intended to include any and all solvents, dispersion media, coatings, antibacterial and 
antifungal agents, isotonic and absorption delaying agents, and the like, compatible with 
pharmaceutical administration. The use of such media and agents for pharmaceutically active 
substances is well known in the art. Supplementary active compounds can also be 
incorporated into the composition.  
 
The present invention also provides an inhibitor of mTor as defined above, for use in 
the treatment or the prevention of transplant rejection, notably chronic transplant rejection (in 
particular NK cell mediated rejection) in a subject who is the recipient of a transplant and who 
has been selected as having at least one functional recipient KIR directed against HLA-I 
ligand missing in donor HLA-I genotype. 
 
Preferably the subject has no DSA. 
Typically, the subject is identified as having transplant rejection or being at risk of 
having transplant rejection according to one of the methods as previously described.  
In one embodiment, the recipient subject presents at least one functional recipient 
inhibitory KIR directed against HLA-I ligand missing in donor HLA-I genotype and has a 
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high proportion of NK cells bearing mismatching functional KIRs directed against HLA-I 
ligands missing in the donor HLA-I genotype. 
 
The present invention also relates to the use of an inhibitor of as defined above for the 
preparation of a medicament for treating or for prevention transplant rejection in a subject 
who is the recipient of a transplant and selected as having at least one functional recipient 
inhibitory KIR directed against HLA-I ligand missing in donor HLA-I genotype. 
 
FIGURES: 
Figure 1: Microvascular inflammation (mvi) in the absence of any donor specific 
antibodies (DSA) is associated with a kidney graft survival as worst as mvi due to non-
complement activating DSA. Kaplan meier curves for kidney graft survival are shown for 
patients diagnosed with mvi and no DSA (mvi+DSA-), patient diagnosed with complment-
independent humoral rejection (mvi+DSA+C3d-) and for control (mvi-DSA-). 
Figure 2: Quantification of different inflammatory cells infiltrating the allograft 
biopsies. Comparison between mvi+DSA- and mvi+DSA+C3d- were done using unpaired t 
test. 
Figure 3: Percentage of NK cells bearing only one functional inhibitory KIR 
(KIR2DL1 or LIR2DL2 and/or 3, KIR3DL1). 
Figure 4: 4A. Percentage of CD107a+ cells in the different subpopulations of 
IL2+ NK cells bearing only one inhibitory KIR (KIR2DL1 or LIR2DL2 and/or 3, 
KIR3DL1, KIR3DL2). Mismatched licensed cells show significantly more activation as 
compared to mathed NK cells or mismatched non licensed NK cells. 4B. Percentage of 
CD107a+ cells in the different subpopulations of IL2+ NK cells bearing a define 
inhibitory KIR (KIR2DL1 or LIR2DL2 and/or 3, KIR3DL1, KIR3DL2). 
Figure: 5A. Percentage of MIP1β+ cells in the different subpopulations of IL2+ 
NK cells bearing only one inhibitory KIR (KIR2DL1 or LIR2DL2 and/or 3, KIR3DL1, 
KIR3DL2). 5B. Percentage of MIP1β+ cells in the different subpopulations of IL2+ NK 
cells bearing a define inhibitory KIR (KIR2DL1 or LIR2DL2 and/or 3, KIR3DL1, 
KIR3DL2). 
Figure 6: Impact of immunosuppressants on missing-self-mediated killing. 6A: 
Graph showing the remaining percentage of B 2 micro KO cells in C57BL/6 mice as function 
of time. 6B. Graph showing the remaining percentage of B 2 micro KO cells in C57BL/6 
mice in the presence of rapamycine 
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EXAMPLES: 
Example 1: Missing self triggers NK-mediated microvascular injuries and chronic 
rejection of allogeneic kidney transplants 
 
Introduction 
Rejection represents the main cause of solid organ transplants loss and therefore an important 
unmet medical need in the current context of severe organ shortage (www.who.int).  
The current immunological paradigm is that rejection is due to the recognition of alloantigens 
(mainly the highly polymorphic donor-specific HLA molecules) by recipient’s adaptive 
immune system. Allorecognition, results in the generation of cytotoxic cellular effectors 
and/or donor specific antibodies (DSA), which drive graft destruction. While the cellular arm 
of the alloimmune response has progressively come under pharmacological control, current 
immunosuppressive armamentarium does not completely prevent the generation of DSA 
(Everly et al., 2013). As a result, antibody-mediated rejection (AMR) is now widely 
recognized as the first cause of allograft loss (Sellarés et al., 2012). 
DSA are massive protein largely sequestrated in the circulation (Hall et al., 1969). They bind 
to directly accessible allogeneic targets expressed by graft endothelium, where they activate 
classical complement pathway and/or recruit innate immune effectors, in particular NK cells, 
which drive antibody-dependent cell-mediated cytotoxicity (ADCC) (Pouliquen et al., 2015). 
While activation of classical complement pathway seems necessary to trigger acute (i.e. 
clinically patent AMR), DSA-mediated microvascular inflammation alone is sufficient to 
promote the development of chronic AMR (Hirohashi et al., 2012). Experimental studies have 
indeed shown that the passive transfer of DSA that were unable to activate complement 
(IgG1), or DSA transferred in RAG1-/-C3-/- mice, were equally good in promoting the 
development of graft arteriosclerosis (Hirohashi et al., 2010, 2012), an effect that was 
completely loss if NK cells were depleted prior the passive transfer of DSA (Hirohashi et al., 
2012). The central role of NK in promoting chronic AMR in the clinical setting is supported 
by transcriptomic analyses of renal graft biopsies showing that 6 among the 23 most 
expressed transcripts in renal allograft with chronic AMR lesions were from NK origin 
(Hidalgo et al., 2010). 
In addition to their ability to collaborate with the humoral arm of adaptive immune system to 
promote target destruction, NK cells are also endowed with autonomous (or “natural”) 
cytotoxic functions. These large lymphocytes constitute indeed the first line of defense 
against intracellular infections and tumor cells. The regulation of this natural cytotoxicity 
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depends on the balance between inhibitory and activating signals that NK sense with their 
battery of cell surface receptors. Among them are the killer-cell immunoglobulin-like 
receptors (KIR). Inhibitory KIR receptors interact with self-MHC class I molecules, thus 
preventing NK-cell mediated killing against healthy cells. In case of infectious or tumoral 
transformation, cells down regulate the expression of MHC class I molecules and become 
susceptible to NK-mediated killing, a process known as “missing self”. 
A few years ago, it has been demonstrated in a murine experimental model of heart 
transplantation that parental grafts transplanted in F1 recipients developed chronic rejection 
with graft arteriosclerosis (Uehara et al., 2005). This process was unlikely to be due to 
antibody-mediated rejection as it happened also in B cell depleted recipients (Uehara et al., 
2005). We undertook the present study to determine whether “missing self” could also 
participate to promote a NK-mediated form of chronic vascular rejection in the setting of 
clinical kidney allotransplantation.  
 
Material and Methods 
Principal cohort 
The reports of all kidney-allograft biopsies performed between September 1st 2004 and 
september 1st 2012 in either Edouard Herriot Hospital or Lyon Sud Hospital, the 2 university 
hospitals of Lyon (France), were screened (2024 biopsies in 938 patients) by means of the 
pathology department’s computer database (DIAMIC). One hundred and forty three patients 
with microvascular inflammation (mvi+) were identified. A renal pathologist and a 
nephrologist reviewed all biopsy specimens, and 9 patients whose biopsy specimens did not 
show significant microvascular inflammation were excluded. Among the 134 patients, 65 who 
displayed no anti-HLA DSA during the same period were identified through the immunology 
department’s computer database. An endothelial flow cross match was performed for these 
patients and one patient who displayed anti-endothelial cell antibodies was excluded. Finally, 
41 patients having DNA samples available for the donor and the recipient were enrolled in the 
study (hereafter called mvi+DSA- group). 
The steps of selection are summarized in figure 1.  
 
Control groups 
Mvi+DSA+C3d- group : 
Following the same process as the principal cohort, 69 patients with microvascular 
inflammation lesions and anti-HLA DSA were identified. Serum samples banked at the time 
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of biopsy were analysed in a blinded fashion for the presence of C3d-binding donor-specific 
anti-HLA antibodies (V.D. at the Etablissement Français du Sang, Lyon, France) with the use 
of single-antigen flow bead assays according to the manufacturer’s protocol (C3d-binding 
antibody assay; Lifecodes). Twenty-nine patients with significant microvascular inflammation 
in the context of complement-independent antibody-mediated rejection (DSA unable to bind 
C3d, mvi+DSA+C3d-) were enrolled in the study. 
The steps of selection are summarized in figure 1.  
 
Mvi-DSA- group : 
The histopathological, immunological and clinical data of patients who received kidney 
transplantation at Edouard Herriot Hospital were screened by means of the departments’ 
computer databases. Information from the three databases were integrated in order to identify 
100 patients without any microvascular inflammation (g+cpt ≤1) on biopsy and without any 
anti-HLA DSA and matched with patients of the principal cohort regarding main baseline 
characteristics. A renal pathologist and a nephrologist reviewed the 100 specimens and 14 
patients whose biopsies showed microvascular inflammation or were not adequate were 
excluded. All the serum samples for these patients were screened and nine patients with anti-
HLA DSA were excluded. Finally, 56 patients having DNA samples available for the donor 
and the recipient were enrolled in the study (hereafter called mvi-DSA- group). The steps of 
selection are summarized in the table 1 below.  
 
All patients received an ABO compatible transplantation with negatives historical and current 
complement-dependent cytotoxicity crossmatches. Clinical data were obtained from two 
independent national registries (Cristal: http://www.sipg.sante.fr/portail/, and Données 
Informatiques Validées en Transplantation: http://www.divat.fr/) and crosschecked. The 
characteristics of the patients are summarized in table 1. 
The end of follow-up was set as January 31th, 2015 (mean follow up duration for the cohort ± 
SD: 69.2 ± 40 months for mvi+DSA- patients; 82.7 ± 48.7 months for mvi+DSA+C3d- 
patients and 57.9 ± 19.9 months for mvi-DSA- patients). Allograft survival in the principal 
cohort (mvi+DSA-) was compared with allograft survival of mvi+DSA+C3d- and mvi-DSA- 
patients. 
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Table 1: flow chart of the study.  
 
Allograft pathology 
Kidney graft biopsies were performed systematically as part of the routine follow-up 
procedure at 3 months and 1-year post transplantation, or in case of rejection suspicion at the 
other time points. 
Renal specimens were fixed in acetic acid-formol-absolute alcohol and paraffin embedded 
sections were stained by routine methods. C4d staining was performed by indirect 
immunofluorescence on frozen sections using an anti-human C4d complement-rabbit clonal 
antibody (clone A24-T, produced by DB Biotech, Kosice, Slovak Republic). The renal 
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pathologist (M.R.) and the nephrologist (A.S.) who reviewed the biopsies specimens were 
blinded to clinical and immunological information.  
Renal allograft lesions were graded according to the Banff classification updated in 2011. 
Histological criteria for significant microvascular inflammation were defined by a sum of the 
scores for glomerulitis and peritubular capillaritis ≥2, with or without concurrent positive C4d 
staining. 
Double stainings with anti-CD34 (endothelial cells) and respectively one antibody among 
anti-CD56 (NK cells), anti-CD3 (T cells), anti-CD68 (macrophages) and anti-66b 
(granulocytes) were performed by immunochemistry on paraffin embedded sections using an 
anti-human CD34 (clone QBEnd10, Dako, Les Ulis, France) and respectively anti-human 
CD56 (clone CD564, produced by Novocastra and distributed by Leica Microsystemes SAS, 
Nanterre, France), anti-human CD3 (clone SK7, Becton Dickinson, Le Pont de Claix, 
France), anti-human CD68 (clone PGM1, Dako, Les Ulis, France)and anti-66b (clone G10F5, 
Becton Dickinson). Computerized quantitative analyses were conducted in collaboration with 
Pasteur Institute. The algorithm allows for precise quantification of inflammatory cells in the 
renal allograft. The quantification of inflammatory cells in mvi+DSA- patients’ biopsies was 
compared to the one of mvi+DSA+C3d- patients’ biopsies (positive control). 
 
Detection of anti-HLA antibodies 
Donor-recipient HLA typing were performed by PCR-SSO reverse (One Lambda, Canoga 
Park, CA, USA). 
Serum samples banked at the time of biopsy from patients with significant microvascular 
inflammation were tested for the presence of donor specific anti-HLA antibodies using 
Screening Flow Beads (LifeScreen, Class I and Class II ID ®, Lifecodes, Immucor, Norcross, 
GA, USA) and Single Antigen Flow Beads (LSA class I and class II®, Lifecodes, Immucor) 
in case of positivity or questionable result of the screening test. All the sera of each patient 
after transplantation were also reviewed and patients with circulating donor specific anti-HLA 
antibodies detected at any time point were excluded from the mvi+DSA- group. 
All the analyses were performed in a blinded fashion by a single trained immunobiologist 
(V.D.) at the Etablissement Français du Sang (Lyon, France). 
 
Detection of anti-endothelial cell antibodies 
An endothelial flow cross match was performed as reported previously in the literature (Canet 
et al., 2012). Two primary cell lines of coronary endothelial cells (#407 and 408) (Promocell, 
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Heidelberg, Germany) were used for this test. For sera containing anti-HLA non-DSA, target 
endothelial cells were HLA-matched to avoid anti-HLA binding. Briefly, 1 or 2 * 105 
endothelial cells were incubated for 30 minutes at room temperature with 25 μl of serum 
diluted at ¼ in PBS 1x FBS 1%. Reactivity of patient’s sera for endothelial cells was revealed 
by incubation with a FITC conjugate F(ab’)2 anti-human IgG (30242, Bio rad, Hercule, CA, 
USA) for 20 minutes at 4 °C. After 3 washes with PBS 1x FBS 1%, the cells were 
resuspended in 200 μl of PBS 1x FBS 1% and analysed by flow cytometry (FACScanto II® 
analyser, Becton Dickinson, Montain View, CA, USA). The fluorescence level was expressed 
as Mean Fluorescence Intensity. A serum containing an anti-HLA class I antibody directed 
against HLA typing of the endothelial cell lines was used as positive control. Negative 
controls were performed using a pool of normal human AB sera from healthy male donors 
(EFS; Lyon, France).  
 
Determination of KIR ligand and KIR receptor genotyping 
These analyses were performed for the principal cohort: mvi+DSA- patients and a control 
group: mvi-DSA- patients.  
Donors’ and recipients’ KIR ligands were determined as following. HLA-C1 and C2 groups 
were determined for the donors and recipients taking into account the HLA C typing obtained 
by PCR-SSO reverse (One Lambda). The presence or not of Bw4 motif was determined for 
the donors and recipients taking into account the HLA A and B typing obtained by PCR-SSO 
reverse (One Lambda). 
Genotyping of 14 KIR genes (2DL1, 2DL2, 2DL3, 2DL4, 2DL5, 2DS1, 2DS2, 2DS3, 2DS4, 
2DS5, 3DL1, 3DL2, 3DL3, 3DS1) and 2 pseudogenes (2DP1, 3DP1) was realized for the 
recipients by PCR-SSO reverse (KIR SSO Genotyping Test, One Lambda) according to the 
manufacturer’s instructions. Number of inhibitory KIRs was determined considering 7 
inhibitory KIRs: 2DL1, 2DL2, 2DL3, 2DL5, 3DL1, 3DL2 and 3DL3. KIR2DL4 was not 
considered as an inhibitory KIR because it has been reported as having both activating and 
inhibitory functions (Campbell and Purdy, 2011; Kikuchi-Maki et al., 2003). Number of 
activating KIRs was determined considering 6 activating KIRs: 2DS1, 2DS2, 2DS3, 2DS4, 
2DS5 and 3DS1. 
AA, BB and AB haplotypes were assigned as following: AA haplotype if none of the 
following KIR gene was present: 2DL2, 2DL5, 2DS1, 2DS2, 2DS3, KIR2DS5, 3DS1; BB 
haplotype if 2DL1, 2DL3, 3DL1, 2DS4 and 2DP1 were absent; Remaining KIR combinations 
were assigned with AB haplotype (according to https://www.ebi.uk/ipd/kir/introduction.html). 
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The functionality of inhibitory KIR receptors was assessed for the one with known MHC 
class I ligands (2DL1, 2DL2, 2DL3, 3DL1, 3DL2). They were considered as functional only 
if the recipient possessed their respective HLA ligand (KIR2DL1/C2; KIR2DL2/C1; 
KIR2DL3/C1; KIR3DL1/Bw4 and KIR3DL2/A*03,*11). The functionality of the only 
activating KIR (KIR2DS1) known to undergo a licensing was also assessed (Fauriat et al., 
2010). It was considered to be functional only if the recipient didn’t possess its ligand. 
 
Statistical analysis 
Categorical variables were expressed as percentages and compared with the chi-squared test. 
Continuous variables were expressed as mean ± standard deviation and compared using 
unpaired t test. 
Graft survival was calculated from the date of biopsy until the beginning of hemodialysis. 
Survival curves were constructed with the Kaplan–Meier method and compared with the log-
rank test. 
All tests were two sided, and P values <0.05 were considered to represent statistically 
significant differences. Statistical analyses were realized using GraphpadPrism® 6.0a for Mac 
OS X. 
 
Results 
Study population 
Of 938 kidney transplant recipients followed over the study period in the 2 institutions 
participating to the study, 65 donor/recipient pairs fulfilled the pre-screening criteria: 
 i) significant microvascular inflammation on graft biopsy (g+ptc ≥ 2), ii) no circulating donor 
specific anti-HLA antibodies in solid phase assay.  
Endothelial flow cross match was performed for 27 out of the 65 sera (41.5 %) to rule 
out the presence of non-HLA antibodies directed against graft endothelium. The others 
patients couldn’t be tested because they had non-donor specific anti-HLA antibodies directed 
against the HLA of the two primary endothelial cell lines available. One patient with positive 
endothelial flow cross match was discarded. 
Finally, the 41 patients fulfilling the inclusion criteria and having DNA available for 
the donor and recipient were enrolled in the study (mvi+DSA-).  
Interestingly, even though mvi+DSA- patients didn’t have anti-graft antibodies they had 
significant microvascular inflammation on their biopsy and a graft survival, which was 
significantly worse than matched control recipients with neither mvi nor DSA (mvi-DSA-). In 
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fact mvi+DSA- graft survival was similar to the one of patients diagnosed with conventional 
antibody-mediated rejection due to non-complement binding DSA (mvi+DSA+C3d-) (Figure 
1). 
As expected, Mvi+DSA- patients and mvi-DSA- patients displayed similar 
characteristics (Table 2), especially regarding the number of HLA mismatches, except for 
microvascular inflammation (p < 0.0001).  
Mvi+DSA- patients and mvi+DSA+C3d- had also similar baseline characteristics, including 
regarding the severity of histological lesions (Table 2 below). 
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Table 2: baseline characteristics 
 
Recipients’ KIR genotypes in mvi+DSA- and mvi-DSA- groups 
First, we analysed whether recipients’ KIR genotype might impact the occurrence of 
microvascular injuries. KIR genotype frequencies were similar in mvi+DSA- and mvi-DSA- 
patients for all the KIR genes (Table 3).  
The numbers of inhibitory and activating KIR genes were also similar between the 2 groups 
(Table 4).  
Recipients could be distributed in 2 haplotypes (A or B) according to the number of activating 
KIR genes: only one activating KIR (KIR2DS4) for A haplotype, in contrast with > 1 
activating KIR for B haplotype. There was no statistical difference in the distribution of 
recipients KIR haplotypes between the two groups (Table 4). 
 
 
Table 3 : KIR gene frequencies 
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Table 4: Number of inhibitory and activating KIR genes, KIR haplotype frequencies 
 
Donors’ and recipients’ KIR ligands in mvi+DSA- and mvi-DSA- groups 
We investigated the donors’ and recipients’ HLA-C1, HLA-C2, HLA-Bw4, and HLA-A3, 
A11 genotype frequencies in mvi+DSA- and mvi-DSA- patients. 
The distribution of recipients’ HLA-C1/2, HLA-Bw4 and HLA-A genotype frequencies were 
similar between both groups (Table 5).  
Looking at donors’ KIR ligands, donors of the mvi+DSA- group tended to be more often 
C1/C1 than donors of the mvi-DSA- group (46.3 % and 33.9 % respectively, p=0.06). We 
observed also a tendency to have less donors which were A3 and/or A11 in mvi+DSA- 
patients than in mvi-DSA- patients (26.8 % and 44.6 % respectively, p=0.09). The frequency 
of HLA-Bw4 positive donors was not different between the 2 groups (p=0.2) (Table 5).  
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Table 5: Distribution of recipient’s and donor’s HLA-C1/2, HLA-A and HLA-Bw4 
genotype frequencies 
 
Functionality of recipients’ KIR receptors in mvi+DSA- and mvi-DSA- groups. 
Only NK cells carrying inhibitory KIR receptors for which the recipients possess 
corresponding HLA ligands are functional and thus susceptible to be activated by “missing 
self” when they sense the absence of MHC class I on donors’ allogenic cells. Functional 
inhibitory KIR gene frequencies were similar between both groups (Table 6). 
Even if the licensing mechanism of activating KIR receptors remains more elusive, it was 
shown to exist for KIR2DS1 (Fauriat et al., 2010). NK cells KIRS2DS1+ of C2+ patients are 
hypo responsive, which is a supplementary mechanism to ensure self-tolerance. In our cohort, 
the proportion of recipients having a functional KIR2DS1 was low and similar between 
mvi+DSA- and mvi-DSA- groups (Table 6). 
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Table 6: Functional KIR gene frequencies 
 
Worst recipients’ functional inhibitory KIR/donors’ HLA ligands matching in 
mvi+DSA- patients 
Considering that the NK clones of an individual expressed heterogeneously all the 
inhibitory KIRs present in the genome and that one KIR/ligand mismatching is enough to 
activate part of the NK cell population, we calculated the total number of mismatches for each 
individual donor/recipient pairs for functional inhibitory KIRs (KIR2DL1, KIR2DL2, 
KIR2DL3, KIR3DL1, KIR3DL2) and their respective donors’ HLA ligands. The proportion 
of patients with at least one mismatch was higher for mvi+DSA- group compared to mvi-
DSA- group (63.4% versus 37.5 %, p=0.03). 
Then, we analysed the effect of each individual KIR/ligand mismatching to see which 
KIR/ligand combinations were overrepresented in mvi+DSA- group as compared with 
controls. More patients were mismatched for KIR3DL1/Bw4 in the mvi+DSA- group 
compared to the mvi-DSA- group (36.4 % versus 10.3 %, p=0.01) (Table 7). For the other 
inhibitory KIRs, no significant difference was found between the 2 groups (Table 7).  
246
 
 
Table 7: Matching and mismatching between functional recipient’s KIRs and their 
respective HLA ligands present in the donors. 
 
Mvi+DSA- patients presented as much CD56+ cells on allograft biopsies as 
mvi+DSA+C3d- patients 
We reasoned that if mvi+DSA- patients develop graft microvascular inflammation due to 
activation of NK by “missing self” on graft endothelium, we should observed activated NK 
cells in their biopsies. We therefore performed a computer-assisted quantification of CD56+ 
cells infiltrating the graft. As positive controls, we used the graft biopsies of patients 
diagnosed with antibody-mediated rejection due to non-complement binding DSA 
(mvi+DSA+C3d-), a condition known to be driven by NK-mediated ADCC.  
In line with our hypothesis, CD56+ cells were present in the allograft biopsy specimens of 
mvi+DSA- patients. Despite the lack of anti-graft antibodies, mvi+DSA- patients had the 
same number of CD56+ cells on their allograft biopsies as mvi+DSA+C3d- patients (Figure 
2). 
We also identified and quantified the other inflammatory cells infiltrating the grafts of 
mvi+DSA- patients. Two other cell lines were particularly represented in the infiltrates: CD3 
cells (T cells) and CD68 cells (macrophages) (Figure 2). On the contrary, CD66b cells 
(granulocytes) were rare in most patients (Figure 2). These results were similar to the one 
obtained in mvi+DSA+C3d- patients. 
 
 
 
 
247
 
Discussion 
To the best of our knowledge, our study is the first to show that NK cells activated by 
“missing self” can trigger microvascular inflammation leading to chronic rejection after solid 
organ transplantation.  
The previous studies evaluating the role of NK in renal transplantation reached 
conflicting results. In a large multicentric study, Tran et al. reported that NK didn’t impact 
long-term allograft survival but they only looked at the matching between HLA ligands of 
KIRs between the recipients and the donors, not performing KIR genotyping (Tran et al., 
2005). Two other teams evaluated the role of NK cells in renal transplantation (Kreijveld et 
al., 2007; Kunert et al., 2007). Whereas the first study didn’t find any impact of KIR/ligand 
matching on the prediction of the risk of acute rejection, the second one showed that 
KIR2DL1+ or KIR2DL2/2DS2 recipients receiving a graft from donors possessing their 
ligands were less at risk of acute cellular rejection. As for the study by Tran et al, these 2 
studies didn’t take into account the functionality of recipients’ KIR receptors, thus 
considering some patients as being mismatched for KIR/ligand combinations while their NK 
cells were in fact bearing unlicensed inhibitory KIRs (and were therefore unable to respond to 
the mismatch). On top of that, these 2 studies used acute rejection as endpoint (Kreijveld et 
al., 2007; Kunert et al., 2007). Although a convenient clinical endpoint (easy to diagnose, 
occurrence in the first 12 months), this might not be relevant to evaluate the impact of NK 
response against the graft since most murine experimental studies have shown that NK cell 
activation by “missing self” rather induce smoldering allograft injuries leading to late 
allograft failure (Uehara et al., 2005; Zhang et al., 2015).  The strength of our study lays in the 
fact that we investigated the role of NK cell activation by “missing self” in the particular 
setting of microvascular injuries and chronic rejection after renal transplantation.  
We included in our study only patients in whom a humoral response against graft 
endothelium has been excluded, as it is the first cause of microvascular injuries and chronic 
rejection after renal transplantation (Pouliquen et al., 2015; Sellarés et al., 2012; Thaunat, 
2012). Not only patients with donor specific anti-HLA antibodies were excluded, but also 
patients with anti-endothelial cells as these antibodies take on great importance, as the 
endothelium is the site of interaction between the graft and the recipient’s immune system 
(Breimer et al., 2009; Jackson et al., 2015; Sun et al., 2008, 2011). 
On top of that, our clinico-biological and genetic data were strengthened by histological 
analyses of grafts using computer-assisted inflammation quantification which allowed us to 
precisely numbered inflammatory cells within the graft. Even though mvi+DSA- patients 
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have no antibodies, the number of NK cells (CD56+) infiltrating their allograft was the same 
as for mvi+DSA+C3d- patients in whom antibodies bind to graft endothelium and recruit NK 
cells, which drive ADCC. Our histological analyses also highlighted the presence of 
macrophages and T cells on allograft biopsies of mvi+DSA- and mvi+DSA+C3d- patients, 
advocating for a final common pathway whatever the mode of NK cell activation.  
We considered only the mismatches between donors’ HLA ligands and recipients’ functional 
KIRs. The patients having at least one KIR/ligand mismatch were more at risk to present 
microvascular injuries. Moreover, the mismatching for KIR3DL1/Bw4 association was 
overrepresented in mvi+DSA- patients. This mismatch was sufficient to trigger NK cell 
activation, which could initiate the recapitulation of lesional mechanism of complement-
independent antibody-mediated rejection: microvascular injuries leading to chronic rejection 
and finally allograft loss. 
Our data challenge the current paradigm that innate immune system can participate to 
rejection only if recruited by adaptive immune system. Here “missing-self” directly activate 
NK cells. In other terms, NK cells have the ability to recognize non-self in the absence of 
danger signal. Our data are in the same line as the results of the team of Lakkis, which have 
shown that monocytes were also able to discriminate self and non-self (Oberbarnscheidt et al., 
2014). 
Currently, efforts are made to allocate HLA compatible transplant (define as an absence of 
pre formed DSA) to recipients. As KIR3DL1 is functional in 65 % of recipients and since its 
matching with Bw4 is not part of allocation criteria, current rules of allocations result in the 
fact that 25 % of the recipients receive a graft that will develop chronic rejection lesions 
exactly as if the recipient has a non-C3d-binding DSA.  
 
We conclude that “missing self” is sufficient to activate NK cells, which can cause a novel 
kind of innate-driven chronic rejection after renal transplantation. Studies are needed to better 
understand the impact of the different immunosuppressive drugs on NK cells. Meanwhile, 
integration of KIR3DL1/Bw4 matching to current strategies of organ allocation could 
improve long-term outcomes. 
 
Example 2: In vitro modelisation of missing-self mediated NK activation 
Materiel and Methods 
At day 0, whole blood samples were collected from healthy donors by venipuncture 
into Acide Citrate Dextrose-containing vials. Peripheral blood mononuclear cells (PBMC) 
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were isolated by Ficoll gradient centrifugation (Eurobio). PBMCs were cultured overnight at 
37°C in 5% CO2 in complete culture medium (RPMI 1640 containing glutamine and 
supplemented with 10 % FBS, hepes and penicillin-streptomycin) supplemented with 500 
UI/ml recombinant human IL-2 (R&Dsystems) or were maintained at 4°C in complete culture 
medium.  
Simultaneously, endothelial cells were seeded (100 000 in each well) in wells of a flat 
bottom 96-well plate coated with gelatin 1% (Sigma). Endothelial cells were cultured 
overnight at 37°C in 5% CO2 in endothelial cell growth culture 2 medium (Promocell).  
 
A day 1, NK cells were isolated using stem cell magnetic kit according to the 
manufacturer’s instructions. Then, purified NK cells were resuspended at 0.5 millions/ml in 
complete RPMI.  
One hundred thousand NK cells were added in each well containing endothelial cells 
after removing endothelial cell culture medium. Five microliter of anti-human CD 107a FITC 
(eBIOH4A3, ebioscience) was added in each well at the beginning of the co-culture. One hour 
after the beginning of the co-culture, golgi stop (DB biosciences) was added in each well. 
Then cells were co-cultured for 3 hours.  
 
After the co-culture, cells were detached with trypsin and recovered in V bottom- 96-
well plates.  
Then cells were stained 20 min at room temperature in 50 µl of the following 
antibodies diluted in PBS1x: 
CD3 APC-H7 (SK7) BD biosciences 1/25e 
CD56 PE CF594 (NCAM16.2) BD biosciences 1/25e 
KIR2DL1/S5 AF 700 (143211) R&Dsystems 1/10e 
KIR2DL3 APC (180701) R&Dsystems 1/10e 
KIR3DL1 BV 711 (DX9) BD bisociences 1/25e 
CD 107a FITC (eBIOH4A3) ebiosciences 1/50e 
Fixable viability dye eFluor 506 ebiosciences 1/1000e 
 
Without washing, the following antibodies were added in 50 µl in PBS1x for an 
incubation of 15 minutes at room temperature: 
KIR2DL1/S1 PE CY7 (EB6B) Beckman Coulter 1/25e 
KIR2DL2-3/S2 PE CY5.5 (GL183) Beckman Coulter 1/25e 
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KIR3DL1-2 PE (REA168) Miltenyi Biotec 1/10e 
 
Then cells were washed twice with PBS1x. After this, cells were fixed with 75 µl of 
Cytofix/Cytoperm® fixation/permeabilization kit (BD Biosciences) 20 min at 4°C. After two 
washing with Permwash, cells were stained 30 min at 4°C in 100 µl of the following antibody 
diluted in Permwash: 
MIP1B V450 (D21-1351) BD biosciences 1/40e 
 
After one washing with PBS1x, cells were resuspended in PBS1x. Then samples 
acquisitions were made on a BD FORTESSA IV flow cytometer (BD Biosciences). Data 
were analysed with FlowJo software (Tree Star).  
 
Results: 
NK cells from healthy donors previously stimulated (IL2+) or not (IL2-) with IL2 
were co-cultured 4 hours with different primary endothelial cell lines bearing different HLA 
class I ligands of inhibitory KIRs.  
NK cell activation is assessed by the expression of the degranulation marker CD107a 
or the chemokine MIP1β. 
The percentage of NK cells bearing only one inhibitory KIR expressing the 
degranulation marker CD107a or the chemokine MIP1β was assessed by flow cytometry in 
the following subpopulations : 
- NK cells with an iKIR having its ligand present on endothelial cells (Matched 
iKIR (M)),  
- non licensed NK cells with a iKIR not having its ligand on endothelial cells 
(Mismatched non licensed iKIR (MM L-)), and  
- licensed NK cells with an iKIR not having its ligand on endothelial cells 
(Mismatched licensed iKIR (MM L+)). 
After 4 hours of co culture the percentage of NK cells expressing CD107a or MIP1B 
was calculated for the following NK cells populations (KIR repertoire staining and analysis in 
NK cell was performed as described in Béziat V, Liu LL, Malmberg J-A, et al. NK cell 
responses to cytomegalovirus infection lead to stable imprints in the human KIR repertoire 
and involve activating KIRs. Blood. 2013;121(14):2678-2688).:  
- NK cells bearing one inhibitory KIR which had its ligands on the endothelial cell 
line (matched NK cells);  
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- NK cells bearing one one non-functional inhibitory KIR which doesn’t have its 
ligand on endothelial cells (mismatched non licensed NK cells); and  
- NK cells with one functional inhibitory KIR which doesn’t have its ligand on 
endothelial cells (mismatched licensed NK cells).  
In the absence of NK cell stimulation with IL2 before the co-culture, none of the 3 
subpopulations of NK cells expressed either CD107A or MIP1B. However, when they were 
stimulated with IL2 before the co-culture, the percentage of mismatched licensed NK cells 
positive for the degranulation marker CD107a and the chemokine MIP1B was significantly 
higher than for matched NK cells and mismatched non licensed NK cells. These results were 
found for the 3 inhibitory KIRs which can be licensed: KIR2DL1, KIR2DL2-3, KIR3DL1. 
The results confirm that NK cells can sense missing-self on primary endothelial cells.   
These results also suggest that NK cells need to be primed to sense missing-self on 
endothelial cells, as without IL2 nothing occurs. 
Figure 3 shows the percentage of NK cells bearing only one functional inhibitory KIR 
(KIR2DL1 or LIR2DL2 and/or 3, KIR3DL1). 
Figure 4A shows the percentage of CD107a+ cells in the different subpopulations of 
IL2+ NK cells bearing only one inhibitory KIR (KIR2DL1 or LIR2DL2 and/or 3, KIR3DL1, 
KIR3DL2). Mismatched licensed cells show significantly more activation as compared to 
mathed NK cells or mismatched non licensed NK cells. 
Figure 4B shows the percentage of CD107a+ cells in the different subpopulations of 
IL2+ NK cells bearing a define inhibitory KIR (KIR2DL1 or LIR2DL2 and/or 3, KIR3DL1, 
KIR3DL2). 
Figure 5A shows the percentage of MIP1β+ cells in the different subpopulations of 
IL2+ NK cells bearing only one inhibitory KIR (KIR2DL1 or LIR2DL2 and/or 3, KIR3DL1, 
KIR3DL2). Figure 5B shows the percentage of MIP1β+ cells in the different subpopulations 
of IL2+ NK cells bearing a define inhibitory KIR (KIR2DL1 or LIR2DL2 and/or 3, 
KIR3DL1, KIR3DL2). 
 
Example 3: Identification of immunosuppressant to be used for transplant 
rejection mediated by missing-self activated NK cells 
a) In vitro model: 
mTOR pathway was selected as a target of interest as mTOR was known to be 
involved in NK cell activation. Furthermore inhibitors of mTOR, such as rapamycin, are 
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already available in clinic. The same experimental setting as previously described (see 
example 2) was used. 
The results show that mTOR efficiently prevents NK cell mediated transplant 
rejection. 
 
b) In vivo cellular model of missing self 
Wild type B6 mice were, injecting with splenocytes coming from a B2 micro KO 
mouse (lacking class I molecules on their surface) and therefore sensitive to the NK 
dependent lysis by missing self.  
To control that the lysis of the cells is not due to another phenomenon, splenocytes 
from a wild-type B6 mouse were injected at the same time. 
 
After the injection, the recipient mice were killed at different time points and their 
spleen were recovered. The splenocytes were analyzed by flow cytometry and the % of 
remaining B2 micro KO cells compared to that injected at day 0 was calculated. 
With the time, B 2 micro KO cells are progressively killed and disappear around day 7 
(see figure 6A). 
 
In mice treated with an inhibitor of mTOR, such as rapamycine, survival of B2 micro 
KO cells is drastically increased which confirm the potential efficacy of this drug in the 
treatment of transplant rejection mediated by missing-self-activated NK cells.  
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CLAIMS: 
 
1. An in vitro method for predicting the risk of transplant rejection in a subject who is 
the recipient of a transplant from a transplant donor, said method comprising:  
the detection of missing-self activation of Natural Killer (NK) cells, wherein the detection of 
missing-self activation of NK cells is indicative of a risk for transplant rejection. 
 
2. The method of claim 1, wherein the detection of missing-self activation of NK cells 
is achieved by the identification of the absence in the transplant donor of a ligand for a 
functional inhibitory Killer-cell Immunoglobulin-like Receptor (KIR) of the recipient subject. 
 
3. The method of claim 1 or 2, wherein the identification of the absence in the 
transplant donor of a ligand of a functional inhibitory KIR of the recipient subject comprises: 
- obtaining the KIR genotype of the recipient subject and the transplant donor HLA-I 
genotype, and 
- comparing the genotype of the recipient functional KIRs with the genotype of the 
transplant donor HLA-I. 
 
4. The method of any one of claims 1-3, further comprising obtaining the HLA-I 
genotype of the recipient subject,  
wherein KIRs are considered functional if the recipient subject expresses their 
corresponding HLA-I ligands. 
 
5. The method of claim 1 or 2, wherein the detection of missing-self activation of NK 
cells comprises 
- co-cultivating stimulated NK cells from the recipient subject with endothelial cells, 
preferably primary endothelial cells; and 
- detecting the presence of a degranulation compound, preferably CD107a. 
 
6. The method of any one of claims 1-5, wherein the recipient subject is a candidate 
recipient subject. 
 
7. A method of selecting a HLA compatible donor transplant for a candidate recipient 
subject comprising:  
258
- obtaining the inhibitory KIR genotype of the candidate recipient subject and the
HLA-I genotype of the transplant donor and the candidate recipient subject; 
- comparing the HLA-I genotype and the KIR genotype of the candidate recipient
subject et determining the functional KIRs; and 
- comparing the genotype of the recipient inhibitory functional KIRs of the candidate
recipient subject with the donor HLA-I genotype, and 
- identifying whether or not a ligand of a functional inhibitory KIR (Killer-cell
Immunoglobulin-like Receptor) of the recipient subject is absent in the transplant donor. 
8. The method of any one of claims 1-7, further comprising determining the proportion
of NK cells in the recipient subject bearing inhibitory functional KIRs directed against HLA-I 
ligand missing in the donor HLA-I genotype.  
9. The method of any one of claims 1-8, wherein the inhibitory KIRs comprise
KIR2DL1, KIR2DL3, KIR2DL5, KIR3DL1, KIR3DL2 and KIR3DL3. 
10. The method of any one of claims 1-9, wherein the transplant is a solid transplant
organ, notably selected from heart transplant, lung transplant, kidney transplant, liver 
transplant, pancreas transplant, intestine transplant, thymus transplant and is preferably 
kidney transplant. 
11- An mTor inhibitor, for use in the prevention or the treatment of transplant
rejection in a subject who is the recipient of a transplant and selected as having at least one 
recipient functional KIR directed against HLA-I ligand missing in donor HLA-I genotype.  
12. An mTor inhibitor for use according to claim 11, wherein the inhibitor is an
inhibitor of mTorC1, notably wherein the inhibitor is rapamycin or one of its rapalog analog. 
13 The method according to any one of claims 1-10 or the m Tor inhibitor for use 
according to claim 11 or 12, wherein the transplant rejection is chronic rejection. 
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ABSTRACT 
The invention relates to an in vitro method for predicting the risk for transplant rejection in a 
transplanted subject. The inventors have shown that innate immune effectors NK cells could 
trigger microvascular inflammation and chronic transplant rejection. NK-mediated rejection 
was due to the lack of expression by the graft of at least one type of HLA-I ligand for an 
inhibitory KIR expressed by recipient NK cells Thus the invention relates to an in vitro 
method for predicting the risk of transplant rejection in a transplanted subject comprising the 
detection of missing-self activation of NK cells. The inventors also showed that mTOR 
inhibitors are efficient to prevent missing-self mediated transplant rejection. The invention 
thus relates to an mTor inhibitor for use in the prevention or treatment of a transplanted 
recipient subject at risk of missing-self mediated transplant rejection. 
260

 
 
1  
2  
262
 
 
 
Efficacité de l’évérolimuS pour le traitement des TrAnsplantés Rénaux 
présentant un Rejet secondaire à l’activation des NK par le « missing-self »  
24 mois 
 
20 
263
264
 
≥
•
o
o
•
o
o
•
o
β
o
265
266
